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Abstract 
Reversible deactivation radical polymerisation represents a versatile route to prepare 
well-defined polymeric materials with complex architecture, controlled molecular weight 
and tuneable end-groups. RDRP techniques have now been translated to heterogeneous 
polymerisations (emulsion, dispersion, suspension etc.) allowing large scale preparation 
of nanoparticles with tuneable cores and shells in an aqueous environment. Such systems 
show great promise in biomedical applications due to their long circulation time, passive 
tumour accumulation, and core-shell architecture capable of drug loading and controlled 
release. The overall aim of this thesis is to assess RAFT emulsion polymerisation as a 
route to prepare nanoparticles for potential biomedical applications, and to study their 
physical properties, cytotoxicity, cellular uptake and in vivo distribution. 
Firstly, the synthesis of nanoparticles from amphiphilic block copolymers via RAFT 
emulsion polymerisation is explored, revealing optimum conditions. Preliminary in vitro 
and in vivo cytotoxicity and biodistribution studies indicated high biocompatibility with 
significant liver accumulation post-injection. Following this, a systematic study 
identifying the effect of nanoparticle rigidity on cellular uptake is explored using a library 
of hard, intermediate or soft cores tuned with their glass transition temperature. 
Intracellular fluorescence studies display an increasing amount of uptake with decreasing 
nanoparticle rigidity, with mechanistic studies suggesting this could be due to a 
preference of the harder nanoparticles to be internalised via clathrin and caveolae- 
mediated endocytosis. In the next chapter, alkyne functional RAFT agents are prepared 
to impart functionality at the nanoparticle surface. It is found that by replacing the initial 
carboxylate with other functionality significantly reduces colloidal stability. Finally, 
polysulfonated macro-RAFT agents are used to synthesise heparin-mimicking 
nanoparticles, via RAFT emulsion polymerisation, capable of stabilising growth factors. 
The nanoparticles outperform linear analogues and heparin itself, suggesting that the high 
local concentration at the particle surface significantly improves bioactivity.  
Overall, this thesis describes how aspects such as particle size, core and shell 
composition, and corona functionality can be modified individually for specific biological 
applications.  
 
 
Chapter 1  
 
Heterogeneous reversible deactivation radical 
polymerisation to generate nanoparticles for 
biological applications 
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1.1 Introduction 
Over the past few decades, nanomaterials, specifically nanoparticles have become 
ubiquitous in modern biomedical research. There are now many examples of organic 
(polymeric, liposomal, protein)1-3 and inorganic (metallic, quantum dots, silica)4-6 
nanoparticles which excel in applications such as cargo (drug/protein/nucleic acid)7-9 
delivery, bio-imaging10 and diagnostics.11 While to date their clinical use has been 
limited,12, 13 ‘nanomedicine’ is an active field of research within the academic and 
industrial world, largely due to the versatility of materials available, and the advantageous 
properties they display. Their large volumes (relative to molecular drugs) are known to 
significantly increase circulation time14 and encapsulate/protect a tremendous amount of 
pharmaceutic payloads.15 Whereas their large surface area has been exploited to improve 
biocompatibility and disease targeting through conjugation of ‘stealthy’ polymers16 and 
bio-active moieties respectively. This property minimises the formation of protein 
coronas, which is known to enhance clearance via the immune system.17 In particular, 
nanoparticles have been studied for their potential use in cancer therapy, mostly driven 
by their ability to passively accumulate in leaky malignant tumour tissue, known as the 
enhanced permeability and retention (EPR) effect.18, 19 Overall these properties can 
improve therapeutic efficacy and minimise clinical side effects while reducing the 
maximum dose requirements. 
Out of the plethora of reported biomedical targeted nanoparticle systems, polymeric 
systems have shown great promise due to their chemical versatility.20 For example, 
factors such as chemical functionality, charge, stimuli-responsivity and degradability can 
be easily introduced by tuning the monomer composition. Furthermore, a variety of 
polymeric nanoparticle architectures (self-assembled micelles,21 nanoworms,22 
polymersomes,23 latex particles,24 branched polymers (hyperbranched25 and 
dendrimers26) and nanogels27) can now be prepared with relative ease. 
Perhaps the most prominent advancements in polymer nanoparticle design have arisen 
from developments surrounding reversible deactivation radical polymerisations (RDRP), 
either based on reversible deactivation (e.g. atom transfer radical polymerisation 
(ATRP),28 nitroxide mediated polymerisations (NMP)29, 30 and single electron transfer-
living radical polymerisation (SET-LRP)31) or degenerative chain transfer (e.g. reversible 
addition fragmentation chain transfer (RAFT)) (Figure 1.1).32 These methods have 
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allowed researchers to prepare materials with narrow molecular weight distributions,33 
versatility in terms of block architecture,34 and functional end-groups.35 Since RDRP is 
well suited for preparing block copolymers, self-assembly has been the most popular 
method to prepare biologically relevant nanoparticles, as the ability to transform intricate 
polymer design into supramolecular structures is appealing from a design perspective.36, 
37 These processes however suffer from scalability limitations, with suspensions above a 
few weight percent being difficult to achieve.38 Furthermore, these nanomaterials may 
disassemble at low concentrations (such as those found endogenously), thus releasing 
their cargo prematurely. 
 
Figure 1.1 Mechanisms of nitroxide mediated polymerisation (NMP), atom transfer radical polymerisation 
(ATRP) and reversible addition-fragmentation chain transfer (RAFT). 
Heterogeneous polymerisations (emulsion,39 dispersion,40 suspension,41 miniemulsion42 
and inverse emulsion)43 are now heavily exploited to generate polymer colloids 
reproducibly at large scales and with environmentally friendly conditions. In many, but 
not all of these systems, compartmentalisation effects (i.e. segregation of propagating 
radicals) leads to fast propagation rates, full monomer conversion, low termination and 
therefore high molecular weight materials. However the multicomponent nature of many 
RDRP techniques mean that these processes cannot be directly translated to 
heterogeneous systems.44, 45 Nonetheless, this approach was initially achieved by Bon et 
al. who described the NMP of styrene in emulsion conditions in 1996.46 However, until 
2007, research on RDRP techniques in dispersed states remained fairly fundamental, of 
Reversible deactivation
Nitroxide mediated 
polymerisation (NMP)
Atom transfer radical 
polymerisation (ATRP)
Degenerative chain transfer
Reversible addition 
fragmentation chain 
transfer (RAFT)
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which there are many reviews on this topic.45-54 Since overcoming many of the obstacles 
initially presented, much of the present work points to applying these to synthesise 
nanomaterials geared towards a range of applications.  
With the increased use biomedical nanoparticles, and RDRP in dispersed states there are 
now many examples using these approaches used to generate nanoparticles for these 
applications. In this chapter, different dispersed state polymerisations will be critically 
analysed but from the perspective of preparing biologically relevant nanomaterials. In 
each section a description of the heterogeneous system, examples from the literature, and 
analysis of the advantages and disadvantages each brings for biological applications will 
be given. It should be noted that only articles which include biological characterisation 
have been reviewed, rather than a full assessment of heterogeneous polymerisation.  
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1.2 Miniemulsion polymerisation 
In conventional miniemulsion polymerisations, a water immiscible monomer is 
emulsified with surfactant in an aqueous continuous phase using external shearing forces 
such as ultrasonication, resulting in kinetically stable, but thermodynamically unstable 
droplets (Figure 1.2a).42 This can also be applied  to a water in oil system - inverse 
miniemulsion polymerisation, in which the polymerisation occurs within aqueous 
monomer droplets dispersed in an oil continuous phase (Figure 1.2b).43 In an ideal system, 
each monomer droplet is converted into a polymeric particle, and as these are effectively 
a mini-bulk/solution polymerisations, this removes the necessity for monomer diffusion 
through the aqueous phase (as in normal emulsion polymerisation) and as such many 
RDRP (RAFT,55-58 ATRP,59-61 and NMP62-65) miniemulsion polymerisations, either 
conventional or inverse, have been reported.  
 
Figure 1.2 Schematic representation of (A) miniemulsion polymerisation and (B) inverse miniemulsion 
polymerisation. I = initiator species, yellow = oil/monomer phase, blue = aqueous phase, red = polymer 
phase. 
A 
B 
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1.2.1 Inverse miniemulsion polymerisation 
Inverse miniemulsion polymerisation enables the preparation of fully hydrophilic 
nanoparticles, in which the polymer chains are cross-linked (covalent or non-covalent) in 
a network like structure giving them the term ‘nanogels’. These are typically swollen 
when suspended in aqueous solutions, making their chemical structure accessible for 
potential degradation triggered by endogenous biochemical stimuli (e.g. glutathione,66 
enzymes,67 pH changes68).  It should be noted that although these are conventionally 
called ‘inverse emulsion’ in reality they are closer to an ‘inverse miniemulsion’ as the 
monomer does not diffuse from large droplets to growing particles. 
Many examples of nanogels synthesised with free-radical polymerisation exist in the 
literature, and are used mainly in drug delivery,69 diagnostics70 and imaging71. However, 
their network-like structure in particular lends them towards encapsulation of 
biomacromolecules, such as proteins and nucleic acids by physical entrapment.  RDRP 
techniques even allow for the distribution of cross-linking points thus a more homogenous 
gel structure directly impacting their biological performance. This has been extensively 
reported for ATRP and RAFT based nanogels.72 Notably there are no NMP inverse 
miniemulsion polymerisations reported, and is likely a consequence of commercially 
available nitroxides being relatively water insoluble. 
 
1.2.1.1 ATRP nanogels 
ATRP relies on an external catalyst (typically a transition metal complex) to reversibly 
deactivate propagating radicals to a dormant state.28 This reliance on a secondary species 
means that for efficient ATRP, the two components must be present in the same phases, 
without significant partitioning. For these reasons inverse miniemulsion polymerisations, 
which are simply compartmentalised aqueous polymerisations, are the most commonly 
used for heterogenous ATRP.  
This was first reported by Matyjaszewski and co-workers who prepared 200 nm 
poly(poly(ethylene glycol) methyl ether methacrylate) (P(PEGMA)) nanogels cross-
linked with a redox responsive disulphide functional dimethacrylate monomer, and were 
synthesised using a cyclohexane continuous phase.61 They highlight that the sonication 
process intended for homogenisation also results in oxidation of the active Cu(I) species 
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back to the Cu(II) complex. For that reason, the authors successfully implemented the 
activators generated by electron transfer (AGET) ATRP mechanism, using ascorbic acid 
as a water soluble reducing agent, alongside a PEG macromolecular ATRP (macro-
ATRP) initiator to limit partitioning into the oil phase. They found that their ATRP  220 
nm nanogels had better colloidal stability, almost doubled swelling ratios, and were 
degradable into individual polymer chains (Ð < 1.5), when compared to analogous 
nanogels prepared with free radical polymerisation.  
In a follow up study, these nanogels were evaluated as potential anticancer agents with 
the encapsulation of up to 16.4 wt% doxorubicin, which released steadily after 
biodegradation with tripeptide glutathione.73 The drug loaded nanogels gave reduced 
viability in in vitro studies against a cervical cancer cell line (HeLa). Further to this, they 
exploited the RDRP approach, and chain extended the initial nanogel with 2-hydroxyethyl 
acrylate (HEA) to introduce hydroxyl functionality to the nanogel surface, and 
subsequently conjugated with bioactive moiety biotin.  
 
Figure 1.3 Typical ATRP inverse miniemulsion polymerisation to produce disulphide cross-linked 
nanogels. Adapted from Matyjaszewski et al.61, 73  
As stated above, the ability to entrap hydrophilic objects within a nanogel matrix remains 
a major advantage. Matyjaszewski and co-workers have thoroughly exploited this 
property with their ATRP nanogel system. Initially they reported encapsulation of 
rhodamine modified dextran (RITC-Dx), as a model for carbohydrate therapeutics.74 
These were entrapped with over 80% efficiency, with a maximum loading of 6.4 wt%. 
Upon degradation with glutathione, the released dextran was able to bind strongly to 
Concanavalin A (ConA), causing aggregation which was monitored by an increase in 
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turbidity with UV-Vis spectroscopy. Analogous non-degradable RITC-Dx loaded 
nanogels were found to accumulate in clathrin coated pits (indicating uptake via clathrin 
mediated endocytosis) in murine osteoblast cells (MC3T3).75 This was then further 
confirmed with TEM by encapsulating gold nanoparticles. By copolymerising PEGMA 
and an RGD (integrin binding peptide) functionalised monomer, an increased cellular 
internalisation of the nanogels was observed.75 To evaluate if protein encapsulation was 
viable during such harsh preparation conditions (sonication, heating high radical flux), 
bovine serum albumin (BSA) was added into the aqueous polymerisation phase. Western-
blot analysis of lysed cells which were treated with BSA-nanogels indicated that a large 
amount of the protein remained native after nanogel preparation (Figure 1.3).75  
Instead of physical entrapment, an alternative approach to generate protein-nanogel 
hybrids was reported, whereby a green fluorescent protein (GFP) was genetically 
engineered such that a phenyl alanine bearing an ATRP initiator was introduced in a site 
specific manner.76 This was used in conjunction with the traditional PEG-ATRP initiator 
described above to produce nanogels with covalently bound GFP. Confocal microscopy 
and fluorescence spectroscopy confirmed the incorporation of 2.1 wt% GFP into the 
nanogels. When compared to physical entrapment, the authors found that no GFP was 
retained after purification, highlighting the importance of covalent attachment. This is 
somewhat contradictory to the identical BSA nanogels above which were readily retained 
after physical entrapment.75, 76  
More recently this AGET ATRP inverse miniemulsion polymerisation approach was 
exploited to produce nanogels capable of encapsulating of nucleic acids. Similar systems 
have been shown to protect these macromolecules from nucleases, potentially enhancing 
gene delivery applications.77 PEGMA was copolymerised with quarternised 2-
(dimethylamino) ethyl methacrylate (qDMAEMA) as a cationic comonomer following 
the same inverse miniemulsion approach. The resulting nanogels had a larger 
hydrodynamic diameter (275 nm) than those without qDMAEMA and a strongly positive 
zetapotential (+43.7 mV) thus making it capable of complexing plasmid DNA. They 
found w/w ratios greater than 5:1 nanogel:pDNA was sufficient to bind plasmids, and 
heparin sulfate could be used to displace it below 10:1. In contrast, siRNA required a ratio 
of at least 15:1 nanogel:siRNA for full complexation and could be displaced up to 25:1. 
Nanogel polyplexes with pDNA encoding for firefly luciferase (FLuc), and silencing 
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siRNA for Renilla luciferase (RLuc) showed comparable transfection and knockdown 
efficiencies to commercially available FuGENE-HD (Figure 1.4).77 
 
Figure 1.4 (A) ATRP inverse miniemulsion polymerisation of qDMAEMA to produce cationic nanogels 
capable of complexing both siRNA and plasmid DNA. Relative transfection efficiency of a (B) plasmid 
containing a firefly luciferase reporter gene and (C) knockdown of Renilla luciferase with siRNA. Adapted 
from Matyjaszewski et al.77 
 
Hollinger and co-workers later used these cationic nanogels to complex siRNA which 
silences Runx2 and Osx, key regulators of osteogenetic differentiation, as a potential 
treatment of heterotopic ossification (abnormal bone growth).78 In general, similar 
silencing capabilities (40-60% reduction in gene expression) were observed between 
nanogels and commercial transfection agent lipofectamine, however no cytotoxic effects 
were evident after nanogel treatment whereas lipofectamine yielded 60% cell viability.78  
 
 
 
 
 
A 
B C 
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1.2.1.2 RAFT nanogels 
In contrast to ATRP, RAFT is a degenerative chain transfer process which does not 
typically require a catalyst, and involves a chain transfer agent (thiocarbonylthio 
compounds) and an external radical source. From a biological perspective, nanogels 
synthesised using RAFT may offer significant advantages over ATRP as the synthetic 
process is simpler, and the presence of excess copper complexes (the most common 
ATRP catalysts) can be cytotoxic.79 While most biologically relevant RAFT nanogels are 
synthesised by precipitation/dispersion polymerisation of thermoresponsive polymers 
(e.g. P(NIPAM)),72 or soluble branched structures, there are a few notable examples using 
inverse miniemulsion procedures for biomedical applications. 
As common RAFT agents are fairly hydrophobic, their applicability in fully aqueous 
polymerisation can be limited. This has been overcome by preparation of hydrophilic 
macro-RAFT agents to enhance water solubility. For instance, Davis and co-workers 
report on the synthesis of cationic DMAEMA based nanogels from a hydrophilic 
P(PEGMA) macro-RAFT agent, previously prepared in acetonitrile, for gene delivery 
applications.80 Inverse miniemulsions were performed with and without macro-RAFT 
agent at 60°C, and cross-linked with a similar disulphide dimethacrylate. Interestingly 
only the RAFT inverse miniemulsion achieved over 98% monomer conversion in 6 h, 
whereas the analogous free radical polymerisation was limited to 90% within the same 
time frame. Narrow dispersity polymers (Ð < 1.3), and consistent average molar masses 
were achieved with the RAFT system, however a small proportion of the macro-RAFT 
agent remained unconsumed. In contrast, the free radical polymerisation (FRP) nanogels 
consisted of much higher molecular weight polymers, however the particles had smaller 
diameters (~100 nm), compared to the RAFT nanogels (~250 nm), both with 
zetapotentials of +42 mV which is in agreement with the ATRP nanogels described 
above. This difference in size depending on polymerisation technique may have 
significant implications on their biological activity. 80 
Klok and co-workers have reported the synthesis of poly(N-(2-
hydroxypropyl)methacrylamide) P((HPMAm)) nanogels using a similar approach.81 
P(HPMAm) is widely used in polymer therapeutics as it shows high biocompatibility, 
tuneable functionality, and is included in materials which have entered clinical trials after 
FDA approval.82 In contrast to the above study, the authors use a solvent mixture of 9:1 
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H2O:Methanol to aid solubility of their RAFT agent. A variety of RAFT P(HPMAm) 
nanogels were synthesised using different experimental conditions (DP, surfactant, 
initiator concentration, cross-linker concentration) as well as a free radical analogue 
cross-linked with a disulphide bridge. With high concentrations of initiator, quantitative 
monomer conversions were attained, yielding P(HPMAm) RAFT nanogels between 150-
200 nm in diameter and dispersities around 1.4 for the component polymers. As a proof 
of concept protein encapsulation experiment, cytochrome C (5 wt%) was added to the 
aqueous phase with 73% incorporation. Release studies showed rapid protein release 
(100% within 1 h) only after disulphide reduction with a phosphine, with none observed 
without nanogel degradation (Figure 1.5).81  
 
 
Figure 1.5 (A) Inverse RAFT miniemulsion polymerisation of HPMAm to produce disulphide cross-linked 
nanogels. (B) Atomic force micrographs of the synthesised nanogels and (C) release of encapsulated 
cytochrome C with (cirlces) and without (squares) addition of Tris(2-carboxyethyl)phosphine 
hydrochloride (TCEP) as a reducing agent. Adapted from Klok et. al.81  
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1.2.1.3 General remarks on RDRP nanogels 
As mentioned previously, inverse emulsion polymerisations are a highly favourable route 
to design fully hydrophilic nanoparticles for loading and transport of biomacromolecular 
cargo. However excess surfactant and the continuous phase (typically cyclohexane) must 
be removed prior to biological use due to inherent cytotoxicity or aqueous 
incompatibility. Surfactant use can be circumvented by utilising amphiphilic RDRP 
control agents (inistab),83, 84 however with this it is impossible to independently tune the 
colloidal stability and the molecular weight of resulting polymers. The sonication 
procedures used are unfeasible in large volume reactors and the low monomer 
concentrations used limit their scale up potential. Nanoparticle size is a key parameter in 
a variety of biomedical applications, with nanoparticles with diameters below 200 nm 
reported being most effective.85 From the above studies, it seems that RDRP inverse 
miniemulsion procedures are rarely able to produce nanoparticles below this threshold, 
potentially limiting clinical translation. Additionally, the above RDRP nanogel 
assemblies use proteins such as BSA and cytochrome C, which are relatively tolerant to 
extreme conditions such as sonication, heating and solvents during purification. 
Therapeutic proteins under these conditions could easily denature thus rendering them 
inactive thus reducing efficacy. In general, RDRP techniques have been shown to 
improve release rate and targeting potential through chain extension with functional 
moieties, however as of yet have not improved synthetic issues limiting their biological 
use.  
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1.2.2 Conventional Miniemulsion polymerisation 
Conventional miniemulsion polymerisation occurs within sub-500 nm monomer droplets, 
stabilised by surfactant. This results in the formation of solid hydrophobic particles 
potentially capable of encapsulating hydrophobic drugs for controlled delivery. While 
some examples of ATRP and NMP miniemulsion polymerisation have been reported,59, 
60, 62-64, 86, 87 none are for biological purposes, with RAFT being the most favoured option 
for this application due to its compatibility with many monomer families, and is easily 
translated from traditional free radical systems, simply by addition of a suitable RAFT 
agent.  
Introduction of glycosylated moieties at the particle surface has been shown to 
significantly improve disease targeting and cellular uptake, especially in immune cells.88, 
89 Yaacoub and co-workers reported the RAFT miniemulsion polymerisation of protected 
glucose and fructose methacrylates, with a subsequent chain extension with either methyl 
methacrylate (MMA) or butyl methacrylate (BMA).90 Polymerisations were attempted 
with three different RAFT agents, with one yielding significantly narrow dispersities, as 
low as 1.10 and particle diameters between 150 and 350 nm. Nonetheless no biological 
characterisation (lectin binding, toxicity etc) were reported, possibly due to the large 
quantities of surfactant present in the polymerisation mixture.90 
It is desirable to avoid conventional surfactants during nanoparticle synthesis, and such 
‘surfactant free’ systems, which use amphiphilic macro-RAFT agent stabilisers are 
prevalent within this field. While not specifically for biological applications, Clavier and 
co-workers report on the RAFT miniemulsion copolymerisation of styrene and various 
boron-dipyrromethene (BODIPY) monomer types (styrenic, acrylate, methacrylate) to 
produce fluorescently labelled nanoparticles.91, 92 This approach used a poly(ethylene 
oxide)-b-(acrylic acid)  (PEO-b-PAA) macro-RAFT agent as the stabiliser and therefore 
avoids the use of conventional surfactants. Depending on the analogue of BODIPY 
monomer used in the polymerisations, some particles were up to 2000 times brighter than 
typical quantum dots, and as such could be useful in bioimaging applications.91 It should 
be noted however that quantum dots are significantly smaller than the nanoparticles 
synthesised here (> 60 nm diameters), which would impact their circulation time. 
An elegant approach which combines miniemulsion polymerisation with nanogel 
formation was described by Stenzel and co-workers using a P(PEGMA)-b-
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P(DMAEMA)-b-P(t-BMA) macro-RAFT agent stabiliser.93 This was chain extended 
with miniemulsion polymerisation using t-BMA and crosslinked with different ethylene 
glycol dimethacrylate (EGDMA) amounts (10, 20 or 30%) resulting in nanoparticles with 
roughly 200 nm diameters. Hydrolysis of the tert-butyl methacrylate cores with 
trifluoroacetic acid yielded swollen P(MAA) nanogels with varying cross-linking 
densities. The anionic core was then used to encapsulate large quantities (50 wt%) of 
anticancer therapeutic doxorubicin with electrostatic interactions, also enabling almost 
quantitative drug loading efficiencies. In release studies, they found that addition of acid 
shrunk the P(MAA) core and swelled the P(DMAEMA) shell resulting in a gated 
squeezing effect releasing over 90% of the encapsulated drug. This translated into a lower 
IC50 concentration for the drug loaded nanoparticles compared to free doxorubicin, which 
is exceptionally difficult to achieve (Figure 1.6).93  
 
 
Figure 1.6 (A) Conventional miniemulsion polymerisation of tert-butyl methacrylate stabilised by a 
P(PEGMA)-b-P(DMAEMA)-b-P(t-BMA) macro-RAFT agent and subsequent hydrolysis with 
trifluoroacetic acid to produce pH gated nanogels. (B) TEM images of P(t-BMA) latexes and (C) release 
of loaded doxorubicin at pH 5.0 and 7.4. Adapted from Stenzel et al.93  
A
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The lack of RDRP miniemulsion polymerisation systems for biologically relevant 
nanoparticles may arise from rising popularity of other techniques yielding similar core-
shell structures without the limitations of miniemulsion polymerisation. For instance, the 
requirement of high shearing limits the scalability of this process in comparison to 
polymerisation-induced self-assembly or conventional emulsion procedures (vide infra). 
Furthermore, the effect of molecular weight control may not influence any biological 
activity, as particle size and surface functionality are controlled by shearing and surfactant 
composition. This may then render FRP and RDRP latexes identical when using 
surfactant stabilised miniemulsion polymerisation, and therefore the added complexity of 
RDRP agents may be redundant. However, a key advantage of RDRP techniques here is 
the introduction of particular functionality at the particle surface, and the evasion of 
conventional surfactant use to improve potential biocompatibility. 
 
 
1.3 Dispersion polymerisation 
 
Figure 1.7 Mechanism of aqueous dispersion polymerisation. I = initiator species, yellow = monomer, blue 
= aqueous phase, red = polymer phase. 
In contrast to other heterogeneous systems, in dispersion polymerisations all of the 
components (monomer, chain transfer agents, initiator) are soluble in the continuous 
phase at the start of the reaction.40 The phase separation then occurs during the 
polymerisation, where the polymer chains reach a critical chain length then become 
insoluble in the continuous phase and precipitate resulting in particle formation (Figure 
1.7). Common RDRP dispersion polymerisations have manifested themselves as a type 
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of polymerisation-induced self-assembly (PISA), which is where a solvophilic unit is 
chain extended with a block which selectively precipitates leading to self-assembled 
nano-objects coated in the initial solvophilic block (Figure 1.8).94 The resulting 
morphologies are then dependent on the solvophobic/solvophilic volume ratio, and are 
often similar to those found using conventional selective solvent self-assembly 
procedures.95, 96  Typically PISA is performed by taking a single solvophilic 
homopolymer and throughout the elongation of the second solvophobic block, the 
morphology reorganises from spheres, to worms, to vesicles and in some cases to lamellae 
as the polymerisation ensues. The in situ self-assembly allows for a much higher solids 
contents (up to 40%) in comparison to conventional self-assembly. Unfortunately, very 
few monomers have been found to display this phenomenon. Many RDRP dispersion 
polymerisations have been reported including NMP,97 ATRP,98  cobalt mediated 
polymerisation (CMP),99 and organotellerium-mediated radical polymerisation 
(TERP),100 however RAFT remains the most popular approach and is the only method 
used for biologically relevant particles. Aspects such as particle morphology, particle size 
and core/shell compositions can be easily tuned using RAFT, and as such, PISA is highly 
attractive from a biological standpoint either for fundamental studies or specific 
applications.  
 
Figure 1.8 Generalised representation of RAFT polymerisation-induced self-assembly from a solvophilic 
macro-RAFT agent by chain extending with a monomer which upon polymerisation becomes solvophobic 
inducing self-assembly into spherical, worm and vesicle morphologies. Adapted from Armes et. al.94   
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1.3.1 Fundamental biological studies 
The design of biomedical nanoparticles is often led by fundamental studies identifying 
the effect of individual physico-chemical properties (size, shape and surface 
functionality)85, 101 on cellular uptake, biodistribution and pharmacokinetics. Non-
spherical nanoparticles have attracted significant interest as many reports suggest they 
have improved cellular uptake and circulation time, and therefore greater therapeutic 
efficacy compared to spherical counterparts.22 As such, PISA represents a promising 
method to probe this feature as morphology can be easily tuned without significantly 
affecting their surface chemistry which is also known to heavily influence biological 
performance. 
 
Figure 1.9 Block copolymers produced using polymerisation-induced self-assembly in alcoholic medium 
for biological applications. Green = functional group used for specific application, blue = solvophilic block, 
red = solvophobic block.  
Boyer and Davis report RAFT PISA of styrene from a P(PEGMA) macro-RAFT in 
methanol, where styrene is soluble but polystyrene is insoluble.102 As expected 
nanoparticle morphology evolved from spheres through to polymersomes with increasing 
monomer conversion. When relating the DP of styrene to the resulting morphology, it 
became apparent that isolating individual morphologies, particularly high aspect ratio 
particles was non-trivial as mixed morphologies could be seen at various chain lengths. 
To probe the in situ encapsulation of a model hydrophobic drug Nile Red was added at 
the start of the polymerisation. UV-Vis analysis showed higher encapsulation with longer 
101 
102 
103 
107 
106 
108 
Ref. Ref. 
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PS chain length (i.e. higher conversion), and Nile Red concentrations over 10 fold of that 
found in the methanol highlighting their potential use in drug delivery.102 
In a subsequent study, styrene was copolymerised with vinyl benzaldehyde (VBA) during 
the PISA process to produce pH-responsive pro-drug imine containing nanoparticles with 
doxorubicin to evaluate the effect of morphology on drug delivery efficiency.103 Narrow 
particle size distributions and the expected morphologies were produced depending on 
styrene chain length. Perhaps one of the major disadvantages in this approach is that large 
DP’s e.g. 5000 were targeted, and therefore specific morphologies were formed at very 
low monomer conversion (< 20%). This meant that extensive purification was necessary 
to fully remove monomeric styrene and methanol before use in biological studies. 
Nonetheless, cellular studies with nanoparticles carrying a 5 wt% drug load indicated 
significantly higher cellular uptake for rod and worm-like micelles,  which yielded the 
lowest IC50 values (0.796 and 0.302 µM for rod and worm-like nanoparticles 
respectively).103 
In a similar approach, Pan and co-workers performed PISA with an aldehyde functional 
methacrylate from a P(DMAEMA) macro-RAFT agent in ethanol for post-
functionalisation.104 In contrast to the above studies, the particle morphology was 
controlled by targeting different solvophobic chain lengths (50, 100, 150, 200 and 250), 
each reaching full monomer conversions in 18 h. Although this eliminated the need to 
remove unconsumed monomer, purification was still necessary to remove the ethanol 
continuous phase. All of the resulting nanoparticles, regardless of morphology, had a 
smaller total diameter, as measured by dynamic light scattering (DLS), below 200 nm, 
which is the cited upper limit for endocytosis.105 Doxorubicin loading was achieved using 
Schiff base formation, which naturally increased with longer aldehyde chain lengths 
reaching up to 16.2 wt%. Similar to the studies described above, DOX-loaded nanorods 
displayed the greatest cytotoxic effects against HeLa cells in comparison to spheres and 
vesicles, however longer nanowires showed minimal activity. This was rationalised with 
cellular uptake studies which indicated that nanorods had greater lysosomal (low pH 
compartment) residence time, thus improving drug release potential.104  
The study of doxorubicin release was further investigated by Gooding and Gaus using 
pair correlation microscopy to probe the intracellular trafficking and site of drug release 
for different shaped nano-objects.106 In this work, similar nanoparticles to those reported 
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by Davis and co-workers were prepared instead with a PS-co-P(VBA) core. Their 
findings indicated that worm and rod-like materials passively enter the nucleus in a five-
fold higher amount than spherical and vesicular systems. Furthermore, attachment of 
nuclear localising peptides resulted in much greater doxorubicin release within the 
nucleus and enhanced cytotoxic effects.106  
Many of the above studies use relatively simple block copolymer compositions 
(P(PEGMA)-b-PS) for nano-object synthesis (Figure 1.9). As dispersion polymerisations 
begins in solution, complex functionality can be introduced through the copolymerisation 
of functional monomers when preparing the solvophilic block which can be further 
utilised for specific biological applications. Kaminskas and Whittaker reported the first 
fundamental in vivo study on particle morphology using nano-objects decorated with 
functional groups generated via PISA.107 In this work, a hydrophilic diblock copolymer 
of poly(glycidyl methacrylate-b-P(PEGMA)) was synthesised to introduce amine 
reactive functionality to the particle surface. Dispersion polymerisation of styrene in 
methanol was then used to generate various nanoparticle morphologies with an amine 
reactive epoxide surface, which were subsequently ring-opened with a tritium labelled 
(3H) ethanolamine for radiolabelling. Biodistribution studies indicated significantly 
higher accumulation in reticuloendothelial organs (liver, spleen) for worms and rods, 
however small 21 nm micelles showed much greater association with tumour tissue.107  
Drug delivery and cancer therapy are not the only applications in which nanomaterials 
can excel within biomedicine. The long circulation times and non-specific biodistribution 
exhibited by these structures makes them ideal imaging agents. In particular there are now 
a number of reports describing dispersion polymerisation to produce nano-objects for 
magnetic resonance imaging (MRI) and the effect of morphology on their contrast.  
Whittaker and co-workers report the synthesis of block copolymer nano-objects with a 
fluorine containing monomer as potential 19F MRI contrast agents.108 The authors 
describe that fluorine density is a major parameter in MRI performance and therefore 
different morphologies may yield different contrasts. Initially a range of PEGA and 
trifluoroethyl acrylate (TFEA) copolymers were synthesised with different feed monomer 
compositions, with relaxivity studies indicating 2.68 wt% TFEA as optimum to avoid 19F 
association. Dispersion polymerisations of styrene and VBA were then performed in 
isopropanol, targeting a total DP of 5000 stopping at 4.4 (spheres), 11.3 (worms), 17.2 
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(vesicles) and 22.5% (compound vesicles) styrene conversion to isolate individual 
morphologies. Relaxivity studies of block copolymer nanoassemblies suggested that T1 
and T2 relaxation was independent of morphology.108  
In a different approach, Davis and co-workers adapted their epoxide functional macro-
RAFT agents to introduce gadolinium chelates into their nano-objects as potential MRI 
contrast agents.109 Polystyrene nano-assemblies were prepared in methanol as described 
above. Prior to gadolinium functionalisation, the epoxide functionality was modified with 
thiols to generate azide functional particles, highlighting the tuneable functionality 
possible with RAFT dispersion. Amine functional Gd-tetra-azacyclododecatetraacetic 
acid (Gd-DOTA) was used to ring open the surface functional epoxides on spherical, 
worm and vesicle nanoparticles. Similarly to Whittaker and co-workers, little difference 
in relaxivity was evident between morphologies.109 
In an earlier study, Davis and Boyer used dispersion polymerisation to generate 
nanoparticles containing iron-oxide nanoparticles which are well-known MRI contrast 
agents.110 In a versatile approach, Fe(II) and Fe(III) salts were fed to aqueous solutions 
of spheres, worms and vesicles which bound electrostatically to the methacrylic acid 
moieties introduced into the macro-RAFT agents. Subsequent addition of ammonia 
resulted in precipitation of iron oxide on the surface of the nanoparticles. Interestingly the 
size of the resulting iron oxide nanoparticles could be tuned by increasing the MAA 
content of the solvophilic sections. In contrast to the above studies, micellar morphologies 
gave the highest transverse relaxivity (r2 = 582 mM-1 s-1), several times higher than 
commercially available contrast agent Feridex (r2 = 100 mM-1 s-1) .110  
1.3.2 Aqueous dispersion polymerisation 
All of the above studies use RAFT dispersion polymerisation within an alcoholic 
medium, which requires extensive purification typically through dialysis before 
biological use. Early developments of aqueous RAFT dispersion polymerisation were 
reported by Hawker and co-workers who described polymerisation of N-
isopropylacrylamide to generate block copolymer micelles in situ.111 Following this 
study, a number of different monomers, such as diethyl acrylamide (DEAm),112 2-
methoxyethyl acrylate (MEA)113, 114 and di(ethylene glycol) methyl ether methacrylate 
(DEGMA)115 were also shown to be capable of dispersion polymerisations, usually 
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utilising the thermoresponsive behaviour of their respective polymers (Figure 1.10). The 
above systems were only capable of producing spherical systems, however over the past 
eight years it has been established that morphological controlled assemblies can easily be 
achieved using other core forming monomers such as 2-hydroxy propyl methacrylate 
(HPMA),96, 116 diacetone acrylamide (DAAm)117-119 and NIPAM (Figure 1.10).120 This is 
potentially useful for biomedical applications, as the formed nano-objects could be 
injected directly for therapy, bolstered by compartmentalisation effects resulting in a 
rapid increase in polymerisation rate and high monomer conversions. Furthermore, the 
cost, abundance and high boiling point of water make this an attractive solvent from an 
industrial perspective potentially enabling scale up of aqueous dispersion 
polymerisations. Given this, a number of aqueous PISA formulations have been 
employed to generate biologically relevant nanoparticles.  
 
 
Figure 1.10 Monomers used for the core-forming block of aqueous dispersion polymerisation-induced self-
assembly.  
Aqueous dispersions of HPMA have been widely used due to its robust control over 
individual morphologies.96, 116, 121-126 Chain extension of a poly(glycerol methacrylate) 
(P(GMA) macro-RAFT agent with HPMA of three different chain lengths (90, 140 and 
220) yielded the conventional sphere, worm, vesicle morphologies.121 Importantly, 
quantitative monomer conversions were observed within 2 h. Upon cooling to room 
temperature, the P(GMA)54-P(HPMA)140 worm-like assemblies formed a soft malleable 
gel at 10 wt% due to worm-worm entanglements. Interestingly further cooling to 4°C 
2-Hydroxypropyl 
methacrylate 
(HPMA)  
N,N-Diethylacrylamide 
(DEAm) (2-Methoxyethyl) acrylate 
(MEA) 
Di(ethylene glycol) methyl 
ether methacrylate 
(DEGMA) 
Diacetone acrylamide 
(DAAm) 
N-isopropylacrylamide 
(NIPAm) 
N-acryloylthiomorpholine 
(NAT) 
 
 
22 
 
resulted in a free flowing solution, which was later found be due to a worm to sphere 
transformation. The authors postulated that such a system could be used as a 
thermoresponsive biological storage medium, which can be sterilised by degelation and 
passing through a typical 0.45 µm filter upon degelation. To probe this the free flowing 
dispersion was contaminated with fluorescently labelled S. aureus and after sterilisation 
negligible contamination was observed. Furthermore the worm-gels were found to be 
fully biocompatible in cell viability assays.121 
In two follow-up publications, this system was shown to be versatile in a number of 
biological applications as a potential replacement for cryopreservation. In one study, the 
authors used the worm-gels as mucin mimics which are known to induce stasis of 
mammalian embryos consisting of pluripotent stem cells in utero.122 Storage of human 
embryos within these worm gels showed significantly greater stability than those in a 
commercially available alternative (Matrigel). Remarkably a high degree of a nuclear 
envelope statin was observed through immunostaining experiments, suggesting cell stasis 
within these conditions. When repeated with only pluripotent stem cell colonies, the 
majority of cells continued to express pluripotency markers rather than those for 
differentiation. The promising results observed are clearly related to the close mucin-
mimicry available (worm-like and hydroxyl rich) through PISA and RAFT dispersion 
polymerisation.122  
Gibson and co-workers have previously shown that polyalcohols are capable of 
mimicking anti-freeze glycoproteins in solvent-free cryopreservation of biologics.127 This 
was recently expanded to use the above HPMA worm-gel system.124 Ice recrystallization 
inhibition studies with worm-gels indicated limited activity, and neither ice growth nor 
nucleation was promoted in these conditions. Interestingly, the worm-gels alone only 
resulted in 20% red blood cell recovery, however a cooperative effect between the worms 
and poly(vinyl alcohol) (PVA) was apparent resulting in over 60% erythrocyte recovery 
with no indication of haemaglutination or abnormal cell shape.  
In the above cases, control over the surface monomer composition was critical to their 
performance in the desired applications. This approach has been employed to introduce 
biologically active moieties. Armes and co-workers described simultaneous co-PISA 
from the previous P(GMA) macro-RAFT agent, and a novel glycosylated poly(galactose 
methacrylate) macro-RAFT agent using HPMA as the core-forming block forming 
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assemblies containing different degrees of galactose at the surface.123 Similar to other 
studies, the dispersions display reversible thermoresponsive gelation between worm and 
spherical assemblies, albeit with less rheological hysteresis than the previous example. 
Lectin binding studies indicated a much faster and greater response from worms and 
vesicles than the respective spherical nanoparticles, which likely contributed to the strong 
cellular uptake observed in live HDF cells.123  
In an inspiring strategy, Huang and co-workers describe protein coated block copolymer 
assemblies via PISA by modifying BSA with an N-hydroxysuccinimide functionalised 
RAFT agent capable of reacting with lysine residues.128 This was then used as the 
solvophilic block and chain extended with HPMA using a mild low temperature light 
activated RAFT to avoid denaturation of the protein during polymerisation. In this case 
however only spherical nanoparticles, albeit with increasing size, were obtained as the 
P(HPMA) chain length increased. Importantly by monitoring the hydrolysis of 4-
nitrophenyl acetate, it was observed that the esterase activity of BSA was retained, and 
the hydrophobic nature of the core was used for encapsulation of a hydrophobic drug 
model, pyrene.128 
1.3.3 Stimuli responsive nano-assemblies 
 
Figure 1.11 Oxidation responsive micelles synthesised by polymerisation-induced self-assembly of N-
acryloylthiomorpholine from a poly(N-acryloylmorpholine) macro-RAFT agent. Adapted from Brendel et 
al.129  
One of the major problems in nanoparticle drug delivery is that most therapeutics can be 
cytotoxic in any area of the body, causing adverse side effects once released from its 
carrier. This has typically been overcome through introduction of functionalities which 
have either a chemical or physical transition after treatment with a particular stimulus.130 
This can either be an external stimulus, such as temperature or light, which can give 
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spatial control over the site of drug release, or using endogenous biochemical stimuli such 
as the low pH and high glutathione content found in cancer tissue. Such a stimuli-
responsive nature has been incorporated into dispersion polymerisations through 
copolymerisation of functional monomers. 
With this in mind, Pan and co-workers report a redox-responsive system using PISA for 
delivery of a topoisomerase inhibitor camptothecin (CPT).131 A disulphide functional 
prodrug containing solvophilic block copolymer was chain extended with benzyl 
methacrylate and a disulphide cross linker as the core-forming block to form 35 nm 
spherical micelles. All of the polymerisations reached full monomer conversion negating 
the need for extensive purification. The covalent drug-monomer approach allowed for 
high (12.8 wt%) drug content, and when incubated with 10 mM GSH (cytosolic 
concentration), 40% drug release occurred over 48 h. Although high loading was 
obtained, IC50 values of the micelles against HeLa cells were found to be between 6-7 µg 
mL-1 which is significantly higher than values reported for free CPT (0.08 µg mL-1).131, 
132 
In a second study, a photo-sensitive system using 2-nitrobenzyl methacrylate (NBMA) 
and a coumarin methacrylate was developed.133 In this work the above monomers were 
chain extended from a P(HPMA) macro-RAFT agent to form spherical, worm-like and 
vesicle nano-objects in methanol as previously described. Upon photoirradiation (UV 365 
nm) it was expected that the nitrobenzyl unit of NBMA would cleave and become a 
carboxylate group, and subsequently cause disassembly of the nano-objects. However, 
inclusion of the coumarin groups resulted in their dimerization as subsequent chain-chain 
cross-linking producing anionic nanogels. This strong transition from hydrophobic to 
hydrophilic was exploited for fast and efficient release of doxorubicin from each of the 
morphologies generated. The vesicle assemblies had the greatest cytotoxicity in 
comparison to worm-like and spherical morphologies.133  
Brendel and co-workers, report an oxidation responsive system as a possible vector to 
inflammatory disorders which exhibit increased levels of reactive oxygen species.129, 134 
By chain extending an N-acryloylmorpholine (NAM) macro-RAFT agent with N-
acryloylthiomorpholine (NAT), a PISA process ensued resulting in 25-75 nm spherical 
micelles depending on the comonomer composition. After incubation with 10 mM 
hydrogen peroxide the thiomorpholine solvophobic block oxidised into a hydrophilic 
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polysulfoxide, resulting in particle disassembly. This was further probed by the reduction 
of fluorescence intensity of a model hydrophobic drug, Nile Red, which was released 
after treatment with hydrogen peroxide, highlighting this systems potential use for drug 
delivery (Figure 1.11).129  
1.3.4 Biomacromolecule encapsulation 
As discussed in the previous section, delivery and transportation of biomacromolecules, 
such as therapeutic proteins are a potential alternative to small molecule drug delivery. 
Polymeric vesicles (polymersomes) have been shown as promising carriers for enzymes, 
proteins and antibodies due to their large hydrophilic compartment.135 Typically 
polymersomes are prepared at low polymer concentrations and with organic solvents, 
using traditional self-assembly methods95 or thin-film rehydration136 of block copolymers 
which becomes problematic at large scales. In the above sections, we have highlighted 
how PISA can be used to produce a variety of morphologies including polymersomal 
vesicles, which may be able to encapsulate cargo in high quantities. Traditional PISA 
protocols are an adaptation of conventional RAFT polymerisations, and as such are 
performed at high temperatures (e.g. 70°C), which could lead to denaturation of 
biological materials. This has been overcome by low temperature PISA protocols, such 
as redox initiation,113 however many of these examples only resulted in spherical 
morphology. Boyer and co-workers reported on the photoinduced PISA of HPMA from 
a PEGylated macro-RAFT agent able to produce spheres worms and vesicles. This 
approach has been extended in three separate studies for protein encapsulation and 
subsequent biological applications.125  
Zhang and co-workers describe an adaptation of Boyer and co-workers HPMA photo-
PISA, where at HPMA concentrations > 15 wt%, higher order morphologies, including 
vesicles could be prepared.137 Using this system full monomer conversions were achieved 
in under 30 mins irradiation. As a proof of concept for encapsulation, fluorescein labelled 
BSA was added into the PISA formulations, which remained 90% active as determined 
by the hydrolysis of 4-nitrophenyl acetate. Interestingly the BSA encapsulated within the 
polymersomes was 65% more active than BSA heated to 70°C, similar to that if the 
polymerisation was conducted with thermally initiation.137  
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Such polymersome-protein hybrids can also be used as enzymatic nanoreactors assuming 
that the membrane is permeable to small molecule substrates. This approach was studied 
by Gibson and co-workers who utilised the above HPMA photo-PISA technique to 
generate separate glucose oxidase (GOx) and horseradish peroxidase (HRP) loaded 
vesicles with encapsulation efficiencies of around 25%.138 First proof of concept 
experiments, showed that HRP vesicles could catalyse the oxidation of 3,3’-
dimethoxybenzidine (DMB) despite the substrates residence in the external medium, 
indicating the vesicle membranes were permeable to small molecules. Furthermore, using 
the GOx and HRP loaded vesicles, D-glucose was metabolised into d-glucono-1,5’-
lactone, producing hydrogen peroxide as a by-product which facilitated the catalytic 
oxidation of DMB by HRP within a separate vesicle (Figure 1.12), highlighting how 
multiple enzymes can be used in a cascade even though they are physically seperated.138  
The above strategy was further utilised by Gibson and O’Reilly in which L-asparaginase 
(ASNS) was encapsulated into the permeable vesicles as a possible treatment for 
lymphoblastic leukaemia. Importantly, the ASNS loaded vesicles showed excellent 
stability towards proteolysis from α-chymotrypsin, whereas free ASNS and PEGylated 
ASNS had no activity after the same treatment. To test this effect in vitro, human lung 
cancer fibroblasts were silenced to inhibit ASNS activity, thus rendering the cells reliant 
on the treated ASNS loaded vesicles for proliferation. In vivo biodistribution studies of 
the ASNS loaded vesicles showed accumulation within the typical organs for nanoparticle 
systems (spleen, liver, kidneys) and slower clearance in comparison to the free enzyme.139  
 
Figure 1.12 Encapsulation of proteins and enzymes using photo-PISA of HPMA to produce permeable 
catalytic polymersomes. Adapted from O’Reilly et al.138 
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Over the last 5-7 years RAFT dispersion polymerisations in the form of PISA has made 
nanoparticle formation more accessible than ever before. The ability to modulate surface 
and core chemistries, as well as particle morphology in one-step has made this particularly 
attractive for fundamental or application driven research at the biological interface. 
Recent synthetic advances now mean that these systems can easily be generated in 
aqueous conditions with no by-products (100% monomer conversion), in low temperature 
and oxygenated conditions.140, 141 Nonetheless, the limited number of core-forming 
monomers capable of aqueous PISA mean that introduction of stimuli-responsivity is a 
challenging prospect, unlike in traditional self-assembly processes. Furthermore, what is 
clear from PISA oriented literature is that the resulting spherical particles are relatively 
small (< 30 nm diameter)94 and unlike in emulsion systems (vide infra), altering the 
molecular weight of the core forming block typically does not modify particle size 
without a morphological transformation, which is not suitable for all applications. Even 
still, if worm-like or polymersomal morphologies are required from novel/unreported 
block copolymer compositions, one must perform the arduous task of producing a 
pseudo-phase diagram by mapping the morphologies of the resulting nano-objects by 
solvophobe chain length and total solids content.  
 
1.4 Suspension polymerisation 
Suspension polymerisations take place within micron sized monomer droplets, using a 
monomer soluble initiator stabilised by conventional surfactants.41 They are similar to 
miniemulsion polymerisations in the sense that they are essentially compartmentalised 
bulk polymerisations, however are dispersed with agitation only and not with sonication 
(Figure 1.13). This typically results in the formation of microparticles (> 1 µm diameter) 
decorated with the surfactants present during the polymerisation. While this chapter is 
focussed on the synthesis of biologically relevant nanoparticles (not micron sized) using 
RDRP, an interesting approach to generate non-spherical nanoparticles has arisen using 
a post-polymerisation strategy pioneered by Monteiro and co-workers using RAFT 
suspension polymerisation.142 As mentioned in the previous section, the formation of non-
spherical, elongated nanoparticles is becoming increasingly important due to their longer 
circulation time and thus greater therapeutic efficacy compared to spherical analogues. 
This approach operates on the use of a thermoresponsive macro-RAFT agents which 
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collapse and become hydrophobic during the high temperatures (70°C) of suspension 
polymerisations. Upon cooling the macro-RAFT agent swells within the aqueous phase, 
and after addition of a small amount of plasticiser, the 1-2 µm spheres transform into long 
worm-like fibrils stabilised by the thermoresponsive shell. Notably in many of the works 
which use this technique, it is mistakenly called a dispersion or emulsion polymerisation 
whereas it is actually a suspension polymerisation.  
 
Figure 1.13 Mechanism of suspension polymerisation. I = initiator species, yellow = oil/monomer phase, 
blue = aqueous phase, red = polymer phase. 
Davis and co-workers have expanded on this approach using poly((diethyleneglycol) 
methyl ether methacrylate)-co-(HPMA) (P(DEGMA)-co-(HPMA)) macro-RAFT agents 
with P(DEGMA) being the thermoresponsive component.143 Following suspension 
polymerisation of styrene droplets stabilised by sodium dodecyl sulfate (SDS), 1 µm 
polystyrene block copolymer spheres were generated, and after cooling and addition of 
different volumes of toluene (20-160 µL mL-1) polymeric nanowires, vesicles and 
lamellae were produced (Figure 1.14). Interestingly, as seen in other supramolecular 
systems, sonication could be used to cut the nanowires into much shorter rod-like 
structures. To expand the scope of this approach Davis and co-workers have now shown 
it is possible to achieve these nano-objects with a variety of polymer cores in multigram 
quantities, and showing high biocompatibility in human endothelial (HUVEC) and 
fibrosarcoma (HT1080) cells regardless of morphology.143, 144  
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Although this technique allows for control over nanoparticle morphology, the specific 
thermoresponsive shell composition required to achieve this phenomenon severely limits 
surface functionality available for further modification. Furthermore, the requirement of 
external cytotoxic surfactants and organic solvents mean that lengthy purification 
procedures must be performed before biological studies, also limiting potential scale-up. 
Relatively little biological work (only cell viability) has been reported using nanoparticles 
prepared with this particular technique thus far. However, it is easy to see that molecular 
drug delivery, bioimaging and other applications not requiring biologics (which may 
denature in the presence of surfactant and organic solvent), could be achieved using this 
approach. Aqueous dispersion polymerisations (as discussed above) can achieve many of 
the same properties (morphology control, tuneable surface and core composition), but can 
be performed in the absence of surfactant and at low temperatures, possibly making this 
suspension polymerisation method less useful. 
 
Figure 1.14 Suspension polymerisation of styrene from a hydrophilic thermoresponsive macro-RAFT 
agent. Upon addition of different volumes of toluene (0, 20, 40, 80 and 160 µL mL-1) and cooling to room 
temperature various morphologies were formed. Adapted from Davis et. al.143  
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1.5 Emulsion polymerisation 
In a typical emulsion polymerisation, the initial reaction mixture is comprised of 
micrometre sized monomer droplets which are immiscible in the aqueous continuous 
phase, surfactant micelles and a water soluble initiator.39 Particles are generated first 
through monomer propagation in the aqueous phase, forming hydrophobic Zmers which 
subsequently nucleate micelles (or self-nucleate in surfactant free emulsion 
polymerisations). Particle growth ensues during polymerisation of monomer which is 
continuously diffusing from monomer droplets into the surfactant micelles, which when 
complete, results in surfactant coated solid latex nanoparticles. This process has been 
implemented using free-radical polymerisation for decades to generate vinyl polymers at 
large scales and in environmentally friendly conditions. The compartmentalisation effect 
enables fast propagation rates, high monomer conversions and importantly low 
termination rates resulting in high molecular products.39 Due to these key advantages, 
especially for industrial applications, much work has gone into translating RDRP 
techniques to emulsion polymerisation. However, the complex monomer and radical 
transfer mechanisms mean that RDRP methods cannot be implemented in ab initio 
emulsion polymerisations by simply adding in a control agent. 
In general, early studies to implement RDRP methods in emulsion processes resulted in 
one or more of the following drawbacks: (1) poor colloidal stability of the resulting latex; 
(2) lack of control over the molar mass, and (3) high Mw/Mn values.44 This was overcome 
by implementing stabilising amphiphilic macroinitiators, which were chain extended in 
the emulsion polymerisation and avoids the use of external surfactant. This was first 
pioneered by Hawkett and co-workers who used poly(acrylic acid)-b-poly(n-butyl 
acrylate) macro-RAFT agent micelles to seed a RAFT emulsion polymerisation of n-butyl 
acrylate (n-BA) leading to colloidally stable uniform block copolymer nanoparticles (Dh 
= 60 nm, PDi < 0.01) which are coated with P(AA) at their surface (Figure 1.16).145, 146 
After dissolution in organic solvent, the block copolymers displayed narrow molecular 
weight distributions (Ð < 1.3) and excellent molecular weight control. This tactic was 
further implemented using NMP (poly(acrylic acid) based macroalkoxyamines) however 
little progress has been made on this topic since 2008, possibly due to its incompatibility 
with methacrylates.147-150 One successful approach, prior to the first reports of RAFT, was 
using methacrylate end-group addition fragmentation chain transfer agents, which have a 
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very low chain transfer constant in solution. However, in the confined space and low 
monomer concentrations of emulsion polymerisation, they become excellent chain 
transfer agents.151 In contrast, ATRP emulsion procedures have mainly focussed on 
inistabs (amphiphilic surfactant-like ATRP initiators) and water soluble initiators using 
either conventional ATRP or ARGET ATRP.152-155 Many examples utilising these 
approaches unfortunately led to broad particle size distributions and unsatisfactory 
molecular weight control likely due to phase separation of the transition metal catalyst 
from the ATRP initiator.53 As such the degenerative chain transfer mechanism of RAFT, 
and its compatibility with most monomer families, have led to this technique being the 
most popular RDRP emulsion polymerisation method and has now been expanded to a 
large range of monomers and stabilisers (cationic, anionic and neutral).156 Many of these 
studies focus on synthetic aspects (kinetics and morphology control)157-159, however some 
features could be useful in designing nanoparticles for biological applications. 
 
Figure 1.15 Mechanism of emulsion polymerisation (1) reaction mixture, (2) initiation phase, (3) 
propagation and diffusion of monomer from monomer droplets to growing particles, (4) final latex particles. 
I = initiator species, yellow = oil/monomer phase, blue = aqueous phase, red = polymer phase. 
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1.5.1 RAFT emulsion polymerisation 
Particle size has been shown to drastically influence biological performance, affecting 
nanoparticle cellular uptake, biodistribution and thus potential therapeutic efficacy.85 
Even though most reports on RAFT emulsion polymerisations yields only spherical 
morphologies the resulting nanoparticles are highly uniform over different size ranges 
(30-200 nm diameters).85 Davis and co-workers have previously shown that particle 
volume has a linear relationship with the molecular weight of the polymeric core and as 
such can be tuned during the core-forming step.160 The particle sizes produced by RAFT 
emulsion polymerisation are significantly larger than those produced by dispersion 
polymerisations (<30 nm diameters), which may make the former more useful in vivo by 
reducing their susceptibility to renal clearance.161  
 
Figure 1.16 Schematic representation of RAFT emulsion polymerisation using an amphiphilic macro-
RAFT agent stabiliser. Adapted from Hawkett et. al.146  
As with the dispersion PISA formulations previously described, the stabilising macro-
RAFT agents in RAFT emulsion processes are imparted at the particle surface. Stenzel 
and co-workers were the first to exploit this approach for biological applications, through 
the introduction of glycosylated moieties, which are known to improve disease targeting 
and bacterial interactions in vivo, when present at the particle surface.162 To achieve this, 
poly(glucose methacrylamide)-b-PS was used to stabilise the emulsion cross-linking 
copolymerisation of styrene and a redox responsive disulphide diacrylate monomer. The 
resulting nanoparticles were produced within 6 h, were fairly uniform (PDi < 0.2) and 
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within a biologically relevant size range (50-80 nm diameters). While the particles did 
disassemble after dithiothreitol addition (DTT), this did not occur in an aqueous 
environment but had to be pre-swollen in organic media making this response unsuitable 
for redox responsivity in vivo. Nonetheless, turbidimetric binding assays revealed a strong 
binding event to lectin Con A, with similar performances evident in bacterial adhesion 
studies. Importantly the RAFT emulsion polymerisation approach yields a particle 
whereby the polymeric corona is covalently attached to the nanoparticle core, thus cannot 
desorb in vivo potentially inducing toxicity or other negative side effects.162 
More recently, Lansalot and co-workers reported RAFT emulsion polymerisation using 
glycopolymer stabilisers. In this work, alginate derived polysaccharide macromonomers 
were copolymerised with NAM and further chain extended with styrene emulsion 
polymerisation to generate polysaccharide coated nanoparticles.163 Surprisingly, when 
emulsion polymerisations were performed with polysaccharide macromonomers, 
severely decreased particle uniformity (Dw/Dn > 1.07) and broadened molecular weight 
distributions (Ð > 1.50) were seen in comparison to pure P(NAM) stabilisers (Dw/Dn < 
1.05; Ð < 1.3).163  
Wang and co-workers report the synthesis of shell cross-linked pH responsive 
nanoparticles using RAFT emulsion polymerisation.164 Emulsion polymerisation of 
styrene was initiated from a poly(2-(dimethylamino)ethyl methacrylate) (P(DMAEMA)) 
and cross-linked during the early phase of the polymerisation with a disulphide diacrylate 
monomer yielding 95 nm particles. Similarly, degradation studies were performed in 
DMF, with particles completely disassembling after addition of DTT. In proof of concept 
drug release studies, indomethacin was encapsulated within the nanoparticles, and due to 
the pH responsive P(DMAEMA) shell, a fast release (70% with 24 h) was evident at pH 
5.4 with the addition of DTT. Finally, although high cell viability was reported against 
human cervical cancer (HeLa) cells, this was only measured with concentrations up to 50 
µg mL-1 yielding 70% viability, which is relatively cytotoxic for such a low 
concentration.164 
One of the major advantages of RDRP methods is the possibility of introducing functional 
groups at both ends of the polymer chain typically imparted by the respective control 
agent(s). These can then be used to introduce biologically relevant functional molecules 
(e.g. nucleic acids, proteins, targeting peptides etc.). This approach was applied to RAFT 
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emulsion polymerisation by Poon et al. who described the post-modification of 
carboxylated particles with microRNA.165 First a poly(acrylamide)-b-PS stabiliser was 
synthesised with a RAFT agent exhibiting a functional carboxylic acid on the reinitiating 
group. This was then chain extended in an ab initio RAFT emulsion polymerisation of 
styrene yielding very small 11 nm nanoparticles. The carboxylic functionality was first 
modified with an amino functional pyridyldisulfide as a redox-responsive linker for the 
microRNA, which was further conjugated at the particle surface in a typical thiol 
exchange reaction. Addition of 10 mM GSH resulted in 60% microRNA release from the 
particle surface over 72 h. They explain that the particular microRNA used (miR-200b) 
can suppress the epithelial-mesenchymal cell transition (Figure 1.17).165 
The high functional group density that RAFT emulsion polymerisation imparts on the 
particle corona was further used for attachment of a rhodamine dye to produce 
nanoparticles capable in in vitro and in vivo imaging applications.166 In this case, Poon et 
al synthesised both 11 and 22 nm polystyrene particles which were subsequently 
conjugated with rhodamine amine at 10 and 12% efficiencies respectively. After 
incubation with HK2 cells, the punctuated structure in fluorescence microscopy images 
indicated endosomal or lysosomal colocalisation, consistent with many other studies. 
Finally, the 22 nm rhodamine labelled nanoparticles were injected intravenously into 
healthy mice, with the highest accumulation occurring in the liver and kidneys.  While 
this was the first in vivo study of latex nanoparticles synthesised via RAFT emulsion, as 
of yet there is no published information on the short- or long-term toxicity of this type of 
nanoparticle in vivo.166   
 
Figure 1.17 Synthesis and post-modification of carboxylic functional polystyrene nanoparticles 
synthesised using RAFT emulsion polymerisation, with amine function rhodamine or microRNA. Adapted 
from Poon et. al.166    
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Not all biological applications are needed to be biomedical. For instance, Carlmark and 
co-workers have recently reported the preparation of both low and high Tg latexes with 
RAFT emulsion polymerisation for cellulose modification. Emulsion polymerisations of 
BMA and MMA were initiated from a P[(DMAEMA)-co-(MAA)] macro-RAFT agent, 
resulting in uniform nanoparticles (PDi < 0.1). The aqueous system allowed for direct 
adsorption onto cellulose fibres monitored using a quartz crystal microbalance. Contact 
angle measurements indicated that P(BMA) latexes induced hydrophobicity before and 
after annealing, whereas with high Tg P(MMA) latexes this only occurred after annealing. 
It was found that these latexes significantly improved the mechanical strength of these 
biocomposites after annealing.167  
From a biological perspective, RAFT emulsion polymerisation is a relatively simple 
method to produce uniform nanoparticles with tuneable (monomer composition) cores 
and corona, specific surface functionality (reinitiating group on RAFT agent) with a 
variable size range (target molar mass), in an aqueous environment without external 
surfactants. Many of the advantages seen here are also comparable with RAFT aqueous 
dispersion polymerisations, which can also produce non-spherical species (except for the 
very few emulsion systems with this property)168 using similar conditions. However, there 
are very few monomers capable of the soluble monomer to insoluble polymer transition 
required for aqueous dispersion polymerisation (vide supra).94 In contrast, the number of 
monomers capable of emulsion polymerisation (i.e. water immiscible molecules such as 
MMA, styrene, BA) is far greater, which may be useful when tailoring core properties. 
Furthermore, the most common use of core-shell nanoparticles is controlled drug 
delivery, powered by the high loading efficiencies of insoluble therapeutics.169 The 
components used in aqueous dispersion polymerisations are typically much more 
hydrophilic components than analogous emulsion polymerisations, potentially limiting 
this application. 
Nonetheless similar core-shell structures with higher order morphologies can also be 
prepared using popular self-assembly procedures such as solvent-switch protocols.95 To 
date, these are the most heavily used methods and have been used to prepare nanoparticles 
far more complex (stimuli-responsiveness,170 degradability171 and specific disease 
targeting172) than any heterogenous RDRP technique. However, as stated above, these 
efforts can only be realised at low concentrations and require organic solvents, thus must 
 
 
36 
 
be purified before biological use. Moreover, the resulting particles are generally dynamic 
and may disassemble at low concentrations, possibly leading to premature clearance in 
vivo.  
There have been some efforts to avoid the use of surfactants without using RDRP methods 
(i.e. surfactant free emulsion polymerisations using conventional free radical 
polymerisation), which can be achieved in one step from monomer directly to 
nanoparticle.173-175 However, these typically lead to a large proportion of high molar mass 
hydrophilic polymers contaminating the continuous phase, which must be removed 
through dialysis or centrifugation. Furthermore, unless specific monomer combinations 
are used with this approach, it is non-trivial to produce sub 200 nm particles which are 
the most efficacious in biological studies.176 As such, RAFT emulsion procedures remain 
perhaps the only route to produce core-shell frozen particles in an organic solvent free 
environment without a high proportion of residual monomer, but with full tuneabiliy of 
surface and core compositions. 
 
1.6 Conclusions and motivation for this work 
Overall, the field of RDRP in dispersed states is undergoing a clear revolution from 
primarily synthetic work towards understanding how it can be implemented in modern 
applications, including biomedicine. It is now well understood how to translate popular 
RDRP techniques with many heterogeneous polymerisations types. Furthermore, the 
biomedical advantages of this have now been exploited to prepare systems applicable for 
delivery (gene and drug), and study fundamental bio-nano interactions in vitro and in 
vivo.  The degenerative chain transfer mechanism of RAFT, and its synthetic versatility 
(monomer compatibility, aqueous and low temperature polymerisations) have resulted in 
this approach being applied in all heterogeneous polymerisations discussed above, with 
NMP and ATRP being largely forgotten. An important factor in this, has been the 
development of RAFT aqueous dispersion polymerisations to produce non-spherical 
nanoparticles, such as rods and vesicles in low temperature environments which show 
enhanced cellular uptake and can be used to entrap hydrophilic cargo. Nonetheless, the 
limited number of core-forming monomers severely reduces the flexibility of this system. 
In contrast, RAFT emulsion procedures can be performed with practically any water 
immiscible monomer, and by modifying the monomer and stabilising macro-RAFT 
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agents involved, the polymer shell, core, particle size and surface functionality can easily 
be tuned. With this in mind, the present examples utilising this approach remain fairly 
fundamental, with few reports of particles specifically designed for improved 
biocompatibility and targeting specific biological applications (i.e. biocompatible 
coronas, orthogonal chemistry for ligand binding and bioactive surface functionality). 
The overall aim of this thesis is to expand RAFT emulsion polymerisation procedures to 
exploit the advantages described above and to purposely design nanoparticle systems 
applicable in biomedicine. This will be achieved by meeting the following objectives: 
 
x Optimise the synthesis of nanoparticles using RAFT emulsion polymerisation 
stabilised by a biocompatible amphiphilic macro-RAFT agent. 
 
x Evaluate their toxicological effects both in vitro and in vivo, as well as their organ 
distribution post injection in mouse models. 
 
x Use RAFT emulsion polymerisation to produce polymeric nanoparticles with 
different core glass transition temperatures to study the effect of nanoparticle 
rigidity on cellular uptake. 
 
x Generate nanoparticles with specific surface functionality for potential post-
modification using RAFT emulsion polymerisation. 
 
x Tune the polymeric shell of nanoparticles synthesised via RAFT emulsion 
polymerisation and use this for a specific targeted biological application. 
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Chapter 2              
 
RAFT emulsion polymerisation as a platform 
to generate well-defined biocompatible 
nanoparticles. 
 
Current approaches to generate core-shell nanoparticles for biomedical applications, are 
limited by factors such as synthetic scalability and circulatory desorption of cytotoxic 
surfactant. Developments in controlled radical polymerisation, particularly in dispersed 
states, represent a promising method of overcoming many of these challenges. In this 
work, well-defined PEGylated nanoparticles were synthesised using RAFT emulsion 
polymerisation to control the particle size and surface composition, and further 
characterised with light scattering, electron microscopy and size exclusion 
chromatography. Notably, the nanoparticles were found to be non-toxic in vitro and 
indeed in vivo even at very high dosages without any purification after particle synthesis. 
Pharmacokinetic and biodistribution studies in mice, following intraperitoneal injection 
of the nanoparticles, revealed a long circulation time and accumulation in 
reticuloendothelial organs.  
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2.1 Introduction 
Polymeric nanoparticles are well established as platforms for drug delivery and bio-
imaging applications.1, 2 Their large size promotes extended circulation times through 
evasion of renal filtration3 as well as passive tumour accumulation through the enhanced 
permeability and retention (EPR) effect4, 5. Conjugation of ‘stealthy’ polymers reduces 
the impact of protein corona formation, reducing trafficking towards other excretion 
pathways.6 Encapsulation/conjugation of chemotherapeutic agents inside these vectors 
protects them from physiological degradation, while also facilitating their transport across 
the cellular membrane. Additionally, their high surface functionality can be exploited by 
attaching specific targeting moieties (antibodies,7 peptides,8 or glycosylated 
functionality9). These properties culminate in higher therapeutic efficacy, tumour 
selectivity and reduced side effects for nanoparticle drug delivery vectors, in comparison 
to their molecular drug counterparts.10  
In nanomedicine, and particularly for cancer therapy, polymeric nanoparticles are 
typically engineered to have diameters of 20 - 200 nm (to exploit the EPR effect),4, 11 a 
hydrophobic core for high drug loading efficiency,12 and a cyto-compatible corona for 
reduced toxicity.13 These criteria can be fulfilled through a multitude of methods, 
including self-assembly of amphiphilic block-copolymers,14, 15 or traditional emulsion 
polymerisation.16 Problematically, these architectures have intrinsic disadvantages which 
limit their clinical use. Self-assembly of block copolymers is typically performed at low 
concentrations, small scales (2-5 mg mL-1) and in the presence of cytotoxic organic 
solvents (DMF, THF, Methanol), affecting safety and synthetic reproducibility. In 
contrast emulsion polymerisation is highly scalable and is conventionally performed in 
aqueous media. Unfortunately, the low  circulatory concentration of both of these systems 
induced their release/disassembly of/into potentially cytotoxic surfactants, reducing their 
biocompatibility, while also increasing their clearance rate which can impact therapeutic 
efficacy.17 This can be overcome with meticulous design of covalently bound 
branched/brush-like polymers (unimolecular micelle), however achieving the large sizes 
(20-200 nm) and scales required for these applications through this method is non-
trivial.18, 19 
Reversible addition fragmentation chain transfer (RAFT) emulsion polymerisation 
provides a potentially elegant solution to overcome many of these challenges by 
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combining the advantages of traditional emulsion polymerisation (fast polymerisation 
rates, green/aqueous conditions and high scalability) with the hallmarks of controlled 
radical polymerisation (narrow and tuneable molecular weight distributions, block 
copolymer synthesis and functional end group fidelity).20, 21 During this process, 
amphiphilic di-block macromolecular RAFT (macro-RAFT) agent stabilisers are self-
assembled into micelles, with the thiocarbonylthio group within the core. These are then 
chain extended during the emulsion polymerisation with hydrophobic monomer (oil 
phase), resulting in ‘frozen’ uniform core-shell latex nanoparticles where the shell is 
comprised of the hydrophilic section of the stabilising agent. Nanoparticles prepared 
using this approach are beneficial for biomedical applications, as the shell is covalently 
attached and cannot desorb from the particle during circulation. Advantageously, this 
process is performed in the absence of organic solvents (aqueous conditions), is highly 
scalable, and the stabiliser can be designed to impart biocompatibility.  
Nevertheless, most of the studies on RAFT emulsion polymerisation focus on their 
synthesis (kinetics and morphology),20, 22-25 with only a few notable studies exploiting 
this technique to generate nanoparticles aimed at biomedical applications. For example, 
Stenzel and co-workers used an amphiphilic poly(glucose methacrylamide)-b-
polystyrene macro-RAFT agent to generate glycosylated nanoparticles, which displayed 
high affinity for E. coli.26 Whereas, Wang and co-workers used RAFT emulsion 
polymerisation to control the monomer composition of the nanoparticle shell, yielding a 
system whereby the release rate of a model hydrophobic drug (indomethacin) could be 
tuned with pH.27 Furthermore, Poon et al have illustrated the potential for surface 
modification of polyacrylamide stabilised polystyrene nanoparticles synthesised from 
RAFT emulsion, initially as micro-RNA carriers, and also fluorescent labelling for 
studies in vitro and in vivo.28, 29 Nonetheless, these nanoparticle systems required 
extensive dialysis purifications, which reduced their scalability potential. Moreover, their 
suitability in complex biological organisms still remains elusive, with little information 
reported about these nanoparticles in cellular assays or live animal models. 
The aim in this chapter was to showcase how RAFT emulsion polymerisation can be used 
to easily generate biocompatible nanoparticles, whilst also probing their toxicity in vitro 
and in vivo. A series of core-shell polymeric nanoparticles with cores of poly(tert-butyl 
acrylate) (P(t-BA)) and poly (n-butyl acrylate) (P(n-BA)), and a cyto-compatible 
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poly(poly(ethylene glycol methyl ether acrylate)) (P(PEGA)) corona were synthesised via 
RAFT emulsion polymerisation. The nanoparticles were characterised with light 
scattering, electron microscopy and size exclusion chromatography. Their toxicity was 
then evaluated in vitro on a colorectal carcinoma cell line (Caco-2), and in vivo on mouse 
models. Finally, a near-infrared (NIR) probe, Cyanine-7.5, was encapsulated into the 
nanoparticles, and preliminary pharmacokinetics and biodistribution were studied using 
an in vivo fluorescence imager. 
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2.2 Results and Discussion 
2.2.1 Strategy 
It has previously been shown that oligomeric amphiphilic diblock macromolecular RAFT 
agents (macro-RAFT) are suitable stabilisers for RAFT emulsion polymerisation.20, 25, 30 
As the aim of this project was to employ this technique to generate biocompatible 
nanoparticles, polyethylene glycol (PEG) was selected as the hydrophilic block of the 
macro-RAFT agents. PEG is well established as the gold standard for imparting 
biocompatibility, ‘stealth’ from the immune system, and colloidal stability, to 
nanomaterials owed to its superior anti-fouling properties, hydrophilicity and steric 
effects.31-33 In general, the hydrophobic block of the macro-RAFT agent stabiliser is 
usually comprised of the same monomer to be used during the emulsion step, and 
therefore are required to be immiscible in water. Based on the above criteria, P[(PEGA)8-
b-(n-BA)8] and P[(PEGA)8-b-(t-BA)]8 were conceived as the initial designs for the 
macro-RAFT agents.   
2.2.2 Synthesis of macromolecular RAFT agent stabilisers 
Macro-RAFT agents, P[(PEGA)8-b-(n-BA)]8 (MRA-nBA) and P[(PEGA)8-b-(t-BA)]8 
(MRA-tBA), were synthesised in two steps (Scheme 2.1). For the first block, 
polymerisation of poly(ethylene glycol methyl ether acrylate) (PEGA) was performed at 
70°C mediated with RAFT agent (propanoic acid)yl butyl trithiocarbonate (PABTC) in 
1,4-dioxane using ACVA as the thermal initiator. PABTC has previously been shown to 
be an excellent chain transfer agent (CTA) for acrylates34 and acrylamides35, and 
importantly the carboxylic acid R-group will be imparted onto the particle surface, 
improving the electrostatic stabilisation of the final nanoparticles. Additionally, it has 
previously been reported that trithiocarbonate end groups cause less toxicity than 
dithiobenzoate.36 The polymerisation was stopped at 91% conversion to maintain high 
chain end fidelity and yielded P(PEGA)8 (MRA-PEGA), which was purified via 
precipitation in diethyl ether to remove residual monomer. MRA-PEGA was 
subsequently chain extended with either tert-butyl acrylate (t-BA) or n-butyl acrylate (n-
BA) to yield MRA-tBA and MRA-nBA, reaching 96% and 94% monomer conversion 
respectively and both purified via precipitation in hexane. Full details for polymerisation 
conditions can be found in Table 2.5.  
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Scheme 2.1. Preparation of MRA-PEGA, MRA-nBA and MRA-tBA via RAFT polymerisation. 
 
Figure 2.1. CHCl3-SEC traces of MRA-PEGA (blue), (A) MRA-nBA (green) and (B) MRA-tBA 
(orange). DLS traces of (C) MRA-tBA and (D) MRA-nBA micelles at 15 mg mL-1 in pure water at 25°C. 
 
Size exclusion chromatography (SEC) of all three polymers indicated narrow molar mass 
distributions, and clear shifts towards higher molecular weight suggesting successful 
chain extensions (Đ < 1.2; Figure 2.1). 1H NMR spectra confirmed excellent agreement 
between theoretical and observed molar masses (Figure 2.2; Table 2.1).  Chromatograms 
of MRA-nBA and MRA-tBA revealed a small high molecular weight shoulder which 
has been attributed to mid- or side- chain branching, expected for acrylate monomers 
(Figure 2.1a and Figure 2.1b). Dynamic light scattering (DLS) indicated the formation of 
uniform micelles (PDi < 0.07) with diameters of 6.4 and 6.2 nm for MRA-nBA and 
A B
C D
MRA-nBA MRA-tBA
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MRA-tBA respectively (Figure 2.1c and Figure 2.1d; Table 2.1). The observed radii (~ 
3-4 nm) are consistent with theoretical values for fully stretched out polymer chains (16 
x 0.25 nm per monomer unit = 4 nm), suggesting that the micelles were spherical in shape. 
Both block copolymer micelles exhibited negative ζ-potentials (ZP), due to the 
deprotonated carboxylic functionality at the corona. Overall, these measurements show 
that MRA-nBA and MRA-tBA should be suitable stabilising agents during RAFT 
emulsion polymerisation, due to the steric and electrostatic stability from the carboxylated 
P(PEGA) corona. 
Table 2.1. Characterisation data for macro-RAFT agents MRA-PEGA, MRA-nBA and MRA-tBA  
 % 
conva 
Mn,th  
(g mol-1)b 
Mn,SEC   
(g mol-1)c 
Mw,SEC  
(g mol-1)c Ð
c Dhd PDie ζ-Potential (mV)f 
MRA-PEGA 91 4100 5100 5800 1.14 - - - 
MRA-nBA 96 5100 6300 7200 1.14 6.6 0.069 -10 
MRA-tBA 94 5100 6000 6950 1.15 6.2 0.069 -11 
aDetermined by 1H NMR spectroscopy. bTheoretical molar masses calculated with Equation 2.12. 
cDetermined by CHCl3-SEC and analysed against PMMA standards. dDetermined using DLS. eCalculated 
using Equation 2.13. fMeasured using a Zetasizer. 
 
 
Figure 2.2. 1H NMR spectra of (a) MRA-PEGA (b) MRA-nBA and (c) MRA-tBA in CDCl3 at 300 MHz. 
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2.2.3 Nanoparticle synthesis via RAFT emulsion polymerisation 
Although RAFT emulsion polymerisation was first introduced over a decade ago, there 
are no universal conditions to achieve low polydispersity nanoparticles and narrow 
molecular weight distributions. Conditions typically vary depending on macro-RAFT 
agent composition, monomer choice and reagent concentrations.24, 37 The RAFT emulsion 
polymerisation process was optimised with a systematic study on initiator type starting 
from conditions adapted from previous work.28, 29 
2.2.3.1 Optimisation of initiator 
Prior to optimisation of initiator type, parameters such as initiator and macro-RAFT agent 
concentrations were established from literature procedures. For the study, n-BA was 
chosen as the monomer as its use has been far more prevalent in the literature as compared 
to t-BA.23, 38, 39 In the first report of RAFT emulsion polymerisation, Hawkett and co-
workers used a macro-RAFT agent concentration of between 1.28 and 5.06 mM for 
successful polymerisations of n-butyl acrylate.40 While Poon et al. used azo-initiator 4,4’-
Azobis(4-cyanovaleric acid) (ACVA, V-501) at high concentrations ([macro-RAFT]0/[I]0 
= 1.1), to generate a high radical flux enabling fast nucleation of seed micelles and 
uniform particle growth, resulting in low polydispersity particles.28 Using reaction 
parameters from these systems, initiators 2,2’-Azobis[2-(2-imidazolin-2-
yl)propane]dihydrochloride (VA-044) and ACVA were investigated as positive and 
negatively charged initiators for RAFT emulsion polymerisation of n-butyl acrylate 
mediated by MRA-nBA at 70°C. These initiators however have vastly different 10 h 
decomposition half-life temperatures (44°C for VA-044, and 69°C for ACVA), therefore 
at the same initial concentration, a larger amount of VA-044 would be consumed at 70°C 
compared to ACVA, per unit time.  
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Equation 2.1. Calculation of the decomposition rate constant (s-1). EA = activation energy of homolytic 
fission of initiator (J mol-1), R = molar gas constant 8.314 (J K-1 mol-1), Tt1/2 = 10 h half-life temperature of 
initiator, Tx = temperature of reaction. 
 
 
55 
 
)(
0)0()( ][][][
ytk
tyt
deIII   
Equation 2.2. Calculation of initiator consumed at time y. [I]t(y) = concentration of initiator at time y (mol 
dm-3), [I]t=0 = initiator concentration at the start of the reaction (mol dm-3). 
From Equation 2.1 and Equation 2.2, it was determined a 5 fold decrease in initial initiator 
concentration ([I]0) was necessary for VA-044, in comparison to ACVA, to ensure the 
same radical flux. For polymerisations using ACVA the same initiator ratios as Poon et 
al were chosen. ([Macro-RAFT]0/[I]0 = 1.1), and therefore [Macro-RAFT]0/[I]0 = 5.5 for 
polymerisations initiated with VA-044. Meanwhile [Macro-RAFT]0 was set to 2.85 mM 
as a compromise of the upper and lower values used by Hawkett and co-workers.20  
 
Scheme 2.2. RAFT emulsion polymerisation of n-BA and t-BA mediated by MRA-nBA and MRA-tBA 
respectively using thermal initiators ACVA and VA-044. 
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Table 2.2. Characterisation data of P(n-BA) and P(t-BA) nanoparticles synthesised using azo-initiators 
VA-044 and ACVA. 
 
aRefers to the target DP of RAFT emulsion polymerisations performed to obtain the third (core forming) 
block. bDetermined by DLS. cDetermined using Equation 2.12. dDetermined by CHCl3-SEC (values are 
obtained by integrating the whole region, including all three peaks), calibrated with PMMA standards. All 
polymerisations reached >99% monomer conversion, determined by gravimetry. 
 
For RAFT emulsion polymerisations, MRA-nBA, thermal initiator (ACVA or VA-044), 
n-BA and water were homogenised and subsequently heated to 70°C for 3 h under 
vigorous stirring. Over the course of the reaction, the emulsions turned milky white as the 
polymerisations proceeded. Syntheses were performed with both ACVA and VA-044 
with five different [M]0/[Macro-RAFT]0 ratios (50, 75, 100, 150 and 200) in order to alter 
the chain length of the third (core-forming) block (Scheme 2.2). ACVA emulsion 
polymerisations were conducted with two equivalents NaOH relative to the initiator to 
ensure complete deprotonation and water solubility. All polymerisations rapidly reached 
full conversion within 3 h, due to the compartmentalisation effects typically found in 
emulsion polymerisations. This is particularly useful in a biomedical context, as residual 
monomers are known to be highly cytotoxic.41 SEC analysis of the dissolved 
nanoparticles exhibited significant shifts toward higher molecular weight from MRA-
nBA traces for both VA-044 and ACVA emulsion polymerisations, suggesting chain 
extension within the core was successful. Interestingly, chromatograms for VA-044 
polymerisations displayed broad dispersities (Ð = 1.35-2.93), unsymmetrical molar mass 
distributions, and in some cases multimodal distributions (Table 2.2, Entry 1-5; Figure 
 Initiator Monomer Macro-RAFT 
DPtargeta 
Dh 
(nm)b PDi
b 
ZP  
(mV)b   
Mn,th 
(g mol-1)c 
Mn,SEC 
(g mol-1)d 
Mw,SEC 
(g mol-1)d 
Ðd 
1 VA-044 n-BA MRA-nBA 200 282 0.12 -31.6 30700 31000 59500 1.92 
2    150 257 0.11 -32.3 24300 25800 75600 2.93 
3    100 139 0.09 -29.5 17900 17800 24500 1.60 
4    75 104 0.10 -30.9 14700 14800 25200 1.70 
5    50 55 0.09 -29.1 11500 11400 15400 1.35 
6 ACVA n-BA MRA-nBA 200 130 0.05 -47.3 30700 25700 48600 1.86 
7    150 92 0.06 -37.8 24300 22500 34000 1.60 
8    100 75 0.06 -35.4 17900 18400 24400 1.39 
9    75 50 0.06 -37.1 14700 14200 18500 1.35 
10    50 28 0.06 -34.2 11500 11500 13300 1.22 
11 ACVA t-BA MRA-tBA 200 119 0.05 -48.5 30700 30700 47000 1.54 
12    150 86 0.05 -45.1 24300 22000 34900 1.58 
13    100 66 0.06 -39.2 17900 16500 24400 1.47 
14    75 49 0.06 -42.6 14700 13300 17600 1.32 
15    50 31 0.07 -37.4 11500 10200 12600 1.23 
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2.3a). In comparison, size exclusion chromatograms for ACVA polymerisations, revealed 
smoother molecular weight distributions and an increasing trend of Mn,SEC with DPtarget 
(11,500 to 30,700 g mol-1) (Table 2.2, Entry 6-10; Figure 2.3b). Nonetheless, these 
polymerisations were not completely controlled as chromatograms exhibited three 
distinct populations: a small high molecular weight shoulder due branching or 
bimolecular termination; a second low molecular population of unconsumed macro-
RAFT agent; and a main narrow population of the targeted polymer. The non-quantitative 
macro-RAFT agent consumption is most likely due to a low chain transfer constant when 
assembled into micelles, and has been observed in other reports of RAFT emulsion 
polymerisations of acrylate monomers.23  The observed molar masses (Mn,SEC) showed 
close agreement with theoretical values (Mn,th), however the discrepancy between Mn,th  
and Mn,SEC is attributed to differences in hydrodynamic volume of PMMA standards with 
the analysed polymers during size exclusion chromatography.  
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Figure 2.3. CHCl3-SEC chromatograms depicting the increasing DPtarget chain extensions (A) MRA-nBA 
with n-butyl acrylate using VA-044 as initiator, (C) MRA-nBA with n-butyl acrylate using ACVA as 
initiator and (E) MRA-tBA with t-butyl acrylate using ACVA as initiator. Chromatograms were obtained 
by dissolving dried nanoparticles in SEC eluent. DLS traces (number distribution) of P(n-BA) nanoparticles 
prepared with (B) VA-044 or (D) ACVA, and P(t-BA) nanoparticles (F) prepared with ACVA as well as 
their respective macro-RAFT agents (dashed grey lines). Measurements were taken at 25°C with 
nanoparticles dilute 1/1000 in pure water. 
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Particle size distributions in solution were analysed using DLS. Nanoparticles synthesised 
using VA-044 generally showed larger particle diameters (Dh = 55 – 282 nm; Table 2.2, 
Entry 1-5; Figure 2.3b), and broader distributions (PDi = 0.09 – 0.12) compared to their 
ACVA counterparts (Dh = 28 – 130 nm; PDi = 0.05 – 0.06; Table 2.2, Entry 6-10; Figure 
2.3d). Intriguingly, both sets of nanoparticles (VA-044 and ACVA) displayed increasing 
particle size with larger DPtarget, suggesting there was a tuneable relationship between 
DPtarget/Mn and particle size.  
The poorer performance of VA-044 polymerisations is likely due to the net positive 
charge formed from initiator derived Zmer’s. These will be electrostatically attracted to the 
carboxylated seed particles increasing the number of radicals present in each growing 
particle.42 This culminates in greater termination events, and also a more neutral surface 
charge, from positive Zmers neutralising the negatively charged carboxylates. This leads 
to reduced electrostatic stability, broader molecular weight distributions and larger 
particle sizes, evident from the SEC, DLS and ZP analysis (Table 2.2). Conversely the 
negative Zmer’s from ACVA will enhance stabilisation and reduce the number of radicals 
per particle.  
It is advantageous for nanoparticles designed for biomedical applications to be between 
20-200 nm such that they can be transported through fine capillary networks, and in 
particular for cancer therapy, exploit the EPR effect.43 Nanomedicine systems larger than 
200 nm therefore can have a reduced therapeutic benefit due to these limitations.  The 
ACVA system represents an ideal method to generate particles for these applications by 
simply modifying the DPtarget, narrow dispersity particles with precisely controlled sizes 
can be prepared. To show the versatility of this approach, the ACVA conditions were 
applied to a second monomer, tert-butyl acrylate (t-BA). SEC and DLS analysis of the 
P(t-BA) nanoparticles revealed similar characteristics to P(n-BA) nanoparticles, with 
narrow dispersity particle size distributions and an increasing trend between Mn and 
particle diameter (Table 2.2, Entry 11-15; Figure 2.3e and f). In general P(t-BA) 
nanoparticles displayed comparable Ð and diameters to their P(n-BA) counterparts. 
Overall, it is clear that using ACVA as the initiator for RAFT emulsion polymerisation 
yields superior nanoparticles, which has been evaluated using two analogous monomers.  
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2.2.3.2 Optimisation of pH 
In the previous section, a variety of nanoparticle sizes were synthesised by modifying the 
[M]:[macro-RAFT] ratio. As the surface of the macro-RAFT agent micelles contained a 
carboxylate moiety, it was important to determine how pH would affect the RAFT 
emulsion polymerisations, as this would alter the surface ionisation and therefore the 
macro-RAFT agent stabilisation. 
Five RAFT emulsion polymerisations of n-BA were performed with DPtarget = 100 and 
different [NaOH]:[macro-RAFT] ratios (0, 0.1, 0.25, 0.75, 1.0). As ACVA contains two 
acid groups, which are required to be deprotonated for full aqueous solubility, changing 
the [NaOH] may induce different solubility properties, therefore inadvertently altering 
[I]0. To circumvent this, azo-initiator 2,2'-Azobis[N-(2-carboxyethyl)-2-
methylpropionamidine]tetrahydrate (VA-057) was employed as this has complete water 
solubility, regardless of pH owed to its zwitterionic structure. These polymerisations 
however, were performed at the 10 h decomposition half-life temperature of 57°, 
therefore the difference in initiator cannot be extracted from this information. The pH of 
each polymerisation mixture was measured prior to heating (Table 2.3; Scheme 2.3).  
 
Scheme 2.3. Preparation of P(n-BA) nanoparticles at various pH. x = 0, 0.1, 0.25, 0.75, 1 eq relative to 
MRA-nBA using VA-057 as thermal initiator. 
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Table 2.3. Effect of pH on RAFT emulsion polymerisations of n-BA mediated with MRA-nBA.  
Mn,th for all entries is 17900 g mol-1. aDetermined by DLS. bDetermined by CHCl3-SEC (values are obtained 
by integrating the whole region, including all three peaks), calibrated with PMMA standards. All 
polymerisations reached >99% monomer conversion, determined by gravimetry. 
 
 
Figure 2.4. Effect of pH (pH = 4.67, 4.87, 5.20, 6.38, 7.09) on RAFT emulsion polymerisations of n-BA 
mediated with MRA-nBA using initiator VA-057. (A) THF-SEC chromatograms of dried latexes, and DLS 
distributions (B) number and (C) intensity of particles diluted 1/1000 in pure water, measured at 25°C. 
  
 
 
   Number distribution 
Intensity 
distribution    
 [NaOH]/ 
[MRA-nBA] pH Dh
a (nm) PDia Dh
a (nm) PDia 
Mn,SEC 
(g mol-1)b 
Mw,SEC 
(g mol-1)b 
Ðb 
1 0 4.67 38 0.07 66 0.12 18200 30800 1.69 
2 0.1 4.87 42 0.07 65 0.10 22600 34800 1.54 
3 0.25 5.20 32 0.06 50 0.14 20500 34900 1.70 
4 0.75 6.38 21 0.05 251 0.58 20000 39200 1.96 
5 1.0 7.09 19 0.05 332 0.60 16400 44000 2.68 
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Polymerisation mixture pH’s ranged from 4.67 (native pH/ no NaOH addition), to 7.09 
for equimolar NaOH addition relative to MRA-nBA. SEC analysis of the resulting 
nanoparticles revealed similar Mn,SEC to theoretical values, however, above pH 5.20 
([NaOH]/[Macro-RAFT] > 0.25) broad molar mass distributions were observed (Ð ≥ 
1.96). Below this value, SEC chromatograms remained comparable to data obtained in 
Section 2.2.3.1 (Figure 2.4a). Particle diameters reduced from 42 nm to 19 nm (number 
distribution) with increasing pH, likely due to the increased electrostatic stabilisation 
from greater charge on the particle surface (Figure 2.4b). Similar to SEC data, DLS traces 
of RAFT emulsion polymerisations performed above pH 5.20 displayed wide and 
multimodal particle size distributions by intensity values (Figure 2.4c). A similar study 
conducted by Lansalot and co-workers revealed a comparable trend for RAFT emulsion 
polymerisation of styrene at different pH’s. They rationalised that the increased ionisation 
of the surface provided an unsuitably hydrophilic environment for chain extension to 
occur uniformly.44 Overall, it is clear that polymerisations performed at acidic pH’s 
yielded uniform particles, with narrower polymer molar mass distributions, compared to 
those at higher pH’s. It is interesting to note that at the native pH, conditions with VA-
057 yielded smaller nanoparticles (38 nm) compared to ACVA (75 nm) at the same 
DPtarget/ Mn (~ 18,000 g mol-1), however, as they were not conducted at the same 
temperature, this could be due to either initiator or temperature effects and cannot be 
compared directly.   
2.2.4 Nanoparticle characterisation 
Only nanoparticles synthesised with ACVA (section 2.2.3.1) were taken forward for in-
depth characterisation, due to the extensive library generated with this system (Table 2.2, 
Entry 6-15). As the RAFT emulsion polymerisations were performed in aqueous 
conditions and reached full monomer conversions, any future biological studies could be 
conducted without removal of cyto-toxic solvents or monomers. Nanoparticle 
characterisation was therefore conducted without post-synthesis purification. 
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2.2.4.1 PEG-tannin aggregation assay 
To elicit if the P(PEGA) block remained at the particle surface, a PEG selective 
aggregation assay was employed based on the well-known property of PEG as a tannin 
binding agent.45-47. This operates on a similar basis to lectin-glycopolymer assays where 
addition of multivalent lectin induces an increase in turbidity/absorbance, caused by 
accumulation of particles. A selection of nanoparticles (t-BA and n-BA) were treated with 
tannic acid and the absorbance was monitored at 500 nm in a UV-VIS spectrometer 
(Figure 2.5). Interestingly, a rapid increase in absorbance (at 500 nm) was observed when 
nanoparticles (both P(t-BA) and P(n-BA)) were treated with tannic acid suggesting high 
availability of PEG in their surface. These results are consistent with other PEG-tannin 
systems, however it is believed this is the first time it has been used to study PEGylation 
of nanoparticles.48 This technique gives a good understanding of the surface properties, 
but cannot quantify how many chains are available at the particle corona.  
 
Figure 2.5. Absorbance-time curves of tannic acid-PEG binding assay measured on a UV-VIS spectrometer 
at 500 nm over 6 minutes with 119, 66 and 31 nm P(t-BA) and 130, 75 and 28 nm P(n-BA) nanoparticles. 
Dashed lines indicate time of tannic acid (10 µg mL-1) addition to nanoparticle solutions (10 µg mL-1). 
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2.2.4.2 Determination of the number of aggregation 
Nanoparticle-cell interactions are generally governed by many parameters, such as size, 
shape and charge. The surface grafting density or the number of aggregation (Nagg), has 
also been shown to heavily influence interactions with biological material.49-51 Typically 
for latexes synthesised by RAFT emulsion polymerisation, this is calculated by 
determining the number of macro-RAFT per unit volume and dividing it by the number 
of particles (Equation 2.3 and Equation 2.4). The Nagg was calculated, revealing an 
increasing trend with particle diameter for both n-BA (600 to 22500) and t-BA (800 to 
17300) nanoparticles. The observed values displayed a comparable trend to those reported 
by Hawkett and co-workers and similar Nagg values, increasing from 2665 and 15800 for 
increasing nanoparticle diameter.20  
  php dD
N 3
6
S
W  
Equation 2.3. Determination of the number of particles per volume. Np = number of particles per mL τ = 
solids content (g mL-1), Dh = average hydrodynamic particle diameter, dp = density of polymeric core.  
p
A
agg N
NRAFTmacroN  ][  
Equation 2.4. Number of macro-RAFT agents per particle (Nagg). 
These equations however are derived with the assumptions that the nanoparticles are 
spherical, are entirely comprised of the core polymer and 100% of the macro-RAFT agent 
is chain extended during the polymerisation, which from our data we know is incorrect 
(Section 2.2.3). This information however can be experimentally measured using 
scattering techniques, overcoming some of these assumptions. 
Static light scattering (SLS) is a powerful technique to study materials in solution and 
allows the direct determination of Nagg. It relies on the intensity of scattered light at 
defined angle θ from an irradiated particle with an incident beam of wavelength λ0. From 
these values, the wave vector (q) can be determined (Equation 2.5). 
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Equation 2.5. Determination of wave-vector (q) using the wavelength of the incident (λ0) and the refractive 
index of the solvent (n) and the angle of measurement (θ)  
The wave vector (q) is inversely proportional to the size of the window of observation, 
hence by varying θ and λ0, information can be garnered about different aspects of the 
measured objects. In the case of light scattering (long wavelength), measurements are 
therefore at low q where entire particles are observed. However, if further information 
was required on the structural properties of the surface (polymer chains), measurements 
would typically be performed at high q with short wavelength irradiation, using small 
angle X-ray (SAXS) or small angle neutron scattering (SANS) (Figure 2.6).  
 
Figure 2.6. Relationship between the wave vector (q) and the domain size of the window of observation. 
All ten nanoparticle suspensions were measured at four concentrations each across 8 
angles (Figure 2.7) and the Rayleigh ratio (Rθ) was determined (Equation 2.6).  
 
Equation 2.6. Determination of Rayleigh ratio. Isolution, Isolvent and Itoluene are the scattering intensities of the 
solution solvent and reference (toluene) respectively. n is the refractive index (nwater = 1.333, ntoluene = 1.496) 
and Rtoluene is the Rayleigh ratio of toluene (Rtoluene = 1.36 x 10-5 cm-1 for λ = 633 nm). 
Subsequently the relationship between refractive index and concentration (dn/dC) was 
determined by measuring multiple nanoparticle concentrations with differential 
refractometry, and the optical constant (K) was evaluated (Equation 2.7).  
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Equation 2.7. Determination of the optical constant. NA is Avogadro’s constant and dN/dC is the constant 
relating to how the refractive index changes with sample concentration, calculated using Equation 2.8. 
 
Equation 2.8. Determination of the change in refractive index with concentration (dN/dC). Z = gradient of 
RI vs concentration, RIconstant = 1,194,000.  
The apparent molar masses (Ma) per particle, were then determined at multiple 
concentrations (Equation 2.9) and values extrapolated to infinite dilution, where particle-
particle interactions are minimal, simplifying the relationship (Equation 2.10; Figure 2.7). 
 
Equation 2.9. Relationship between the Rayleigh ratio and apparent molar mass (Ma).  
aMR
KC 1 
T
 
Equation 2.10. Simplified relationship between the Rayleigh ratio and apparent molar mass (Ma).  
The Nagg was further calculated by dividing this by unimer Mw estimated from SEC 
chromatograms (Equation 2.11) in Section 2.2.3. 
unimerw
particlea
agg M
M
N
,
,  
Equation 2.11. Calculation of number of aggregation (Nagg). Ma,particle = apparent particle molar mass 
determined by SLS. Mw, unimer = weight average molar mass of particle unimers approximated with SEC. 
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Table 2.4. Determination of whole particle molar masses (Ma) and number of unimer aggregates per particle 
(Nagg) for both P(n-BA) and P(t-BA) nanoparticles. 
 
 
 
 
 
 
 
aDetermined by DLS. bDetermined using differential refractometry and Equation 2.8 cDetermined using 
SEC against PMMA standard. dDetermined by SLS. eDetermined using Equation 2.11. 
Surprisingly, for both sets of nanoparticles, the experimental Nagg showed excellent 
agreement with theoretical values calculated above. Consistent findings were observed 
where Nagg increased with particle size, ranging from Nagg < 1000 for the smallest 
nanoparticles, up to > 15,000 for the largest (Table 2.4). This finding suggests that there 
must be some rearrangement in macro-RAFT agents, and therefore does not maintain the 
same Nagg during the polymerisation process. This trend also can be rationalised as larger 
nanoparticles have a larger surface area, hence require greater stabilisation than smaller 
nanoparticles.  
 
    
  Experimental Theoretical 
Nanoparticle core DPtarget Dh
a (nm) dn/dCb 
Mw,SEC  
(g mol-1)c 
Ma  
(Mg mol-1)d 
Naggd Nagge 
P(n-BA) 200 130 0.105 48600 1060  21800 22500 
 150 92 0.147 34000 350  10300 10100 
 100 75 0.107 24400 157  6600 7400 
 75 50 0.149 18500 21 1200 2700 
 50 28 0.107 13300 6.9  520 600 
P(t-BA) 200 119 0.088 47000 777  16500 17300 
 150 86 0.08 34900 283  8100 8300 
 100 66 0.082 24400 127  5200 5100 
 75 49 0.106 17600 37  2100 2700 
 50 31 0.77 12600 13  1000 800 
 
 
68 
 
 
 
 
 
 
69 
 
 
Figure 2.7. KC/RT vs q2 and concentration vs apparent molar mass (Ma) plots for P(n-BA) and P(t-BA) 
nanoparticles across 4 concentrations, measured using static light scattering.  
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2.2.4.3 Cryogenic transmission electron microscopy 
From the previous characterisation methods, the particle size, zetapotential and Nagg have 
been determined. To confirm the shape, nanoparticles were imaged with cryogenic 
transmission electron microscopy (Cryo-TEM). Electron micrographs revealed spherical 
nanoparticles with sizes that correlated well with diameters determined by DLS, and the 
absence of any aggregate formation. Although the images showed relatively uniform 
nanoparticle distributions, any discrepancy between particle sizes could be due to the 
thickness of the formed ice layer, where particles towards the bottom may appear smaller 
in relation to those at the top.  
 
Figure 2.8. Cryo-TEM images of undiluted P(t-BA) (left column) and P(n-BA) (right column) 
nanoparticles deposited on lacey carbon coated grids.   
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2.2.5 Toxicity studies 
Having extensively characterised the synthesised nanoparticles, their biocompatibility 
was evaluated in vitro and in vivo.  
2.2.5.1 In vitro cell viability 
All ten nanoparticles, without prior purification, were exposed to colorectal carcinoma 
(Caco-2) cells for 72 h across six concentrations (2 mg mL-1 – 100 ng mL-1), and the in 
vitro cell viability measured using the SRB assay. None of the nanoparticles inhibited cell 
growth up to 0.5 mg mL-1. Nonetheless, the 75 nm P(n-BA), and all P(t-BA) nanoparticles 
with Dh > 31 nm showed reduction in cell proliferation at 2 mg mL-1 (Figure 2.9), but this 
concentration is far greater than any envisaged clinical dosage for these, or other similar 
systems. 
 
Figure 2.9. Antiproliferative activity of P(n-BA) (28 – 130 nm) and P(t-BA) (31 – 119 nm) on Caco-2 cells 
(seeded 10,000 per well) over 72 h at 2, 0.5, 0.2, 0.01, 0.001 and 0.0001 mg mL-1 monitored as a function 
of cell biomass with the sulforhodamine B assay. Data are expressed as the arithmetic mean ± standard 
deviation of two independent experiments performed in triplicate (N=6). 
2.2.5.2 In vivo toxicity 
Satisfied that the synthesised particles were non-toxic in vitro, the 49 and 86 nm t-BA, 
and the 50 and 93 nm n-BA nanoparticles were chosen for the in vivo toxicity studies as 
these were the most comparable between the two core varieties. To assess the in vivo 
toxicity, two experiments were performed by Dr Robert Dallmann, Kristin Abraham and 
Helena Xandri-Monje at the Warwick Medical School, University of Warwick, UK. 
Firstly, an acute toxicity study, where mice were treated with one intraperitoneal (i.p.) 
dose of nanoparticles at two concentrations (1.2 mg kg-1 and 12 mg kg-1), and secondly, 
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sub-acute toxicity, whereby mice were treated with multiple doses, once per day, however 
only at the higher concentration. In both experiments, body weight and well-being 
parameters such as fur, appetite and activity were monitored for a period of 7 days after 
i.p. administration. Control experiments (mice administered with PBS and not injected) 
were performed in parallel (Figure 2.10). 
 
Figure 2.10. Acute (left column) and 7 day repeated (right column) toxicity in mice for the 50 and 93 nm 
n‐BA, and 49 and 86 nm t‐BA nanoparticles at both 1.2 mg kg−1 (grey lines) and 12 mg kg−1 (black lines), 
measured as a function of animal body weight monitored over 7 days (N = 3 for acute toxicity, N = 6 for 7 
day repeated dosing). Controls of PBS injection (N = 3 for both acute toxicity and 7 day dosing) and 
noninjected (N = 2 for both acute toxicity and 7 day dosing) mice are also displayed. Data is reported as 
mean ± SEM. Arrows indicate administration points. 
Encouragingly, in both acute and sub-acute experiments, minimal toxicity effects were 
observed for all nanoparticles tested. All mice administered with nanoparticle 
suspensions had similar weight changes to control treatments or, in some cases higher 
body weight. Importantly, none of the mice showed any reduction in body weight over 
the seven day period, nor any loss of fur, appetite or reduction in activity even for very 
high doses (12 mg kg-1).  This observed biocompatibility in vitro and in vivo is likely due 
to the dense P(PEGA) shell on all of the nanoparticles, known to reduce immune response 
through low adsorption of serum proteins.52 This is in accordance with a report from 
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Tamanoi and co-workers, showing limited toxicity for intraperitoneally administered 
mesoporous silica nanoparticles through full serological, haematological and 
histopathological investigations.53 
2.2.6 Preliminary biodistribution studies 
NIR fluorescence is a highly sensitive and non-invasive method to study 
pharmacokinetics, biodistribution and organ accumulation.54 Having established a low 
toxicity profile in vivo and in vitro, NIR probe, Cyanine 7.5 amine (Cy7.5), was therefore 
encapsulated into intermediate sized 50 nm P(n-BA) nanoparticles following an adapted 
procedure from Resch-Genger and co-workers.55 This approach works by swelling the 
particles with ca. 10% organic solvent, in the presence of the hydrophobic dye, 
partitioning it into the core of the nanoparticles. The particles were purified by extensive 
dialysis, and analysed with fluorescence spectroscopy (Figure 2.11) 
 
Figure 2.11. Fluorescence emission spectrum of Cy7.5 loaded 50 nm P(n-BA) nanoparticles diluted 1/100 
in pure water excited at 780 nm and emission profiles monitored from 785 to 900 nm. 
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Figure 2.12. Biodistribution studies after a single i.p. injection of Cy7.5 loaded 50 nm P(n-BA) 
nanoparticles (1.2 mg kg-1) in mice. Distribution was monitored using the 800 nm fluorescence channel 
with a LICOR Pearl® Trilogy. (A) Pharmacokinetic study over 76 h (B) 360° view of 76 h time point (C) 
Ex vivo images of organs samples 76 h after injection.  
A dilute suspension of NIR-particles (1.2 mg kg-1) was administered to male mice via i.p. 
injection, and the nanoparticle distribution was followed periodically over 76 h using a 
LICOR NIR in vivo imager. Prior to injection, no fluorescence signal was observed from 
any part of the animal (control). A bright signal from the abdominal cavity was 
immediately detected after administration, which decreased rapidly during the first 2 h of 
exposure, likely due to adsorption into systemic circulation (Figure 2.12a and Figure 
2.13). This was followed by slow clearance, over the next 74 h (Figure 2.12a and Figure 
2.13), with 36% of the injected dose being retained at the end of the experiment. Ex vivo 
imaging of the excised organs (76 h) revealed high nanoparticle accumulation in the liver, 
with significant quantities also found in the intestine and spleen, and only small amounts 
in the heart or fat of the animal (Figure 2.12 and Figure 2.14). Some of the intestinal 
signal may be attributed to NIR chlorophyll fluorescence.56 This was examined by 
imaging the faeces of non-injected mice, which showed a small but detectable 
fluorescence in the 800 nm region (Figure A2.1). However, it is unlikely that a large 
proportion of the fluorescence detected from the intestine is only due to diet, as no signal 
is observable around the anus area of untreated mice. Furthermore, anal fluorescence 
starts to be detected in treated mice 1 h post injection. This suggests that the majority of 
the NIR emission is indeed associated with the nanoparticles. Interestingly, a large 
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fluorescence signal was also observed in both kidneys. However, this accumulation 
appears outside the cortex region, most probably being trapped in surrounding connective 
tissue. Therefore, the particles are likely being excreted via the gastrointestinal/ 
hepatobiliary system. This excretion route is well known for nanoparticles, as their size 
is above the renal filtration limit (4.5 -5 nm)57, and will typically accumulate in the liver, 
spleen and intestine.58  
There are relatively few reports on the biodistribution and pharmacokinetics of 
intraperitoneally administered polymeric nanoparticles.59, 60 Nonetheless, this system can 
still be compared to similar studies using non-polymeric nanomaterials. For example, in 
contrast to 100 nm mesoporous silica nanoparticles (MSN), this system shows far quicker 
clearance from the peritoneal cavity, (64% after 76 h compared to 0-5% after 160 h), but 
greater accumulation in the abdominal organs (liver, spleen, intestine).53 Meanwhile, a 
similar study on gold nanoparticles revealed almost complete clearance within 24 h, with 
similar accumulation in the liver and spleen.61 Overall, these results indicate that P(n-BA) 
nanoparticles may prove effective against liver and intestinal cancers as they are 
deposited and retained in these organs. Importantly, the observed intestinal accumulation 
(probably due to hepatobiliary clearance) may enhance their drug delivery potential, 
(compared to other systems which are mainly retained in the peritoneal cavity) as it is 
possible for secondary re-adsorption to occur.58  
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Figure 2.13. Total fluorescence, measured with the 800 nm channel of a LICOR Pearl®trilogy observed 
from entire mouse over 76 h after a single intraperitoneal injection (1.2 mg kg-1) of Cy7.5 loaded 50 nm 
P(n-BA) nanoparticles. 
 
Figure 2.14. Total fluorescence per unit area of excised organs, measured with the 800 nm channel of a 
LICOR Pearl®trilogy, 76 h after a single intraperitoneal injection (1.2 mg kg-1) of Cy7.5 loaded 50 nm P(n-
BA) nanoparticles. 
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2.3 Conclusion 
By generating a library of P(PEGA) shell and P(n-BA) and P(t-BA) core nanoparticles, 
we have shown that RAFT emulsion polymerisation is a highly versatile method to 
synthesise biocompatible nanomaterials. Furthermore, this approach is particularly 
interesting for its industrial scale up potential as reactions are performed in 
environmentally friendly aqueous environments, and reach full consumption of cytotoxic 
monomer within a matter of hours. These advantages allow use of the nanoparticles for 
biological purposes without prior purification. The particles displayed no toxicity in in 
vitro and in vivo experiments, and relatively long retention in mice post administration 
with high accumulation in the liver. Overall, this synthetic approach has the potential to 
influence future nanoparticle design aimed at biomedical applications. 
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2.4 Experimental 
2.4.1 Materials 
Poly(ethylene glycol) methyl ether acrylate (PEGA, average Mn = 480 g mol-1), n-butyl 
acrylate (n-BA, >99%) and t-butyl acrylate (t-BA 98%), bromo-propionic acid (>99%), 
1-butanethiol (99%), carbon disulphide (>99%) and tannic acid (ACS reagent) were 
obtained from Sigma-Aldrich. All monomers above were passed through 
basic aluminium oxide to remove inhibitor before use. Dimethyl sulfoxide-d6 (99.9% D 
atom), chloroform-d3 (99.8% D atom), were obtained from Sigma Aldrich and used 
for 1H NMR spectroscopy. Thermal initiators 4,4′-azobis(4-cyanovaleric acid) (ACVA, 
>98%, Aldrich), 2,2’-Azobis[2-(2-imidazolin-2-yl)propane]dihydrochloride (VA-044) 
and 2,2'-Azobis[N-(2-carboxyethyl)-2-methylpropionamidine]tetrahydrate (VA-057) 
(Wako) were used as received. Cyanine 7.5 amine was purchased from Lumiprobe. TEM 
grids were purchased from EM Resolutions Ltd (Sheffield, UK). RAFT agent, 2-
(((butylthio)carbonothioyl)thio)propanoic acid (PABTC) was synthesised as previously 
described.20 Materials for cell culture were purchased from Greiner Bio-one (Germany), 
and culture medium prepared in-house.  
2.4.2 Instrumentation and Analysis 
2.4.2.1 NMR spectroscopy 
1H and 13C NMR spectra were recorded on a Bruker DPX-250, DPX-300, DPX-400 or 
DPX-500 spectrometer using deuterated solvent (materials section). The residual 
protonated solvent was used as an internal reference 
 
2.4.2.2 Size exclusion chromatography 
SEC was performed using an Agilent 390-LC MDS instrument equipped with differential 
refractive index (DRI), viscometry (VS), dual angle light scatter (LS) and two wavelength 
UV detectors. The system was equipped with 2 x PLgel Mixed C columns (300 x 7.5 mm) 
and a PLgel 5 µm guard column. The eluent was CHCl3 with 2% TEA (triethylamine) 
additive. Samples were run at 1 mL min-1 at 30°C. Poly(methyl methacrylate), and 
polystyrene standards (Agilent EasyVials) were used for calibration. Ethanol was added 
as a flow rate marker. Analyte samples were filtered through a GVHP membrane with 
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0.22 μm pore size before injection. Respectively, experimental molar mass (Mn,SEC) and 
dispersity (Đ) values of synthesized polymers were determined by conventional 
calibration using Agilent GPC/SEC software. 
 
2.4.2.3 Theoretical molar mass calculation 
CTA
M
thn MCTA
pMMM  
0
0
, ][
][
 
Equation 2.12. Calculation of theoretical number average molar mass (Mn,th) where [M]0 and [CTA]0 are 
the initial concentrations (in mol dm-3) of monomer and chain transfer agent respectively. p is the monomer 
conversion as determined by 1H NMR spectroscopy. MM and MCTA are the molar masses (g mol-1) of the 
monomer and chain transfer agent respectively. 
 
2.4.2.4 Dynamic light scattering, size and zeta-potential 
Size and ζ-potential measurements were carried out using a Malvern Zetasizer Nano-ZS 
at 25°C with a 4 mW He-Ne 633 nm laser at a scattering angle of 173° (back 
scattering).  Measurements were taken assuming the refractive index of: polyethylene 
glycol for macro-RAFT agents, and the refractive index of the core material (e.g. n-butyl 
acrylate, t-butyl acrylate) for latex particles. DLS samples of latex particles were prepared 
by diluting by 1000 with 1 mL of water and measured unfiltered in 1.5 mL polystyrene 
cuvettes for measuring size and a Malvern DTS-1070 zeta cuvette for ζ-potential. Diblock 
copolymer macro-RAFT agent samples were measured at the concentration of a typical 
RAFT emulsion polymerisation (15 mg mL-1). Samples were incubated for 60 seconds at 
25°C prior to measurement. Measurements were repeated three times with automatic 
attenuation selection and measurement position. Results were analysed using Malvern 
DTS 6.20 software. PDi values were calculated using the following equation. 
Measurements of ζ-potential were modelled with the Smoluchowski theory.      
2
2
hd
PDi V  
Equation 2.13. Calculation of nanoparticle polydispersity (PDi) from standard deviation (σ), and diameter 
(d). 
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2.4.2.5 Static light scattering 
Static light scattering measurements were conducted using an ALV-CGS3 system (ALV-
Langen) operating with a vertically polarized laser with wavelength λ = 632.8 nm and 
conducted on the non-fluorescent nanoparticle derivatives. The measurements were 
performed at 20°C over a range of angles (20, 30, 50, 70, 90, 110, 130 and 150 degrees) 
with water as the solvent. Samples were measured unfiltered. The intercepts for each 
concentration of plots for q vs KC/R were then plotted against concentration, and the 
intercept of the latter graph was taken as the apparent molar mass.  
2.4.2.6 Different Refractometry 
Measurements were performed with an RI-101 from Shodex (O0=632 nm). The refractive 
index increment was measured in water using 5 concentrations of nanoparticles and the 
dn/dC was calculated using Equation 2.8. 
2.4.2.7 Cryogenic-transmission electron microscopy 
8 µL of the sample was applied to a glow-discharged lacey carbon grid (EM Resolutions), 
blotted for 4 seconds and frozen in liquid propane/ethane (30% 70% v/v) using a custom-
made plunge-freezing device. Grids were imaged in the JEOL 2200FS with a Gatan K2 
camera and a Gatan 914 cryo-holder cooled to -180 ˚C.   
2.4.2.8 Fluorescence spectroscopy 
Fluorescence emission spectra were measured using an Agilent Cary Eclipse fluorescence 
spectrometer. Studies were performed by exciting at the absorption maxima of Cy7.5 (800 
nm) and measured from 805 nm to 875 nm. The photomultiplier voltage was set such that 
the maxima was below 1000 arbitrary units. Samples were diluted 1:100 fold in pure 
water for measurement.  
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2.4.3 Synthetic Procedures 
2.4.3.1 Synthesis of (propanoic acid)yl butyl trithiocarbonate (PABTC)20 
A 50% w/w sodium hydroxide solution (9.68 g NaOH, 0.242 mol, 1.1 eq) in water was 
added to a mixture of butanethiol (20 g, 0.22 mol, 1 eq) dissolved in acetone (11 mL). 
Water (40 mL) was added and the solution was stirred for 30 min at room temperature. 
Carbon disulphide (17.32 g, 0.228 mol, 1.025 eq) was added and the orange solution was 
stirred for 30 minutes at room temperature, then cooled in ice below 10°C. 2- 
Bromopropionic acid (34.9 g, 0.228 mol, 1.025 eq) was added slowly, monitoring the 
temperature, and subsequently a further 19.36 g of 50% w/w sodium hydroxide solution 
was added. The reaction mixture was left to stir for 18 h at ambient temperature. 200 mL 
of water was added to the reaction mixture, cooled in ice, and a 10 M solution of HCl was 
added dropwise until the pH reached between 2-3. The resulting precipitate was filtered, 
washed with water, and recrystallised in hot hexane to afford 36.53 g of 2-
(((butylthio)carbonothioyl)thio)propanoic acid. Yield = 70%. 1H NMR (400 MHz, 
CDCl3) δH 6.06 (br, 1H, CO2H), 4.86 (q, J = 7.4 Hz, 1H, SCH), 3.37 (t, J = 7.4 Hz, 2H, 
CH2S), 1.69 (quint, J = 7.5 Hz, 2H, CH2CH2S), 1.63 (d, J = 7.4 Hz, 3H, SCHCH3), 1.43 
(sext, J = 7.5 Hz, 2H, CH3CH2CH2), 0.94 (t, J = 7.3 Hz, 3H, CH3CH2). 13C NMR (100 
MHz, 298 K CDCl3) δc 175.4 (COOH), 47.2 (SCH), 37.1(CH2S), 29.88 (CH2CH2S), 
22.1(CH3CH2CH2), 16.4 (CH3CH), 13.6 (CH3CH2CH2). FTIR (cm-1): 3093, 2958, 2929, 
2871, 2362, 2340, 1454, 1412, 1285, 1230, 1200, 1089, 1059, 912, 861. MS (ESI) m/z 
237.0 [M-H], 238 [M-]  
2.4.3.2 P(PEGA)8 (MRA-PEGA) synthesis 
PABTC (0.31 g, 1.30 x 10-3 mol), PEGA (5 g, 10.4 x 10-3 mol) and ACVA (from a pre-
made stock solution in 1,4-dioxane) (18 mg, 6.51 x 10-5 mol) were dissolved in 4.9 mL 
1,4-dioxane in a 25 mL round bottom flask equipped with a magnetic stirrer bar. The 
solution was fitted with an appropriately sized rubber septum, and purged with nitrogen 
for 20 minutes. The round bottom flask was subsequently immersed in an oil bath 
preheated to 70°C and stirred for 3 h. The reaction vessel was cooled to ambient 
temperature and opened to oxygen to quench further polymerisation. The polymer was 
purified by precipitation into a mixture of 20% hexane and 80% diethyl ether (v/v), 
collected, and the precipitation repeated once more. Finally, the precipitated polymer was 
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dissolved in DCM, transferred to a 20 mL vial, the DCM evaporated and dried in a 
vacuum oven overnight at 40°C to yield P(PEGA)8 as a yellow viscous liquid (4.5 g).  
2.4.3.3 Macro-RAFT agent synthesis 
Both MRA-nBA and MRA-tBA macro-RAFT agents were synthesized with the 
following general procedure, as an example P(PEGA)8-P(n-BA)8 (MRA-nBA) is 
described. n-Butyl acrylate (0.25 g, 1.95 x 10-3 mol) and 0.68 mL of a 5 mg ml-1 ACVA 
stock solution in 1,4-dioxane (3.4 mg, 1.21 x 10-5 mol) were added to MRA-PEGA (0.94 
g, 2.43 x 10-4). The polymerisation mixture was purged with nitrogen for 20 minutes and 
heated to 70°C for 3 h. The resulting polymer solution was cooled to room temperature 
and subsequently purified by precipitation in hexane. The yellow viscous liquid was re-
dissolved in dichloromethane and the precipitation was repeated once more. Finally, the 
solvent was evaporated under reduced pressure to yield the di-block macro-RAFT agent 
as a yellow viscous liquid (0.95 g). 1H NMR spectra and SEC chromatograms can be 
found above (Figure 2.2 and Figure 2.1) respectively.   
Table 2.5. Summary of polymerisation conditions for Macro-RAFT agents. All reactions were performed 
at [M] = 1M, T = 3 h at 70°C using ACVA as thermal initiator and 1,4-dioxane as the solvent. 
 
2.4.3.4 RAFT emulsion polymerisation procedure 
Nanoparticles of different sizes and core compositions were prepared by altering various 
conditions, full details can be found in Table 2.6. As an example, P[(PEGA)8-b-(t-BA)8-
b-(t-BA)200] was prepared as follows. 1.43 mL of a 10 mg mL-1 sodium hydroxide stock 
solution (14.3 mg, 3.6 x 10-4 mol) was added to a suspension of ACVA (50 mg, 1.8 x 10-
4 mol) in water (8.57 mL) and stirred for 30 min to ensure full solubility. P[(PEGA)8-b-
(t-BA)8] (MRA-tBA) (0.145 g, 2.85 x 10-5 mol) was dissolved in 7.71 mL of water, in a 
25 mL round bottomed flask and equipped with a magnetic stirrer. 1.45 mL of the above 
ACVA stock solution was added, the vial fitted with a rubber septum, and the solution 
was deoxygenated with dinitrogen gas for 20 minutes. Deoxygenated t-BA (0.83 mL, 
2.14 x10-3 mol) was added via syringe and the polymerisation mixture was immersed in 
 Monomer RAFT agent [M]0/[RAFT]0 [CTA]0/[I]0 Conversion (%) 
MRA-PEGA PEGA PABTC 9 20 91 
MRA-nBA n-BA MRA-PEGA 8 20 96 
MRA-tBA t-BA MRA-PEGA 8 20 94 
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a 70°C oil bath and stirred for 3 h at 400 RPM. Monomer conversion was determined via 
gravimetric techniques. 
Table 2.6. Synthetic conditions used to generate P[(PEGA)8-b-(n-BA)8-b-(n-BA)n] and P[(PEGA)8-b-(t-
BA)8-b-(t-BA)n] nanoparticles (where n = 200, 150, 100, 75 and 50) using RAFT emulsion polymerisation.  
Product  Macro-RAFT agent Monomer 
[M]0/ 
[CTA]0 
[CTA]0/ 
[I]0 
[M] 
 (mol L-1) 
P[(PEGA)8-b-(n-BA)8-(n-BA)200] MRA-nBA n-BA 200 1.1 0.57 
P[(PEGA)8-b-(n-BA)8-(n-BA)150] MRA-nBA n-BA 150 1.1 0.428 
P[(PEGA)8-b-(n-BA)8-(n-BA)100] MRA-nBA n-BA 100 1.1 0.285 
P[(PEGA)8-b-(n-BA)8-(n-BA)75] MRA-nBA n-BA 75 1.1 0.214 
P[(PEGA)8-b-(n-BA)8-(n-BA)50] MRA-nBA n-BA 50 1.1 0.143 
P[(PEGA)8-b-(t-BA)8-(n-BA)200] MRA-tBA t-BA 200 1.1 0.57 
P[(PEGA)8-b-(t-BA)8-(n-BA)150] MRA-tBA t-BA 150 1.1 0.428 
P[(PEGA)8-b-(t-BA)8-(n-BA)100] MRA-tBA t-BA 100 1.1 0.285 
P[(PEGA)8-b-(t-BA)8-(n-BA)75] MRA-tBA t-BA 75 1.1 0.214 
P[(PEGA)8-b-(t-BA)8-(n-BA)50] MRA-tBA t-BA 950 1.1 0.143 
 
All polymerisations were performed in aqueous conditions, with [macro-RAFT]0 = 2.85 mM and reached 
full (>99%) monomer conversion. 
 
2.4.3.5 PEG binding assay 
Tannic acid was diluted to a concentration of 10 µg mL-1 in deionised water. Nanoparticle 
suspensions were diluted with deionised water to a concentration of 10 µg mL-1. 1 mL of 
the nanoparticle suspensions were transferred to a polystyrene cuvette and placed in the 
UV-VIS spectrometer. Absorbance measurements were recorded once every 1 s. After 1 
min, 250 µL of the tannic acid solution was added via micropipette and mixed briefly 
without allowing the pipette tip into the detection window. The absorption was monitored 
for a further 4 minutes. 
2.4.3.6 Encapsulation of Cyanine 7.5 
Cy7.5 (1 mg) was added to 1 mL of 10% DMF in THF and sonicated until the powder 
had fully dissolved. 100 µL of the Cy7.5 solution was added to 900 µL of nanoparticle 
suspension and shaken for 1 h. The suspension was then dialysed (3500-5000 Da MWCO) 
against pure water for 48 h to remove residual DMF and THF. Loaded particles were used 
immediately after encapsulation for in vivo fluorescence studies.  
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2.4.4 In vitro studies 
2.4.4.1 Cell culture 
Caco-2 cells were purchased from ECACC (European Collection of Animal Cell Culture, 
Salisbury, UK) and cultured as single monolayers at 37°C in a humidified atmosphere 
containing 5% CO2. Cells were cultured in a 50:50 mixture of Dulbecco’s Modified Eagle 
Medium (DMEM) and HAMS F12 supplemented with 10% of foetal calf serum, 1% of 
L-glutamine and 1% penicillin/streptomycin sub-cultured at regular intervals, and 
passages made by trypsinising cells when at 80-90% confluence. 
2.4.4.2 Cell viability assay 
Caco-2 cells were seeded at a density of 10,000 cells per well in a flat bottomed clear 96 
well plate and incubated for 24 h. Nanoparticles were diluted with cell culture medium 
into a 2 mg mL1 suspension. The stock solution was then serially diluted to make solutions 
of 100 ng mL1, 1 µg mL-1, 10 µg mL-1, 100 µg mL-1, 500 µg mL-1 and 2 mg mL-1. The 
cells were incubated in the presence of the nanoparticle suspensions for 72 h. To 
determine the cell viability the sulforhodamine B colourimetric assay was used. 50 µL of 
cold 50% trifluoroacetic acid were added to each well of the plate and left to incubate for 
1 h at 4°C. The plate was subsequently washed 10 times with slow running tap water to 
remove excess trifluoroacetic acid and the plate was heated gently with warm air to 
remove moisture. 50 µL of 0.4% sulforhodamine B (prepared in 1% acetic acid) were 
added to each well of the plate and the plate was allowed to stand for 30 min at ambient 
temperature. Excess dye was removed by washing the plate 5 times with 1% acetic acid. 
200 µL of 10 mM Tris base solution (pH 10.5) was added to each well of the plate and 
left to stand at ambient temperature for 1 h. The absorbance of each well was measured 
at 570 nm on a BioRad iMark 96-well microplate reader. The experiments were carried 
out as duplicates of triplicates in two independent experiments. 
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2.4.5 In vivo studies 
2.4.5.1 Animal handling 
All in vivo studies were conducted on male CD1 mice purchased from Charles River 
(UK). Upon arrival, mice were allowed to adjust to the new environmental condition for 
at least two weeks. Humidity and temperature were kept between 45 to 60% and between 
20 to 24°C, respectively, and animals had 12 hours of light per day with light onset at 
07:00. Mice had ad libitum access to food and water. All in vivo experiments were carried 
out in accordance with the Animal Scientific Procedure Act 1986 under the Procedure 
Project Licence (PPL) number 70/3685.  
2.4.6 In vivo toxicity 
For acute, single dose toxicity evaluation, 29 six to seven week old male mice were 
randomised into eight groups and intraperitoneally (i.p.) injected with the different 
nanoparticles (N=3/group), vehicle (PBS, N=3) or nothing (N=2). Nanoparticle groups 
were injected with 49 and 86 nm P(t-BA), and 50 and 93 nm P(n-BA) nanoparticles at 
either 1.2 mg kg-1 (0.2 mg ml-1 in 200 µl PBS) or 12 mg kg-1 (2 mg ml-1 in 200 µl PBS). 
Of note, nanoparticle dilutions were prepared in sterile PBS under aseptic conditions and 
stored at 2 to 8°C until treatment. After injection, mice were monitored daily for the 
following 7 days, and body weight as well as signs of pain or distress were recorded.  
For the repeat dosing study, 35 six-week old male mice were selected. Mice were 
randomised into four nanoparticle treatment groups (N=6/groups) and 2 control groups 
(PBS N=3; no-injection N=2) as described above. Each mouse was i.p. injected daily with 
12 mg kg-1 (200 µl of 2 mg ml-1) 49 and 86 nm P(t-BA), and 50 and 93 nm P(n-BA) 
nanoparticles or PBS for five consecutive days. The second control group was not injected 
and left untreated. After the first injection, mice were monitored daily for the following 
8 days, and body weight as well as signs of pain or distress were recorded.  
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2.4.7 In vivo biodistribution  
For biodistribution studies, CD1 mice were injected intraperitoneally with a single dose 
of Cy 7.5 labelled P(n-BA) 50 nm nanoparticles (1.2 mg kg-1). In vivo fluorescence was 
followed periodically up to 76 h post injection using a LICOR Pearl® Trilogy in vivo 
imager on the 800 nm channel. Pharmacokinetic curves were obtained by quantifying the 
total fluorescence coming from the animal using open access software Image Studio 
LiteTM. Organs were excised and imaged immediately. Organ fluorescence/ unit area was 
established by drawing around each organ and dividing this value by the area reported in 
the software.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
87 
 
References 
1. M. Elsabahy and K. L. Wooley, Chem. Soc. Rev, 2012, 41, 2545-2561. 
2. M. Beija, R. Salvayre, N. Lauth-de Viguerie and J.-D. Marty, Trends Biotechnol., 
2012, 30, 485-496. 
3. F. Alexis, E. Pridgen, L. K. Molnar and O. C. Farokhzad, Mol. Pharm., 2008, 5, 
505-515. 
4. H. Maeda, H. Nakamura and J. Fang, Adv. Drug Delivery Rev., 2013, 65, 71-79. 
5. H. Maeda, J. Controlled Release., 2012, 164, 138-144. 
6. P. C. Ke, S. Lin, W. J. Parak, T. P. Davis and F. Caruso, ACS Nano, 2017, 11, 
11773-11776. 
7. D. A. Richards, A. Maruani and V. Chudasama, Chem. Sci., 2016, 8, 63-77. 
8. M. Roveri, M. Bernasconi, J.-C. Leroux and P. Luciani, J. Mater. Chem. B, 2017, 
5, 4348-4364. 
9. B. Kang, T. Opatz, K. Landfester and F. R. Wurm, Chem. Soc. Rev, 2015, 44, 
8301-8325. 
10. L. Zhang, F. X. Gu, J. M. Chan, A. Z. Wang, R. S. Langer and O. C. Farokhzad, 
Clin. Pharmacol. Ther. (St. Louis), 2008, 83, 761-769. 
11. A. Albanese, P. S. Tang and W. Chan, Annu. Rev. Biomed. Eng., 2012, 14, 1-16. 
12. X. Tao, S. Jin, D. Wu, K. Ling, L. Yuan, P. Lin, Y. Xie and X. Yang, 
Nanomaterials, 2015, 6, 2. 
13. A. Verma and F. Stellacci, Small, 2010, 6, 12-21. 
14. A. Rösler, G. Vandermeulen and H.-A. Klok, Adv. Drug Delivery Rev., 2001, 53, 
95-108. 
15. J. Zhang, J. Tanaka, P. Gurnani, P. Wilson, M. Hartlieb and S. Perrier, Polym. 
Chem., 2017, 8, 4079-4087. 
16. J. Ugelstad and F. Hansen, Rubber Chem. Technol., 1976, 49, 536-609. 
17. T. Sun, Y. S. Zhang, B. Pang, D. C. Hyun, M. Yang and Y. Xia, Angew. Chem., 
Int. Ed., 2014, 53, 12320-12364. 
18. G. Cheng, A. Böker, M. Zhang, G. Krausch and A. H. E. Müller, Macromolecules, 
2001, 34, 6883-6888. 
19. M. Hartlieb, T. Floyd, A. B. Cook, C. Sanchez-Cano, S. Catrouillet, J. A. Burns 
and S. Perrier, Polym. Chem., 2017, 8, 2041-2054. 
20. C. J. Ferguson, R. J. Hughes, D. Nguyen, B. T. Pham, R. G. Gilbert, A. K. Serelis, 
C. H. Such and B. S. Hawkett, Macromolecules, 2005, 38, 2191-2204. 
21. P. B. Zetterlund, S. C. Thickett, S. Perrier, E. Bourgeat-Lami and M. Lansalot, 
Chem. Rev., 2015, 115, 9745-9800. 
 
 
88 
 
22. T. P. Davis, N. Truong Phuoc, M. Dussert, M. R. Whittaker and J. F. Quinn, 
Polym. Chem., 2015, 6, 3865-3874. 
23. M. Chenal, L. Bouteiller and J. Rieger, Polym. Chem., 2013, 4, 752-762. 
24. W. Zhang, F. D’Agosto, O. Boyron, J. Rieger and B. Charleux, Macromolecules, 
2012, 45, 4075-4084. 
25. D. E. Ganeva, E. Sprong, H. de Bruyn, G. G. Warr, C. H. Such and B. S. Hawkett, 
Macromolecules, 2007, 40, 6181-6189. 
26. S. R. S. Ting, E. H. Min, P. B. Zetterlund and M. H. Stenzel, Macromolecules, 
2010, 43, 5211-5221. 
27. G. Jiang, Y. Wang, R. Zhang, R. Wang, X. Wang, M. Zhang, X. Sun, S. Bao, T. 
Wang and S. Wang, ACS Macro Lett., 2012, 1, 489-493. 
28. C. K. Poon, O. Tang, X.-M. Chen, B. T. T. Pham, G. Gody, C. A. Pollock, B. S. 
Hawkett and S. Perrier, Biomacromolecules, 2016, 17, 965-973. 
29. C. K. Poon, O. Tang, X.-M. M. Chen, B. Kim, M. Hartlieb, C. A. Pollock, B. S. 
Hawkett and S. Perrier, Macromol. Biosci., 2016, 17. 
30. M. Siauw, B. S. Hawkett and S. Perrier, J. Polym. Sci., Part A: Polym. Chem., 
2012, 50, 187-198. 
31. F. M. Veronese and G. Pasut, Drug Discov. Today, 2005, 10, 1451-1458. 
32. J. M. Harris and R. B. Chess, Nat. Rev. Drug Discovery, 2003, 2, 214-221. 
33. K. Knop, R. Hoogenboom, D. Fischer and U. S. Schubert, Angew. Chem., Int. Ed., 
2010, 49, 6288-6308. 
34. L. Martin, G. Gody and S. Perrier, Polym. Chem., 2015, 6, 4875-4886. 
35. G. Gody, T. Maschmeyer, P. B. Zetterlund and S. Perrier, Macromolecules, 2014, 
47, 3451-3460. 
36. D. Pissuwan, C. Boyer, K. Gunasekaran, T. P. Davis and V. Bulmus, 
Biomacromolecules, 2010, 11, 412-420. 
37. J. Rieger, W. Zhang, F. o. Stoffelbach and B. Charleux, Macromolecules, 2010, 
43, 6302-6310. 
38. F. Wang, Y. Luo, B.-G. Li and S. Zhu, Macromolecules, 2015, 48, 1313-1319. 
39. Y. Guo, X. Gao and Y. Luo, J. Polym. Sci., Part A: Polym. Chem., 2015, 53, 1464-
1473. 
40. C. J. Ferguson, R. J. Hughes, B. T. Pham, B. S. Hawkett, R. G. Gilbert, A. K. 
Serelis and C. H. Such, Macromolecules, 2002, 35, 9243-9245. 
41. S. S. Gosavi, S. Y. Gosavi and R. K. Alla, Dent. Res. J., 2010, 7, 82-87. 
42. K. Y. van Berkel, G. T. Russell and R. G. Gilbert, Macromolecules, 2003, 36, 
3921-3931. 
 
 
89 
 
43. M. Gaumet, A. Vargas, R. Gurny and F. Delie, Eur. J. Pharm. Biopharm., 2008, 
69, 1-9. 
44. I. Chaduc, A. Crepet, O. Boyron, B. Charleux, F. D’Agosto and M. Lansalot, 
Macromolecules, 2013, 46, 6013-6023. 
45. H. P. S. Makkar, M. Blümmel and K. Becker, Br. J. Nutr., 1995, 73, 897-913. 
46. J. Niu, D. J. Lunn, A. Pusuluri, J. I. Yoo, M. A. O'Malley, S. Mitragotri, T. H. Soh 
and C. J. Hawker, Nat. Chem., 2017, 9. 
47. N. Silanikove, N. Gilboa, I. Nir, A. Perevolotsky and Z. Nitsan, J. Agric. Food 
Chem., 1996, 44, 199-205. 
48. M. Shin, K. Kim, W. Shim, J. Yang and H. Lee, ACS Biomater. Sci. Eng., 2016, 
2, 687-696. 
49. R. Gref, M. Lück, P. Quellec, M. Marchand, E. Dellacherie, S. Harnisch, T. Blunk 
and R. H. Müller, Colloids Surf., B, 2000, 18, 301-313. 
50. X.-J. Du, J.-L. Wang, W.-W. Liu, J.-X. Yang, C.-Y. Sun, R. Sun, H.-J. Li, S. Shen, 
Y.-L. Luo, X.-D. Ye, Y.-H. Zhu, X.-Z. Yang and J. Wang, Biomaterials, 2015, 
69, 1-11. 
51. M. Pröhl, S. Seupel, P. Sungur, S. Höppener, M. Gottschaldt, J. C. Brendel and 
U. S. Schubert, Polymer, 2017, 133. 
52. J. V. Jokerst, T. Lobovkina, R. N. Zare and S. S. Gambhir, Nanomedicine, 2011, 
6, 715-728. 
53. J. Lu, M. Liong, Z. Li, J. I. Zink and F. Tamanoi, Small, 2010, 6, 1794-1805. 
54. J. Eichler, J. Knof and H. Lenz, Radiat. Environ. Biophys., 1977, 14, 239-242. 
55. T. Behnke, C. Würth, K. Hoffmann, M. Hübner, U. Panne and U. Resch-Genger, 
J. Fluoresc., 2011, 21, 937-944. 
56. L. Fan, Q. Wu and M. Chu, Int. J. Nanomed., 2012, 7, 3071-3080. 
57. W. B. Liechty and N. A. Peppas, Eur. J. Pharm. Biopharm., 2012, 80, 241-246. 
58. M. Longmire, P. L. Choyke and H. Kobayashi, Nanomedicine (London, England), 
2008, 3, 703-717. 
59. H. L. Reddy and R. S. Murthy, Biomed. Pap., 2004, 148, 161-166. 
60. P. Maincent, P. Thouvenot and C. Amicabile, Pharm. Res., 1992, 9, 1534-1539. 
61. R. R. Arvizo, O. R. Miranda, D. F. Moyano, C. A. Walden, K. Giri, R. 
Bhattacharya, D. J. Robertson, V. M. Rotello, J. M. Reid and P. Mukherjee, PloS 
one, 2011, 6. 
 
 
Chapter 3  
 
Probing the effect of nanoparticle rigidity on 
cellular uptake 
 
Nanoparticles are well established as vectors for the delivery of a wide range of 
biologically relevant cargo. The design of these materials has been led by numerous 
fundamental studies investigating size, shape, charge and functionality on mammalian 
cellular uptake. Nanoparticle rigidity however has been studied to a far lesser extent. 
This parameter can easily be controlled using the intrinsic glass transition temperature 
(Tg) of polymers. Here, we explore this property with a systematic study using a library 
of core-shell spherical PEGylated nanoparticles with three different polymeric core 
rigidities: hard, medium and soft, controlled with Tg, synthesised by RAFT emulsion 
polymerisation. The cellular internalisation, and uptake pathway was investigated, with 
results indicating that softer particles are taken up faster and in higher amounts, with a 
3 fold increase over harder analogues. In addition, this study indicates major differences 
in the cellular uptake pathway, with harder particles being internalised through clathrin- 
and caveolae- mediated endocytosis as well as macropinocytosis, while softer particles 
were taken up with mainly caveolae- and clathrin/caveolae-independent endocytosis. We 
have also studied if size and rigidity have any complimentary effect, however our smaller 
(50 nm) derivatives did not show any appreciable differences in uptake efficiency 
suggesting that rigidity as a parameter in the biological regime may indeed be size 
dependent.  
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3.1 Introduction 
Over the last two decades, a multitude of studies have been dedicated to understand how 
individual nanoparticle properties (size1, 2, shape3, 4, charge5, 6, functionality7, 8 etc) 
influences their biological interactions in vitro and in vivo. In particular, understanding 
how these affect the degree and mechanism of cellular uptake is vital for improving their 
pharmacological efficacy. It is well established that the mechanical properties of 
biomaterials are important for maintaining specific biological functions9,10,11, however 
the effect of nanoparticle rigidity/elasticity on biological systems remains loosely 
explored. The current literature surrounding stiffness mediated cellular uptake has no 
general consensus on whether harder12, 13 or softer particles13-15 are preferentially taken 
up. Based on simulation data, it is however clear that the ability for soft nanoparticles to 
deform when interacting with the cell surface has a dramatic influence on their 
mechanism of uptake.16 This therefore can either increase the adhesion energies required 
to complete internalisation if single particles are taken up (making hard easier to 
internalise than soft). This deformation can also increase the chance for cooperative 
uptake i.e. 2 or more particles at once (making soft preferentially internalised than hard). 
Nonetheless, simulation data cannot paint the entire picture for nanoparticle interactions 
with complex biological systems, especially when considering uptake mechanisms such 
as receptor-mediated endocytosis. So far, the effect of rigidity on cellular uptake has 
mainly been studied with large particles (~ 1 µm),17, 18 but again have yielded conflicting 
results, with either rigid or flexible particles preferentially internalised.17 Furthermore, 
although drug delivery vectors using smaller nanoparticles (10 – 200 nm) have shown 
greater therapeutic efficacy,19 few studies have focused on rigidity at this scale.  
This lack of consensus on the degree of cellular uptake of particles may arise from the 
range of methods used to control nanoparticle rigidity. For example, the rigidity of 
colloidal hydrogels20 were previously modified by adjusting the crosslinking density,21 
regulating the water content of the particle core directly impacting the flexibility of the 
nanoparticle. Rigidity of layer-by-layer(LbL)/templated nanocapsules22 was adapted by 
tuning the charge density and/or number of layers of oppositely charged polyelectrolytes 
present around the nanocapsules.14  Unfortunately, these approaches may also impact 
other physicochemical properties (particle size, shape, surface ionisation and 
 
 
92 
 
hydrophobicity)1, 6, 7 which are known to heavily influence cellular uptake, making the 
effect of rigidity difficult to characterise in itself.12  
A traditional method of controlling flexibility in bulk polymeric materials is to vary the 
monomer composition and thus the glass transition temperature (Tg).23 Tg is defined as 
the midpoint of the temperature range at which a material transforms from a hard state to 
a soft state. This change in properties arises due to a distinct change in mobility of chains 
within the polymeric matrix upon reaching the Tg. As Tg is an intrinsic material property, 
this method poses significant advantages over other techniques as one simply has to 
choose the correct monomer composition to tune nanoparticle rigidity. It can therefore be 
postulated that if a polymer nanoparticle possesses a Tg >> 37°C this would result in a 
hard state in physiological conditions, however, if the Tg << 37°C it would exist in a soft 
state. Tg has been used to modify the rigidity of nanoparticles (synthesised via 
miniemulsion polymerisation) by increasing the alkyl side chain lengths of 
polyalkylmethacrylates (from one to 16 carbon; poly(methylmethacrylate) to 
poly(stearylmethacrylate)),24. These results showed that a decrease in Tg triggered an 
increase in cellular uptake of nanoparticles over a wide range of cell lines. However, the 
use of longer side chains led to both lower Tg and increased surface hydrophobicity, which 
is known to drastically impact cellular uptake.7 To achieve a real understanding of the 
importance of rigidity in cellular uptake, nanoparticles with different Tg should be 
generated with identical surface chemistry, such that changes in hydrophobicity and other 
physical properties do not interfere with the study.  
In chapter 2, RAFT emulsion polymerisation was used to generate well-defined core-shell 
nanoparticles, whereby the surface and core chemistry could be easily tuned, as well as 
particle size. Nanoparticles synthesised with this approach lend themselves towards 
fundamental studies, as they maintain their structural integrity at low concentration, and 
a variety of core monomers can be used to adapt the desired particle rigidity. In this 
chapter, a series of inert uniform PEGylated core-shell nanoparticles (with diameters of 
50 and 100 nm) were synthesised via RAFT emulsion polymerisation with three differing 
core rigidities/Tg and identical surface chemistry. Using these, we have evaluated various 
aspects of their cellular internalisation, including degree of uptake, uptake pathway, and 
intracellular trafficking. 
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3.2 Results and discussion 
The aim of this chapter was to utilise RAFT emulsion polymerisation to generate 
nanoparticles of different rigidity, and investigate the degree and mechanism of their 
cellular uptake. We hypothesised that polystyrene (PS) (Tg,lit = 100°C) , poly(t-butyl 
acrylate) (P(t-BA)) (Tg,lit = 43°C), and poly(n-butyl acrylate) (P(n-BA))  (Tg,lit = -54°C)25 
had appropriate Tg as the polymeric materials to obtain ‘hard’ ‘medium’ and ‘soft’ core 
nanoparticles respectively. In addition, we wanted to examine if rigidity effects were size 
dependent, therefore both 100 and 50 nm diameter nanoparticles of hard, medium and 
soft varieties were targeted for this study. In chapter 2, we showed how RAFT emulsion 
polymerisation could be used to prepare PEGylated P(n-BA) (‘soft’) and P(t-BA) 
(‘medium’) nanoparticles, with diameters ranging from ~30 nm to ~130 nm. Hence prior 
to conducting this study, similar PEGylated PS based nanoparticles were synthesised as 
a ‘hard’ rigidity derivative.  
3.2.1 Optimising styrene RAFT emulsion polymerisations 
3.2.1.1 Synthesis of styrene based macro-RAFT agent 
Initially, an analogous macro-RAFT agent P(PEGA)8-b-Sty8] (MRA-PS) was prepared 
by chain extending MRA-PEGA (synthesised in Section 2.2.2) using adapted literature 
conditions and purified as mentioned above (Section 2.2.2; Scheme 3.1).26 
 
Scheme 3.1 Preparation of MRA-PS via chain extension of MRA-PEGA in dioxane at 90°C. 
Similarly to MRA-nBA and MRA-tBA, size exclusion chromatograms of MRA-PS 
revealed narrow molecular weight distributions, comparable experimental Mn to 
theoretical values obtained from 1H NMR spectra,  and a shift toward higher molar mass 
suggesting successful chain extension (Figure 3.1a and Figure 3.1b). As with the P(t-BA) 
and P(n-BA) analogues, dynamic light scattering of MRA-PS in aqueous conditions 
revealed the formation of uniform 6.5 nm micelles (PDi = 0.07; Figure 3.1c), suggesting 
it would be able to stabilise RAFT emulsion polymerisations.  
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Figure 3.1. Characterisation data for MRA-PS (A) CHCl3-SEC chromatograms of MRA-PEGA (blue) and 
MRA-PS (red and (B) dynamic light scattering (intensity distribution = black line, volume distribution = 
green line, number distribution = red line) of self-assembled micelles at 7.5 mg mL-1 in pure water measured 
at 25°C (C) 1H NMR spectrum in d6-DMSO at 300 MHz 
Table 3.1. Summary of characterisation data for MRA-PS.  
 % 
conva 
Mn,th  
(g mol-1)b 
Mn,SEC   
(g mol-1)c 
Mw,SEC  
(g mol-1)c Ð
c Dhd PDie 
MRA-PEGA 
MRA-PS 
91 
92 
4100 
4900 
5100 
6000 
5800 
7000 
1.14 
1.17 
- 
6.5 
- 
0.070 
aDetermined by 1H NMR spectroscopy, bTheoretical molar masses calculated with Equation 2.12, 
cDetermined by CHCl3-SEC and analysed against PMMA standards, dDetermined using DLS, eCalculated 
using Equation 2.13. Data for MRA-PEGA (synthesised in Section 2.2.2) is repeated here for clarity. 
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3.2.1.2 Styrene RAFT emulsion polymerisation 
For RAFT emulsion polymerisations of styrene, the conditions used in section 2.2.3 were 
initially employed to chain extend MRA-PS by 200 monomer units (Scheme 3.2). 
Surprisingly, the resulting latex appeared colloidally unstable, with significant separation 
between the aqueous and polymer phases (Figure 3.2a). DLS revealed broad particle size 
distributions with PDi between 0.11 and 0.21 and average hydrodynamic diameters 
between 36 and 84 nm depending on distribution type, confirming the poor performance 
and stability of these latexes (Figure 3.2a; Table 3.2, Entry 1). It should be noted that any 
sediment/coagulum would not be easily detected by DLS, as these could be well above 
the optimum size range for this technique (1-1000 nm), potentially accounting for the low 
average particle diameter.  
 
Scheme 3.2. RAFT emulsion polymerisation of styrene mediated with MRA-PS  
 
Figure 3.2 Photograph of polystyrene latexes synthesised with (A) [MRA-PS] = 2.85 mM + [M] = 570 
mM and (B) [MRA-PS] = 5.70 mM + [M] = 570 mM, [MRA-PS] = 1.425 mM + [M] = 570 mM and [MRA-
PS] = 1.425 mM and [M] = 427 mM. 
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To test alternative conditions, analogous reactions were performed with MRA-PS at both 
200% (5.70 mM) and 50% (1.425 mM) of its original concentration (2.85 mM), while 
keeping [M] (570 mM) constant (Table 3.2, Entry 2 and 3). This modification in [MRA-
PS] causes variation in DPtarget with the 200% and 50% concentrations yielding chain 
lengths of 100 and 400 respectively. Both concentrations yielded similar nanoparticle 
diameters (~100 nm). At the higher concentration (5.70 mM), the resulting latex, although 
colloidally stable, was more viscous and had a broad PDi (0.162). In comparison, at a 
lower concentration (1.425 mM) the nanoparticle suspension remained colloidally stable, 
had narrow PDi (0.058) and was completely fluid (not viscous). Finally, a fourth 
polymerisation was conducted whereby the monomer concentration was reduced to 427 
mM (75% the original value), [MRA-PS] at 1.425 mM (optimum) and therefore a DPtarget 
of 300 (Table 3.2, Entry 4; Figure 3.2b). As in section 2.2.3, when [M] was reduced, the 
resulting particle diameter reduced from 107 nm for DPtarget = 400, to 64 nm DPtarget = 
300 and retained a narrow PDi (Figure 3.3).  
Although not all latexes had narrow particle size distributions, size exclusion 
chromatograms displayed relatively low Ð values (≤ 1.42), compared to the P(n-BA) and 
P(t-BA) nanoparticles synthesised above (section 2.2.3). This is largely due to a reduced 
amount of the side-chain branching and unconsumed macro-RAFT agent, unlike the P(t-
BA) and P(n-BA) nanoparticles synthesised in chapter 2. This could be explained by the 
low propagation rate constant (kp) of styrene in the early phase of the polymerisations, 
artificially increasing the chain transfer constant (Ctr = ktr/kp), and therefore improving the 
chain extension efficiency of MRA-PS compared to MRA-nBA and MRA-tBA. This 
could also explain why high MRA-PS concentrations result in colloidal instability, as the 
number of growing particles increases as a function of [MRA-PS] when all macro-RAFT 
agents are consumed, which may promote collisions in solution and therefore induce 
aggregation/sedimentation (Figure 3.3). Furthermore, this could also be an effect of 
superswelling, which is where the high proportion of oligomeric diblock stabilisers swell 
with a large quantity of monomer, causing destabilisation.27, 28  
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Table 3.2 Characterisation data for styrene RAFT emulsion polymerisations with different [MRA-PS] and 
[M]. 
aRefers to the target DP of RAFT emulsion polymerisations performed to obtain the third (core forming) 
block. bDetermined by DLS. cDetermined using Equation 2.13. dDetermined using Equation 2.12. 
eDetermined by THF-SEC (values were obtained by integrating the whole polymer region), calibrated with 
PS standards. All polymerisations reached >99% monomer conversion, determined by gravimetry, and 
were performed at 70°C. 
 
 [MRA-PS] (mM) [M](mM) 
DPtargeta 
Dh 
(nm)b PDi
c 
Mn,th 
(g mol-1)d 
Mn,SEC 
(g mol-1)e 
Mw,SEC 
(g mol-1)e 
Ðe 
1 2.85 570 200 36 0.113 25600 28000 36500 1.30 
2 5.70 570 100 101 0.162 15300 8000 9800 1.23 
3 1.425 570 400 107 0.058 46500 33900 48100 1.42 
4  1.425 427 300 64 0.048 36100 26200 32800 1.25 
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Figure 3.3 (left column) DLS intensity (black), volume (green line) and number (red line) traces and THF-
SEC chromatograms (right column) for styrene RAFT emulsion latexes (black line) chain extended from 
MRA-PS (green line) with different [MRA-PS] and [M]. 
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3.2.2 Development of a fluorescent labelling strategy 
Having successfully optimised RAFT emulsion polymerisation of styrene (above), n-BA 
and t-BA (chapter 2), our next objective was to establish a method of quantifying the 
cellular uptake of these nanoparticles. Fluorescent labelling is a popular and versatile 
method of visualising, and quantifying biomaterial distribution, both in vitro and in vivo. 
The wide range of commercially available functional fluorophores, and organelle specific 
fluorescent probes, allows for highly specific measurements of uptake rate and 
intracellular location for a wide range of materials, including nanoparticles. Labelling 
typically involves the partial modification of nanoparticle surfaces with water soluble 
derivatives of common fluorophores (fluorescein, rhodamine, cyanine, etc.). However, 
small differences in nanoparticle surface hydrophobicity has been shown to heavily 
influence uptake degree and rate,7 therefore modification of the particle core is the 
preferred method to introduce fluorescent moieties without significantly changing other 
physicochemical properties. Charleux and co-workers recently reported the use of 
borondipyrromethene (BODIPY) monomer fluorophores to label nanoparticles using a 
phase inversion RAFT emulsion polymerisation of styrene.29 These hydrophobic 
BODIPY monomers were copolymerised in the nanoparticle core during the 
polymerisation. The resulting nanoparticles were shown to be 200-2000x brighter than 
quantum dots, with high quantum yields (0.20 < Φ 0.35). These monomers therefore 
represent a facile method to fluorescently label nanoparticles, with minimal modification 
of the procedures developed above.  
3.2.2.1 BODIPY acrylate synthesis 
From the library of BODIPY monomers generated by Charleux and co-workers, 
polymeric nanoparticle cores copolymerised with a phenolic acrylate derivative 
(BODIPY acrylate) had the highest brightness and quantum yield, in comparison to the 
other monomers.29 Additionally, as some of the targeted nanoparticles are polyacrylates 
(t-BA and n-BA), using an acrylate fluorescent monomer should yield a random 
distribution of fluorophore along the polymeric chain, limiting any aggregation induced 
fluorescence quenching.30 
BODIPY acrylate (BODIPYA) was therefore synthesised via a two pot, four step 
approach, using literature procedures.29 BODIPY phenol was first prepared via a three 
step, one pot approach, typically used to create the BODIPY centre. Firstly, an acid 
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catalysed condensation of kryptopyrrole and 4-hydroxybenzaldehyde was performed to 
afford the dipyrromethane 1. This was oxidised to dipyrromethene 2 using DDQ, which 
was subjected to a mild base, and boron trifluoride diethyl etherate yielding BODIPY 
phenol with 30% yield.  
 
Scheme 3.3. Synthetic approach to generate BODIPYA. 
BODIPY acrylate was prepared by esterification of BODIPY phenol with acryloyl 
chloride, in the presence of a mild base to afford BODIPYA with 70% yield. Both 
structure and purity of compounds were confirmed with 1H NMR, 13C NMR, 19F NMR, 
IR, mass spectroscopy and HPLC. The spectroscopic properties of BODIPYA were 
assessed with fluorescence and absorbance spectroscopy, revealing an excitation maxima 
of 528 nm and an emission maxima of 542 nm (Figure 3.4) in chloroform. 
 
Figure 3.4. Normalised absorbance and fluorescence spectra (λex = 528 nm) of BODIPYA (10 µg mL-1) in 
chloroform. 
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3.2.2.2 Solution copolymerisation of BODIPYA 
For the polymerisation of BODIPYA, 1 mol% fluorescent monomer (relative to PEGA) 
was copolymerised with PEGA, using solution RAFT polymerisation, targeting a total 
DP of 10 using conditions established in section 2.2.2. The resulting polymer was 
analysed with SEC using RI detection and UV detection set to 520 nm to assess the 
incorporation of BODIPYA within the polymer chain. 
 
Scheme 3.4. Copolymerisation of PEGA with BODIPYA (1 mol%) mediated with RAFT agent PABTC. 
Chromatograms revealed close agreement between UV520 nm and RI traces suggesting 
successful incorporation of the fluorescent monomer. However, the presence of a low 
molecular weight species in the UV520 nm traces indicated that BODIPYA had not been 
fully consumed during the polymerisation using these conditions (Figure 3.5). Having 
shown that BODIPYA is a facile method to fluorescently label polymers in homogenous 
systems, we proceeded by testing this in a heterogeneous RAFT emulsion polymerisation.  
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Figure 3.5. THF-SEC chromatograms of crude P[(PEGA)10-co-(BODIPYA)0.1] using both RI detection 
(black full line) and UV detection at 520 nm to assess BODIPYA incorporation (pink dashed line), and of 
pure BODIPYA (pink full line). 
3.2.2.3 RAFT emulsion copolymerisation of BODIPYA with n-BA 
RAFT emulsion copolymerisations of BODIPYA and n-BA were performed with a 
DPtarget of 170 using conditions from chapter 2, but with the addition of 0.1 wt% (relative 
to [M]) BODIPYA pre-dissolved in the monomer phase. 
.  
Scheme 3.5 RAFT emulsion copolymerisation of n-BA with BODIPYA mediated with MRA-nBA. 
DLS analysis of the resulting latex revealed uniform nanoparticles (PDi < 0.05) with a 
diameter of 108 nm, suggesting addition of BODIPYA (at this concentration) did not 
perturb the RAFT emulsion process. Similarly to the solution polymerisations above, size 
exclusion chromatograms revealed successful incorporation of BODIPYA into the 
polymer chains within the core of the nanoparticle, as observed by the overlap between 
RI and UV520 nm traces.  Unfortunately, as in the solution state polymerisation, a small 
amount of fluorescent monomer remained unconsumed, potentially due to the slow 
diffusion of BODIPYA into the growing nanoparticles, a feature which was also observed 
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by Charleux and co-workers.29 Any non-covalently bound BODIPYA has potential to 
leak out of the nanoparticles during storage leading to non-specific uptake of free dye, 
and inconclusive results from cellular uptake experiments. To negate these issues, the free 
BODIPYA must be purified from the nanoparticles. 
 
Figure 3.6 (A) DLS distributions (intensity (black), volume (green) and number (red)) of P{[(PEGA)8-b-
(n-BA)8]-b-[(n-BA)99.9%-co-(BODIPYA)0.1%]170 nanoparticles diluted 1/1000 in pure water, measured at 
25°C. (B) THF-SEC of dried P[(PEGA)8-b-(n-BA)8]-b-[(n-BA)99.9%-co-(BODIPYA)0.1%]170 nanoparticles 
dissolved in eluent using RI detection (black full line) and UV detection at 520 nm detection (pink dashed 
line), and of BODIPYA (pink full line). 
As BODIPYA was highly hydrophobic, dialysis against pure water would not be 
sufficient to remove any free fluorophore.  Procedures were henceforth conceived where 
the dialysis media contained a high percentage of organic solvent to solubilise 
BODIPYA. We found that a 60/40 1,4-dioxane/water (v/v) mixture fully solubilised 
BODIPYA without any precipitation for 24 h (data not shown). It was possible however, 
that in these conditions the nanoparticles may dissolve, as the core polymers (P(t-BA), 
P(n-BA), PS) and P(PEGA) shell were soluble in organic solvents, resulting in particle 
collapse. To examine this effect, ~100 nm non-fluorescently labelled nanoparticles with 
all three polymeric cores were diluted with a solvent mixture of 60/40 1,4-dioxane/water 
mixture (v/v), shaken for 24 h at 25°C and the particle size distribution monitored with 
DLS. All three nanoparticles displayed high colloidal stability with no disassembly, or 
aggregation caused by the presence of organic solvent (Figure 3.7). Surprisingly the 
nanoparticles showed an increase in diameter from ~100 nm to ~140 nm, which can be 
attributed to either solvent induced core swelling, or a discrepancy between viscosity of 
A B
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the chosen dispersant during measurements (water) and the actual solvent mixture. As 
1,4-dioxane has a higher viscosity (1.37 cP) than water (1.0 cP) in any binary mixture of 
these solvents, the nanoparticles will have a slower diffusion rate than in pure water. As 
DLS estimates particle sizes by their diffusion rate, this artificially enlarges the 
nanoparticle size reported.  
 
Figure 3.7. Particle size distributions in 60/40 dioxane/water (v/v) solvent mixture (red line) and in pure 
water (black line) for 100 nm non-fluorescent PS, P(n-BA), and P(t-BA) nanoparticles, both at 25°C 
measured with DLS. 
To investigate the above conditions for dialysis purification, an analogous RAFT 
emulsion polymerisation was performed where a 10-fold increase in BODIPYA (1 mol%) 
was introduced into the reaction mixture. This led to 50% unconsumed BODIPYA, in 
comparison to 7% at 0.1 mol%, which therefore allows us to visualise the purification 
process with greater sensitivity. The increased proportion of unconsumed BODIPYA also 
suggests there may be a maximum amount that can be incorporated. The nanoparticles 
were then dialysed against a 60/40 1,4-dioxane/water (v/v) mixture and the relative 
amount of free BODIPYA in the latex was monitored by comparing the BODIPYA 
integrals and polymer integrals from UV520 nm SEC traces after each media change (4 h, 
16 h and 96 h). Starting at 50% free BODIPYA (relative to polymer peak) before dialysis, 
a steady decrease was observed over time, with only 5%, 2% and 0.07% detected after 4 
h (1st change), 16 h (2nd change) and 96 h (3rd change) respectively (Figure 3.8a), without 
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a decrease in the polymer peak intensity. The particles were then extensively dialysed 
against pure water to remove 1,4-dioxane from the latex. Once complete, the resulting 
particle size distribution remained narrow, with similar average diameters as before 
purification and no observable aggregate formation (Figure 3.8b and Figure 3.8c). 
 
Figure 3.8. Purification of free BODIPYA from P(PEGA)8-b-P(n-BA)8-[P(n-BA)99%-co-
P(BODIPYA)1%]170 nanoparticles via dialysis with a 100k MWCO membrane against a 60/40 1,4-
dioxane/water (v/v) mixture, monitored over 96 h with (A) SEC (UV detection at 520 nm). DLS 
distributions (intensity (black), volume (green) and number (red)) (B) before and (C) after dialysis 
purification. 
Overall, these results indicate that BODIPYA can be successfully copolymerised into the 
nanoparticle polymeric chains during RAFT emulsion. Dialysis against a water/dioxane 
mixture enables removal of unconsumed fluorescent monomer, without disturbing the 
colloidal stability of the latex, all which can be monitored simply using UV520 nm detection 
with SEC. 
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3.3 Synthesis and characterisation of Hard, Medium and 
Soft nanoparticles 
Having successfully optimised styrene RAFT emulsion polymerisations (Section 3.2.1), 
and implemented a fluorescent labelling strategy (Section 3.2.2), the nanoparticle rigidity 
study was initiated by synthesising a series of six fluorescently-labelled 100 nm and 50 
nm nanoparticles. As discussed in Section 3.2, both of these particle sizes would be 
generated with either PS, P(t-BA) or P(n-BA) cores and for clarity will be referred to as 
100H, 100M, 100S, 50H, 50M, and 50S for 100 nm and 50 nm hard, medium and soft 
nanoparticles.  
 
Figure 3.9 (A) Preparation of core-shell nanoparticles via RAFT emulsion polymerisation. (B) Graphical 
representation of hard, medium and soft nanoparticles. 
A library of BODIPYA-labelled PS, P(t-BA) and P(n-BA) with different rigidities were 
prepared using adapted procedures from section 3.2.2.3 (Figure 3.9). Particle size was 
tuned by controlling either the DPtarget or the initiator type (ACVA or VA-057), as shown 
in section 2.2.3.1 (full conditions can be found in Table 3.7), with all polymerisations 
achieving high monomer conversions (> 98%) within 3 h. Additionally, as some 
characterisation techniques, such as static light scattering (λ0 = 533 nm), can be perturbed 
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by coloured samples, an analogous series of non-labelled nanoparticles were prepared 
using the same conditions but omitting the addition of BODIPYA. 
DLS and ζ-potential analysis revealed negatively charged (-30 mV), uniform 
nanoparticles (PDi ~0.05), with diameters close to targeted values for both fluorescent 
and non-fluorescent analogues (Figure A3.1 and Figure A3.2). Negligible differences in 
particle diameter or PDi were observed in culture medium Dulbecco’s Modified Eagle 
Medium (DMEM) suggesting the suspensions would be colloidally stable during cell 
uptake experiments (Table 3.3).  
Table 3.3. Characterisation data of synthesised nanoparticles. 
   Hydrodynamic diameter and ζ-potential    
   Water  DMEM   
Full title Core Abb. 
Dh 
(nm)a PDi
b 
ZP 
(mV)c 
 Dh 
(nm)a PDi
b  Tg/°C
d 
Fluorescent           
100 nm Hard  PS 100H 107.6 0.054 -31  112.4 0.051  90.0 
100 nm Medium P(t-BA) 100M 102.7 0.056 -25  102.8 0.082  37.8 
100 nm Soft P(n-BA) 100S 101.5 0.058 -28  104.7 0.062  -57.5 
50 nm Hard PS 50H 53.6 0.062 -24  52.7 0.058  90.0 
50 nm Medium P(t-BA) 50M 57.9 0.056 -35  49.1 0.065  31.4 
50 nm Soft P(n-BA) 50S 54.2 0.047 -30  55.4 0.050  -58.3 
           
Non-fluorescent           
100 nm Hard  PS 100HNF 100.1 0.054 -29  109.0 0.056  91.0 
100 nm Medium P(t-BA) 100MNF 102.3 0.058 -27  108.4 0.064  37.5 
100 nm Soft P(n-BA) 100SNF 105.3 0.058 -31  107.1 0.051  -56.5 
50 nm Hard PS 50HNF 58.5 0.056 -27  61.5 0.052  82.5 
50 nm Medium P(t-BA) 50MNF 52.5 0.040 -31  50.4 0.052  32.9 
50 nm Soft P(n-BA) 50SNF 54.0 0.049 -25  58.3 0.058  -57.8 
 
aMean of three measurements using dynamic light scattering (number distribution). bCalculated using 
Equation 2.13. cMean of three measurements. dMeasured using differential scanning calorimetry. Subscripts 
with ‘NF’ refer to non-fluorescent nanoparticles. All data reported is for nanoparticles after dialysis 
purification against a 60/40 1,4-dioxane/water (v/v) mixture. 
SEC chromatograms of both fluorescent (RI and UV520 nm detection) and non-fluorescent 
(RI detection only) nanoparticles indicated successful chain extension from their 
respective macro-RAFT agents. From UV520 nm traces, fluorescent derivatives displayed 
a large proportion of unconsumed BODIPYA. All fluorescently labelled nanoparticles 
were therefore subjected to the two-step dialysis procedure established in section 3.2.2.3. 
The complete removal of unconsumed BODIPYA from the polymer latexes was evident 
from SEC (UV520 nm detection), while RI detection showed a large reduction in the amount 
of residual macro-RAFT from the latexes. Retention of the bright orange coloured latex 
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(Figure 3.10a), and the polymer signal in the UV520 nm SEC detection (Figure A3.3), 
suggested a high amount of fluorescent monomer remained incorporated, with dialysis 
procedures completely removing any free BODIPYA. Importantly, the particle size 
distributions showed negligible differences after purification (Figure A3.1). Furthermore, 
the unconsumed macro-RAFT agent in non-fluorescent analogues (100HNF, 100MNF, 
100SNF, 50HNF, 50MNF and 50SNF) was removed by dialysis against pure water, as 
confirmed by SEC (RI detection; Figure A3.4). Notable differences in Mn,SEC between 
fluorescent and non-fluorescent nanoparticles were observed, which may be ascribed to 
differences in chain extension efficiency (amount of residual macro-RAFT agent), 
leading to either smaller or larger chain length, due to the presence of BODIPYA. 
Table 3.4. SEC data for dissolved nanoparticles. 
  
 Non-fluorescent Fluorescent 
Mn,th  
(g mol-1)a 
Mn,SEC  
(g mol-1)b 
Mw,SEC  
(g mol-1)b Ð
b Mn,SEC  (g mol-1)b 
Mw,SEC  
(g mol-1)b Ð
b 
100H 46,500 42,000 47,900 1.14 52,000 64,900 1.23 
50H 25,800 28,500 33,000 1.18 40,800 50,600 1.24 
100S 26,800 32,800 42,600 1.27 35,300 53,450 1.51 
50S 20,400 21,900 26,000 1.19 27,200 37,000 1.36 
100M 26,800 31,500 41,500 1.32 24,400 31,300 1.28 
50M 21,600 25,900 33,200 1.28 23,100 29,600 1.28 
 
aCalculated using Equation 2.12 and 1H NMR spectroscopy. bDetermined with THF-SEC calibrated with 
PMMA standards.  
 
Fluorescence measurements of the fluorescent nanoparticles showed similar emission and 
excitation profiles to free BODIPYA (Figure 3.4), suggesting that differences in core 
chemistry did not affect their spectroscopic properties (Figure A3.5). When placed under 
a UV lamp (λ=365 nm), bright green fluorescence could be observed from the 
nanoparticles (Figure 3.10b). 
Differential scanning calorimetry was used to evaluate the Tg of all twelve nanoparticles. 
Thermograms revealed Tg values of approximately 90°C, 37°C and -55°C for soft, 
medium, and hard varieties, which are in close agreement to literature values for PS, P(t-
BA) and P(n-BA) respectively (Figure A3.6 and Figure A3.7). Interestingly, traces for all 
soft nanoparticles displayed a small melting transition at approximately 0°C, which could 
be attributed to trace water.  
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Figure 3.10. Digital photographs of the BODIPY labelled nanoparticles 100H, 100M, 100S, 50H, 50M and 
50S under natural and UV light (λ = 365 nm). 
Transmission electron micrographs of the fluorescent nanoparticles displayed similar 
particle sizes to those obtained with DLS, and confirmed their spherical morphology. 
Unsurprisingly, the low Tg (P(n-BA)) analogues were not visible under room temperature 
dry microscopy, likely due to these nanoparticles flattening as a consequence of 
flexibility. Cryo-TEM (performed by Dr Saskia Bakker, University of Warwick) was 
therefore employed to image the P(n-BA) (soft) nanoparticles, clearly showing spherical 
nanoparticles with similar sizes to those found with DLS. 
 
Figure 3.11. Dry state transmission electron micrographs of 100H, 100M, 50H, 50M (deposited on 
graphene oxide coated lacey carbon grids) and cryogenic transmission electron micrographs of 100S and 
50S (deposited on lacey carbon grids). Cryo-TEM images were obtained by Dr Saskia Bakker, University 
of Warwick. 
 
A B
A 
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Solution phase particle size and morphology were further elucidated with a combination 
of small angle neutron scattering (SANS) and static light scattering (SLS). As described 
in section 2.2.4, these techniques are complimentary and can give information on different 
size domains of nanomaterials. For these experiments, only the non-fluorescent 100 nm 
analogues were investigated as the incident beam wavelength (λ0= 533) in SLS is 
exceptionally similar to the excitation maxima for the fluorescent nanoparticles, and as 
SLS relies on the intensity of scattered light at various angles, any absorption will 
artificially reduce this value leading to erroneous results. Additionally, due to beam-line 
limitations only the 100 nm particles were assessed. By combining SLS and SANS data, 
a wider q range could be observed. The scattering profiles of all three nanoparticles 
showed similar features, such as a plateau at low q (q < 0.002; Figure 3.12b). With the 
combined SLS measurements, data fits using hard sphere models with particle radii of 
550Å and dispersities between 0.05 and 0.15 showed good agreement with acquired data. 
Overall, the characterisation data confirmed the synthesised particles were highly similar 
to those targeted, with negligible structural differences between the different particles 
(except rigidity), making them suitable for this study. 
 
Figure 3.12. Small angle neutron scattering (blue circles), static light scattering profiles (green circles) and 
fits (red line) of 100HNF, 100MNF and 100SNF diluted in deuterium oxide. 
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Figure 3.13 Height profiles of a single (A) 100 nm and (B) 50 nm particles with hard (green), medium 
(blue) and soft (orange) rigidities respectively determined by AFM. Data obtained by Dr Kai Yu and Dr 
Christopher Hodges at the University of Leeds. 
To elucidate rigidity differences, the height profiles of the six fluorescently labelled 
nanoparticles were studied using AFM after deposition on silanised glass slides. These 
studies were performed by Dr Kai Yu and Dr Christopher Hodges at the University of 
Leeds, UK. The heights of both hard derivatives (100H and 50H) matched theoretical 
values, however the lower Tg (~-59°C) of the soft derivatives (100S and 50S) caused 
particle flattening, spreading them by almost two-fold compared to the hard analogues. 
Interestingly, the medium (Tg = 37°C) nanoparticles for both sizes displayed an 
intermediate maximum height suggesting these analogues did indeed have intermediate 
rigidity (Figure 3.13). AFM images of the nanoparticles can be found in the appendix 
(Figure A3.8). 
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3.4 Biological studies 
In the above section, a library of 50 and 100 nm, fluorescent and non-fluorescent 
nanoparticles were synthesised and extensively characterised using a multitude of 
techniques. Both sets of nanoparticle sizes show almost identical physicochemical 
characteristics (particle size, shape and surface charge), except for rigidity; and 
fluorescent derivatives were completely free of unattached fluorophore. Prior to an in-
depth cellular uptake study, comprehensive cytotoxicity and membrane activity 
experiments were performed. 
3.4.1 Cytotoxicity 
In the previous chapter, anti-proliferative activity studies of similar nanoparticles (P(n-
BA) and P(t-BA) cores) in human colorectal adenocarcinoma cells (Caco-2), revealed 
negligible cytotoxicity. As we were introducing an additional nanoparticle system (PS 
cores), and fluorescently labelled species which had been exposed to high concentrations 
of 1,4-dioxane, the anti-proliferative activity of the six fluorescently labelled 
nanoparticles was studied with a range of cell lines using the SRB assay. Experiments 
were performed with murine embryonic fibroblasts (NIH 3T3), human ovarian 
adenocarcinoma (A2780), human colorectal adenocarcinoma (Caco-2) and human 
prostate cancer (PC3) with 72 h exposure with a range of concentrations (0.5 mg mL-1 – 
10 ng mL-1) (Figure 3.14). All six nanoparticles displayed around 100% cell viability at 
all concentrations in all cell lines, suggesting that the introduction of BODIPYA, or 
presence of residual 1,4-dioxane had a negligible effect on cytotoxicity on both healthy 
and cancer cells of various types. 
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Figure 3.14 Antiproliferative activity of 100H, 100M, 100S, 50H, 50M, 50S fluorescently-labelled 
nanoparticles, each incubated with NIH 3T3, A2780, Caco-2 and PC3 cells for 72 h, as measured using 
typical protocol for the SRB assay. 
 
3.4.2 Membrane activity 
The membrane activity of the nanoparticles was established using a haemolysis assay 
using sheep blood. This assay requires absorbance measurements between 400-600 nm 
wavelengths, which is around the absorption maxima of BODIPYA, hence experiments 
were performed using the non-fluorescent nanoparticles. Three concentrations (0.1, 0.05 
and 0.01 mg mL-1) of each nanoparticle diluted in phosphate buffer saline (PBS) were 
incubated for 1 h with a dilute erythrocyte suspension and the absorbance recorded at 415 
nm to monitor haemoglobin release. Control experiments with pure water and PBS 
(negative controls) and, 1 wt% Triton-X (positive control, 100% haemolytic activity) 
were performed in parallel. All of the nanoparticles displayed less than 8% haemolytic 
activity (in comparison to Triton-X), with either similar or less haemoglobin released in 
comparison to water (8%) or PBS (7.5%) (Figure 3.15). Overall, this suggests that the 
particles have low membrane interactions, likely due to the negative surface charge and 
P(PEGA) surface (steric repulsion), which disfavours interaction with the negatively 
charged lipid membrane. No notable differences in membrane activity were observed 
between nanoparticle rigidities.5  
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Figure 3.15. Haemolytic activity of the non-fluorescent nanoparticles 100HNF, 100MNF, 100SNF, 50HNF, 
50MNF and 50SNF measured with % release of haemoglobin as compared to positive control triton-x (1 
wt%), and negative controls (H2O and PBS). 
3.4.3 Fluorescence correction factor calculation 
Prior to any cellular uptake studies, fluorescence correction factors were established to 
enable direct quantitation between compounds. This was imperative as the UV520 nm SEC 
showed that a different amount of BODIPYA was incorporated into the nanoparticles, 
which would result in a different fluorescence intensity.  In the following cellular uptake 
studies (vide infra), uptake was monitored using a Cytation3TM imaging plate reader with 
an RFP filter cube (λex = 531 ± 20 nm, λem = 593 ± 20 nm). Fluorescence intensities were 
therefore determined across a range of concentrations for all six fluorescently labelled 
nanoparticles using the above wavelengths (Figure 3.16). A linear fit was applied to the 
acquired intensities, and the slope used to calculate the correction factors. Correction 
factors were normalised for 100 and 50 nm particles separately, with both soft varieties 
(50S and 100S) set to 1.00 (Table 3.5).  
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Figure 3.16. Fluorescence normalisation/calibration curves for different particles to account for differences 
in fluorescence intensity. λex = 531 nm λem = 593 nm (Settings for RFP imaging cube in Cytation 3 imaging 
system) 
Table 3.5. Fluorescence correction factors normalised to 100S for 100 nm particles and 50S for 50 nm 
particles. 
 
 
 
 
 
aR2 values determined using a linear fit on Origin Pro 2016. 
 
 
 
 
 
 
 
  Slope R2 a Correction factor 
100H 70602 0.9997 1.38 
100M 70810 0.9999 1.39 
100S 51125 0.9994 1.00 
50H 70568 0.9995 1.74 
50M 55731 0.9995 1.38 
50S 40529 0.9991 1.00 
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3.4.4 Cellular uptake studies 
As experiments were performed with two different particle sizes (50 nm and 100 nm), at 
the same mass concentration (e.g. 100 µg mL-1) the 100H and 50H, for example, would 
have vastly different particle concentrations (e.g. particle mL-1), calculated using 
Equation 2.11. For instance, in a typical uptake experiment the mass concentration (100 
µg mL-1) would equate to 1.9 x 1011 mL-1 for 100 nm particles but 1.5 x 1012 for 50 nm 
particles, almost an order of magnitude difference. For clarity, uptake will therefore only 
be compared within particle sizes, and not between them.  
3.4.4.1 Effect of particle concentration  
Initially a cellular uptake study was performed with all six fluorescently labelled 
nanoparticles at three different concentrations (200 µg mL-1, 100 µg mL-1 and 50 µg mL-
1), to establish at what concentration the particles were detectable. The different 
concentrations of nanoparticles were incubated with colorectal carcinoma cells (Caco-2) 
for 2 h, at 37°C, and the cellular uptake efficiency was quantified by fluorescence imaging 
(Cytation3 imaging system), and normalised to the ‘soft’ nanoparticles for both sizes at 
200 µg mL-1 as in section 3.4.3 (Figure 3.17). 
 
Figure 3.17. Relative intracellular fluorescence intensity after 2 h incubation with 100H, 100M, 100S, 50H, 
50M and 50S nanoparticles with Caco-2 cells across three concentrations (200 µg mL-1, 100 µg mL-1 and 
50 µg mL-1). The reported data represent the mean ± standard deviation for two independent experiments 
with each treatment performed in triplicate. Asterisks indicate relevant statistically significant results as 
determined by an analysis of variance (ANOVA) statistical test and a Tukey-Kramer post hoc test (*p ≤ 
0.05, **p ≤ 0.01), with a 95% confidence interval. 
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As a general trend, an increase in intracellular fluorescence was observed with higher 
treatment concentration. At 50 µg mL-1 relatively little difference in uptake was observed 
between particles, suggesting that not enough nanoparticles were internalised to 
accurately detect any fluctuations between rigidity. However, for both 100 µg mL-1 and 
200 µg mL-1 the variation was much higher and in general had lower variation between 
replicates. For these reasons, future experiments were performed at 100 µg mL-1. This 
preliminary experiment shows a greater cellular uptake of the 100S nanoparticles 
compared to 100H and 100M, with a less pronounced trend for the 50 nm derivatives 
(Figure 3.17).  
3.4.4.2 Time dependent cellular uptake 
 
Figure 3.18. Relative intracellular fluorescence intensity after 2 h (blue), 4 h (red), and 24 h (green) 
incubation with 100H, 100M, 100S, 50H, 50M and 50S nanoparticles with (A) PC3 cells and (B) Caco-2 
cells at 100 µg mL-1 for 50 nm particles. The reported data represent the mean ± standard deviation for two 
independent experiments with each treatment performed in triplicate. Asterisks indicate relevant 
statistically significant results as determined by an analysis of variance (ANOVA) statistical test and a 
Tukey-Kramer post hoc test (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001) with a 95% confidence interval. 
To better elucidate the differences between nanoparticle rigidities, a time-dependent 
uptake experiment was performed. All six labelled nanoparticles were incubated for 2 h, 
4 h and 24 h at 37°C with both PC3 and Caco-2 cells and intracellular fluorescence 
normalised as above (section 3.4.3). For 100 nm particles, a clear correlation was 
observed between uptake efficiency/uptake rate with decreasing rigidity. 100S 
nanoparticles displayed greater internalisation than the medium and hard counterpart 
((2.9 x for 100S-100H) and (1.5 x for 100S-100M) after 24 h), following the trend 100S 
> 100M > 100H. This difference was best observed in PC3 cells, where cells treated for 
only 2h with 100S nanoparticles displayed almost double the uptake than 100H 
A B
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nanoparticles treated for 24 h. In contrast, the 50 nm nanoparticles all displayed similar 
internalisation after 24 h (Figure 3.18a). Similar values were observed in Caco-2 cells 
supporting the observed trends (Figure 3.18b). It should be noted that the larger errors 
observed in Caco-2 data arise from inconsistent cell morphology leading to poorer 
analysis of images from the Cytation3 imaging systems. Overall, these results suggest 
that differences in rigidity may be size dependent with smaller sizes less affected than 
larger sizes. Vogt and co-workers reported that for thin films with >100 nm film 
thickness, the elastic moduli matched those of bulk materials. However, if the thickness 
of the film was <50 nm, the onset of confinement effects reduced the difference in elastic 
moduli for materials with differing Tg, making them more similar to each other.31 
Interestingly, this could explain the differences that we observe for the internalisation of 
our particles. Rigidity should influence both degree and rate of cellular uptake if particles 
behaved as bulk materials (100 nm diameter systems; soft nanoparticles are preferred 
over medium and hard nanoparticles). However, it is possible that at smaller sizes (50 nm 
diameter), the differences in rigidity are negligible thus reducing the effect on cellular 
uptake. 
Notably, in both cell lines and for all nanoparticles, an increasing trend was observed with 
incubation time, with much higher internalisation after 24 h than 2 h and 4 h. This is 
indicative of nanoparticle accumulation, likely due to the a higher rate of endocytosis 
over exocytosis, well known for nanomaterials.8 
As mentioned in section 3.1, there is little consensus in the literature on how particle 
rigidity affects cellular uptake, with either material variation (shape, size and surface 
hydrophobicity), cell line effects (cancer vs immune cells), and different experimental 
conditions (incubation time, particle concentration and measurement techniques) cited for 
the diverse results reported. 12-16, 32-36 Nonetheless, our nanoparticles showed a similar 
trend than that reported by Lorenz et al. They showed increased cellular uptake, in both 
malignant and primary cells, with reducing particle rigidity using uncoated 140 nm latex 
nanoparticles, prepared by altering the poly(n-alkyl methacrylate) cores. However, it 
should be noted that by increasing the side chain length of their polymers (methyl 
methacrylate to stearyl methacrylate), they also heavily influence the surface 
hydrophobicity of these nanoparticles, making rigidity effects indiscernible. In contrast, 
the P(PEGA) shell on our nanoparticles is expected to eliminate this entirely.  
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3.4.4.3 Energy dependency 
 
Figure 3.19. Relative intracellular fluorescence intensity after 2 h incubation at 37°C (red) and 4°C (blue; 
inhibition of energy-dependent pathways) with 100H, 100M, 100S, 50H, 50M and 50S nanoparticles with 
(A) PC3 cells and (B) Caco-2 cells at 100 µg mL-1. The reported data was normalised to 37°C data and 
represent the mean ± standard deviation for two independent experiments with each treatment performed 
in triplicate. Asterisks indicate relevant statistically significant results as determined by an ANOVA and 
post-hoc Tukey-Kramer test (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001). 
In order to probe the energy dependency of nanoparticle internalisation, the above uptake 
experiment was performed at 4°C, but with a 2 h incubation. This reduction in 
temperature inactivates the production of adenosine triphosphate (ATP) and therefore 
energy dependent pathways. In both cell lines, all nanoparticles displayed a large 
reduction in cellular uptake (~60-70%; p < 0.001), suggesting that the uptake mostly relies 
on energy dependent pathways, such as endocytosis. This is in accordance with much of 
the previous literature on nanoparticle uptake pathways.37-39 It should be noted that a 
complete reduction (100%) in intracellular fluorescence was not observed. It is likely that 
this is due to an imperfect inactivation of energy dependent pathways, and not a small 
amount of passive uptake, with similar observations made in other studies.7, 40  
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3.4.4.4 Endocytosis mechanism 
 
Figure 3.20. Relative intracellular fluorescence intensity after 3 h pre-treatment with endocytosis inhibitors 
for clathrin- (chloropromazine) and caveolae-(genistein) mediated endocytosis and macropinocytosis 
(amiloride), and subsequent 2 h incubation with 100H, 100M, 100S, 50H, 50M and 50S nanoparticles with 
(A) PC3 cells and (B) Caco-2 cells at 100 µg mL-1 compared. The reported data represent the mean ± 
standard deviation for two independent experiments with each treatment performed in triplicate. Asterisks 
indicate relevant statistically significant results as determined by an ANOVA and post-hoc Tukey-Kramer 
test (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001). 
There are many possible endocytic uptake mechanisms for uptake of nanoparticles, 
including: clathrin-mediated endocytosis, micropinocytosis, caveolae-mediated 
endocytosis, and other independent endocytosis pathways. These pathways can be 
selectively blocked by addition of specific endocytosis inhibitors: chlorpromazine for 
clathrin mediated endocytosis; amiloride for macropinocytosis; and genistein for 
caveloae mediated endocytosis into the culture medium. By conducting cellular uptake 
experiments with these inhibitors, differences in uptake mechanism between different 
nanoparticle rigidities can be elucidated. Both Caco-2 and PC3 cells were pre-treated with 
each of the above endocytosis inhibitors for 3 h and then exposed to each of the labelled 
nanoparticles. Intracellular fluorescence was then monitored relative to an untreated (no 
endocytosis inhibitor) control. After treatment with chlorpromazine, which inhibits the 
assembly of clathrin on endosomal membranes, a larger reduction in uptake was observed 
for 100H (60-80% decrease) than for 100M and 100S, which showed similar 10-20% 
reductions. In contrast, the 50 nm particles had a smaller difference in uptake between 
50H (50% reduction) and 50M/50S (0-20% reduction) nanoparticles. This suggests that 
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for both sizes, the harder nanoparticles were preferentially taken up via clathrin-mediated 
endocytosis over the medium and soft analogues. Treatment with amiloride, a compound 
which inhibits macropinocytosis by targeting the Na+/H+ exchange at the cell surface, 
showed similar results to chlorpromazine addition, with the exception of 50M and 50S. 
These nanoparticles showed a surprising increase in intracellular fluorescence (60% 
increase) compared to the untreated controls. This is typically attributed to a decrease in 
exocytosis caused by the inhibitor.41 Finally, caveolae inhibition with genistein, a 
tyrosine-kinase inhibitor which reduces the recruitment of dynamin II, a key protein in 
caveolae mediated endocytosis, displayed vastly different results between particle sizes 
and rigidities. Interestingly, for the 100 nm derivatives a clear trend was observed in PC3 
cells, where the lower reduction in uptake (i.e. less uptake via caveolae mediated 
endocytosis) correlated with increasing flexibility (70% > 55% > 30% reduction for 100H 
> 100M > 100S respectively). For 50 nm nanoparticles a 40-50% decrease was observed, 
however this was similar regardless of rigidity (Figure 3.20). 
Our results indicate that nanoparticle rigidity significantly impacts their uptake 
mechanism. Soft and medium rigidity nanoparticles mostly go through caveolae-
mediated endocytosis or other independent endocytosis pathways, while hard 
nanoparticles are taken up through a combination of the three pathways tested, with a 
clear preference for clathrin and caveolae mediated endocytosis. This effect on caveolae 
mediated endocytosis has been previously reported for larger 1 µm hydrogel particles, 
with no prior knowledge on nanoscale particles.15 It is well known that caveolae can act 
as mechanosensors on the cell surface, capable of responding to mechanical stress by 
acting as membrane reservoirs.42, 43  It is therefore possible that particles with higher 
rigidity may induce a greater caveolae response after interaction with the cellular 
membrane. This could account for the clear trend observed in the 100 nm particles, and 
also explain why relative internalisation between the 50 nm derivatives via caveolae-
mediated endocytosis was similar, supporting our previous hypothesis that differences in 
rigidity are less pronounced with smaller size nanoparticles. 
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3.4.5 Intracellular trafficking 
Confocal laser scanning microscopy (CLSM) was used to further study the intracellular 
trafficking and location of the nanoparticles after internalisation. Initially, PC3 cells were 
incubated with each of the labelled nanoparticles for 2 h, 4 h and 24 h at 37°C and for 2 
h at 4°C, similarly to the uptake experiments in section 3.4.4.2 and section 3.4.4.3. 
Lysosomes and nuclei were selectively stained with LysoTrackerTM Deep Red and 
Hoechst 33258 respectively. 
 
Figure 3.21. CLSM images of PC3 cells incubated with fluorescently-labelled nanoparticles (green; 100H, 
100M, 100S, 50H, 50M and 50S) at 100 µg mL-1, incubated for 2 h at 37°C. Lysosomes and nuclei were 
stained with LysotrackerTM Deep Red (final concentration 50 nM) and Hoechst 33258 (final concentration 
5 µg mL-1) respectively. Merged images are a combination of green and red channels. Scale bars are 50 µm 
in length. 
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Figure 3.22. CLSM images of PC3 cells incubated with fluorescently-labelled nanoparticles (green; 100H, 
100M, 100S, 50H, 50M and 50S) at 100 µg mL-1, incubated for 2 h at 4°C. Lysosomes and nuclei were 
stained with LysotrackerTM Deep Red (final concentration 50 nM) and Hoechst 33258 (final concentration 
5 µg mL-1) respectively. Merged images are a combination of green and red channels. Scale bars are 50 µm 
in length. 
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Figure 3.23. CLSM images of PC3 cells incubated with fluorescently labelled nanoparticles (green; 100H, 
100M, 100S, 50H, 50M and 50S) at 100 µg mL-1, incubated for 4 h at 37°C. Lysosomes and nuclei were 
stained with LysotrackerTM Deep Red (final concentration 50 nM) and Hoechst 33258 (final concentration 
5 µg mL-1) respectively. Merged images are a combination of green, red and blue channels. Scale bars are 
50 µm in length. 
 
After incubation at 4°C, no fluorescence was observed from any of the labelled 
nanoparticles, nor from the LysotrackerTM Deep Red channel (Figure 3.21). This is in 
accordance with the previous cellular uptake experiment (Section 3.4.4.3), confirming 
that uptake of the nanoparticles was indeed energy dependent.  
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Figure 3.24. CLSM images of PC3 cells incubated with fluorescently labelled nanoparticles (green; 100H, 
100M, 100S, 50H, 50M and 50S) at 100 µg mL-1, incubated for 4 h (left) or 24 h (right) at 37°C. Lysosomes 
and nuclei were stained with LysotrackerTM Deep Red (final concentration 50 nM) and Hoechst 33258 
(final concentration 5 µg mL-1) respectively. Merged images are a combination of green, red and blue 
channels. Scale bars are 50 µm in length. 
Imaging of cells treated for 2 h (Figure 3.21), 4 h (Figure 3.23) and 24 h (Figure 3.24) at 
37°C showed a high degree of colocalisation between fluorescent nanoparticles and 
LysoTrackerTM (Pearsons correlation coefficient (PCC) = >0.65) was observed, with all 
particles reaching the lysosome within 2 h of incubation. Interestingly, it has been 
previously shown that soft microcapsules (4-5 µm diameter) display faster accumulation 
in the lysosome as compared to stiff ones.14 However, there were no obvious differences 
in the intracellular distribution between our soft and hard nanoparticles (for incubations 
2 h or longer). Overall, this verified our previous uptake experiments, and confirmed the 
conventional endosomal-lysosomal trafficking route as the main internalisation 
mechanism for the nanoparticles.  
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3.5 Conclusions 
In conclusion, using a library of core-shell nanoparticles with three different core Tg and 
the same surface properties we have investigated the effect of nanoparticle rigidity on the 
degree, rate and mechanism of uptake by mammalian cells (PC3 and Caco-2). Our study 
has demonstrated that this parameter does indeed have a significant effect, with softer 
nanoparticles being internalised faster and to a higher degree than their harder 
counterparts. This effect however was more prominent for the larger 100 nm particles, 
with 50 nm particles only displaying minor favourability towards softer particles after 2 
and 4 h, and almost none after 24 h. We anticipate that at smaller diameters, confinement 
effects reduce the difference in rigidity between nanoparticles of different core Tg, thus 
reducing the impact on cellular uptake. All of the core-shell particles were internalised 
through energy dependent mechanisms, however particles of different rigidity follow 
different internalisation pathways: harder nanoparticles go through a combination of 
clathrin- and caveolae- mediated endocytosis, as well as non-specific macropinocytosis, 
while softer and medium rigidity nanoparticles are preferentially taken up by caveolae- 
and other independent endocytosis mechanisms. Interestingly with 100 nm particles, we 
saw an increasing trend in uptake via caveolae-mediated endocytosis of hard > medium 
> soft nanoparticles, possibly due to their known mechanosensing behaviour at the cell 
surface, however further investigation is required to fully explain this. Finally, no 
differences were observed in the intracellular localisation of these nanoparticles, with all 
following the expected endo-lysosomal route. Overall, our results demonstrate rigidity is 
a fundamental physicochemical factor in nanoparticle cell uptake, paying particular 
attention to how this interacts with other important parameters such as nanoparticle size. 
This study also highlights the usefulness of RAFT emulsion polymerisation, allowing the 
generation of precisely designed nanoparticles for a fundamental biological study. 
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3.6 Materials and Methods 
3.6.1 Materials  
Styrene (>99%), kryptopyrrole (>99%), DDQ (>99%), 4-hydroxybenzaldehyde (>99%), 
acryloyl chloride (>99%) was obtained from Sigma-Aldrich and all monomers above 
were passed through basic aluminium oxide to remove inhibitor before polymerisation. 
Dimethyl sulfoxide-d6 (99.9% D atom) and chloroform-d3 (99.8% D atom), were obtained 
from Sigma Aldrich and used for 1H NMR spectroscopy. Thermal initiators 4,4′-azobis(4-
cyanovaleric acid) (ACVA, >98%, Aldrich), 2,2’-Azobis(cyclohexanecarbonitrile) (VA-
088, 98%, Aldrich) and 2,2'-Azobis[N-(2-carboxyethyl)-2-
methylpropionamidine]tetrahydrate (VA-057, 98%, Wako) were used as received. RAFT 
agent, 2-(((butylthio)carbonothioyl)thio)propanoic acid (PABTC) was synthesised as 
previously described.44 Macro-RAFT agents MRA-nBA (P[(PEGA)8-b-(n-BA)8] and 
MRA-tBA (P[(PEGA)8-b-P(t-BA)8] were synthesised in chapter 2. BODIPY acrylate was 
synthesised as previously described (data below).29 PABTC was synthesised using 
previously described conditions as in chapter 2 (Section 2.4.3.1).44 Solvents were 
acquired from commercial sources. Materials for cell culture were purchased from 
Greiner Bio-one, and culture medium prepared in-house. 
 
3.6.2 Instrumentation and Analysis 
3.6.2.1 NMR spectroscopy 
1H NMR and 13C NMR spectra were recorded as described in section 2.4.2.1 
 
3.6.2.2 Size exclusion chromatography  
CHCl3-SEC was performed using conditions described in section 2.4.2.2 
 
THF-SEC was performed using conditions described below: Agilent 390-LC MDS 
instrument equipped with differential refractive index (DRI) and dual wavelength UV 
detectors. The system was equipped with 2 x PLgel Mixed D columns (300 x 7.5 mm) 
and a PLgel 5 µm guard column. The eluent was THF with 2% TEA (triethylamine) and 
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0.01% BHT (butylated hydroxytoluene) additives. Samples were run at 1 mL min-1 at 
30°C. Poly(methyl methacrylate) and polystyrene standards (Agilent EasyVials) were 
used for calibration. Analyte samples were filtered through a GVHP membrane with 
0.22 μm pore size before injection. Respectively, experimental molar mass (Mn,SEC) and 
dispersity (Đ) values of synthesised polymers were determined by conventional 
calibration using Agilent SEC software. BODIPY functionalised polymers were analysed 
with the UV detector set to 520 nm. 
 
3.6.2.3 Theoretical molar mass calculation 
Theoretical molar masses were calculated as described in section 2.4.2.3 
 
3.6.2.4 High performance liquid chromatography (HPLC) 
HPLC was performed using an Agilent 1260 infinity series stack equipped with an 
Agilent 1260 binary pump and degasser.  The flow rate was set to 1.0 mLmin-1 and 
samples were injected using Agilent 1260 autosampler with a 100 μL injection 
volume.  The temperature of the column was set at 25 °C. The HPLC was fitted with a 
phenomenex Lunar C18 column (250 x 4.6 mm) with 5 micron packing (100Ǻ). Detection 
was achieved using an Agilent 1260 variable wavelength detector. UV detection was 
monitored at λ = 520 nm. Methods were edited and run using Agilent OpenLAB online 
software and data was analysed using Agilent OpenLAB offline software. Mobile phases 
solvents used were HPLC grade and consisted of mobile phase A: 100% water, 0.04% 
TFA; mobile phase B: 100% methanol, 0.04% TFA using a gradient of 50 - 100% 
methanol over 30 minutes. 
 
3.6.2.5 Dynamic light scattering and ζ-potential  
DLS and ζ-potential measurements were carried out as described in 2.4.2.4. DLS 
measurements in DMEM (phenol red free) were performed at 37°C, and the optical 
constants set the same as water. PDi values were calculated as in Equation 2.13.    
 
 
 
 
129 
 
3.6.2.6 Small angle neutron scattering 
Experiments were performed at the instrument D11 at the Institut Laue-Langevin (ILL) 
in Grenoble, France. A wavelength of λ = 6 Å with a polydispersity of Δλ/ λ = 10% was 
used. The scattering intensity was detected on a 3He gas detector (CERCA) with a 
detection area of 96 × 96 cm2 and a pixel size of 3.75 × 3.75 mm2. Narrow Hellma quartz 
glass cells (type 110-QS) with 1 mm sample thickness were used. Samples were measured 
at three sample-detector distances of 1.2 m, 10 m and 20 m to cover a wide range of 
scattering vector, q, with a decent measurement time. Q is defined as: 
 
𝑄 =
4𝜋 sin
𝜃
2
𝜆
 
Equation 3.1. Calculation of scattering vector Q 
 
Where θ is the scattered angle and λ is the incident neutron wavelength. The incoherent 
scattering of water was measured as secondary calibration standard at 10 m sample-
detector distance. All data were corrected for transmission, empty cell scattering and 
background scattering to receive absolute values for the differential cross section. 
Additional q values were measured with static light scattering. The solutions of 
nanoparticles were prepared by diluting the latexes by 1000 fold by direct dilution in D2O. 
Scattering fits were calculated using a hard sphere model using open access software 
SASfit.  
 
3.6.2.7 Static light scattering 
Static light scattering measurements were performed as described in section 2.4.2.5.   
 
3.6.2.8 Differential Refractometry.  
Differential refractometry was performed as described in section 2.4.2.6. 
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3.6.2.9 Differential Scanning Calorimetry 
Measurements were performed on dry samples of particle suspensions using a Mettler 
Toledo DSC1 using a scan rate of 10 K/min in a temperature range of -100 to 150°C. The 
glass transition temperature (Tg) was recorded as the first derivative (dH/dT) of the second 
heating run.  
3.6.2.10 Transmission electron microscopy 
Nanoparticles were diluted 1/1000 in pure water and a 10 μL drop of the diluted sample 
was immediately deposited onto a hydrophobic surface (plastic petri dish). The graphene 
oxide-coated surface of the TEM grid was then placed on the droplet for 1 minute, then 
left to dry before imaging. A JEOL 2100FX electron microscope at an acceleration 
voltage of 200 kV was used to carry out the imaging. 
3.6.2.11 Cryogenic-transmission electron microscopy 
Cryo-TEM images were obtained using conditions described in section 2.4.2.7. 
3.6.2.12 Fluorescence excitation/emission spectroscopy 
Fluorescence emission spectra were measured using an Agilent Cary Eclipse fluorescence 
spectrometer. Studies were performed by exciting at the absorption maxima of BODIPYA 
(528 nm) and measured from 530 nm to 750 nm. Excitation spectra were measured by 
setting the maximum emission to 542 nm, and recording from 300 to 530 nm. The 
photomultiplier voltage was set such that the maxima was below 1000 arbitrary units.  
3.6.2.13 Atomic force microscopy and height profiles 
Microscope slides were cleaned by sonication in Milli-Q water for 30 min, after which 
the glass slides were air-dried and left in a UV-ozone cleaner (Bioforce Nanoscience, 
USA) for 3 h to eliminate remnant organics. The UV-cleaned slides were rinsed with 
Milli-Q water and air-dried before being left in a desiccator. 2 mL (3-
Aminopropyl)triethoxysilane (APTES) was added into a watch-glass and left in the same 
desiccator overnight for silanization. The success of silanization was confirmed by 
wetting angle measurement of the glass slides, increasing from 15 ± 2.3° (before 
silanization) to 50 ± 3.1° (after silanization). 
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A Bioscope II AFM (Bruker, USA) was used to carry out particle imaging using 
sharpened silicon nitride probes with a spring constant of 43.5 N/m (sensitivity: 38.5 
nm/V) in tapping mode in dry state, scanning at 0.5 HZ (512 lines per image). Silanized 
microscope slides were cut (15 × 24.5 mm) and were dipped into particle dispersions 
(100H, 100M, 100S, 50H, 50M and 50S) with a concentration of ~ 0.05 mg mL-1 for 30 
min to ensure particle adsorption on the silanized microscope slides, after which the 
microscope slides were rinsed with Milli-Q water to remove excess particles and left to 
air-dry before imaging. 
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3.6.3 Synthesis 
3.6.3.1 BODIPY phenol synthesis 
Hydroxybenzaldehyde (0.5 g, 4.07 mmol, 1 eq) was added to a stirred solution of 
kryptopyrrole (1 g, 8.11 mmol, 2 eq) in 200 mL anhydrous dichloromethane in an oven-
dried 500 mL round bottomed flask. The mixture was purged with dinitrogen for 15 
minutes. Four drops of trifluoroacetic acid (catalytic amounts) was added to the above 
mixture, turning it to a deep red colour, then sealed with a rubber septum and left to stir 
at room temperature overnight and progress checked using thin layer chromatography 
(100% DCM). In a separate flask, 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (0.92 g, 
4.07 mmol, 1 eq) was dissolved in 100 mL dichloromethane and added dropwise to the 
reaction mixture via syringe turning the solution a turbid black-red colour and left to stir 
at room temperature for 4 h. Diisopropylethylamine (3.67 g, 5 mL, 28.5 mmol, 7 eq) and 
subsequently boron trifluoride diethyl etherate (11.64 mL, 44.77 mmol, 11 eq)  were 
added slowly via syringe and left to stir for 1 h at room temperature. The reaction mixture 
was then poured on to a 10-15 cm silica pad and washed using dichloromethane using 
Buchner filtration and the filtrate collected and subsequently evaporated under reduced 
pressure. The crude product was then dissolved in a small amount of dichloromethane 
and purified using automatic column chromatography using an eluent of 100% 
dichloromethane to yield BODIPY phenol as a bright red powder (488 mg, 30% yield). 
1H NMR (500 MHz, 298 K, CDCl3) δH (ppm) 7.06 (d, J = 8.4 Hz, 2H, Ar-H), 6.87 (d, J 
= 8.4 Hz, 2H, Ar-H), 4.94 (s, 1H, Ar-OH), 2.46 (s, 6H, CH3), 2.23 (q, J = 7.6 Hz, 4H, 
CH2-CH3), 1.28 (s, 6H, N=C-CH3), 0.91 (t, J = 7.6 Hz, 6H, CH2-CH3). 13C NMR (125 
MHz, CDCl3) δc (ppm) 156.07 (C-OH), 153.51 (C-CH3), 140.10 (C=C-C), 138.43 (N=C-
CH3), 132.71 (C-CH2-CH3), 131.17 (C=C-Ar), 129.70 (OH-C-CH), 128.07 N-C), 116.02 
(C-CH), 17.08 (C-CH2-CH3), 14.64 (C-CH2-CH3), 12.42 (C-CH3), 11.85 (N=C-CH3). 
19F NMR (282 MHz, CDCl3)   δF -145.57 (dd, J = 66.5, 32.1 Hz, BF2). FTIR v cm-1: 3476 
(s, O-H non-H bonded), 2961 (m, C-H aromatic), 2925 (m, C-H alkane), 2864 (m, C-H 
alkene), 1474 (s, aromatic C=C). ESI-MS: expected m/z = 419.21 [M+Na]+, found m/z = 
419.2 [M+Na]+.  
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Figure 3.25. 1H NMR spectrum of BODIPY phenol (CDCl3, 500 MHz) 
 
Figure 3.26. DEPT-135 13C NMR spectrum of BODIPY phenol (CDCl3, 125 MHz) 
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3.6.3.2 BODIPY acrylate synthesis 
1,8-Diazabicyclo[5.4.0]undec-7-ene (152 mg, 1 mmol, 2 eq) was added dropwise to a 
solution of BODIPY phenol (200 mg, 0.5 mmol, 1 eq), in a sealed 20 mL vial, turning it 
from bright red to dark brown. Acryloyl chloride (67.5 mg, 0.75 mmol, 1.5 eq) was added 
dropwise at which point the solution reverted to its original colour, and left to stir 
overnight at room temperature. Progress was monitored using thin layer chromatography. 
The reaction mixture was evaporated under reduced pressure and purified using automatic 
column chromatography using an eluent of 30% petroleum ether and 70% 
dichloromethane to yield BODIPY acrylate (160.1 mg, 70% yield). 1H NMR (500 MHz, 
CDCl3) δH (ppm) 7.22 (q, J = 8.6, 4H, Ar-H), 6.58 (d, J = 17.3, 0.7 Hz, 1H, CH=CH(H) 
), 6.29 (dd, J = 17.3, 10.4 Hz, 1H, COO-CH=CH2), 5.99 (d, J = 10.5, 0.7 Hz, 1H, 
CH=CH(H)), 2.46 (s, 6H,N=C-CH3), 2.24 (q, 4H, C-CH2-CH3), 1.26 (d, J = 7.6 Hz, 6H, 
C-CH3), 0.91 (t, J = 7.6 Hz, 6H, C-CH2-CH3). 13C NMR (126 MHz, CDCl3) δC (ppm) 
164.12 (COO-CH=CH2), 153.97 (COO-C), 151.02 (CH3-C), 139.09 (C=C-C), 138.37 
(CH3-C=N), 133.39 (CH3-CH2-C), 132.94 (COO-CH=CH2), 130.82 (N-C=C), 129.48 
(O-C-CH), 127.83 (COO-CH-CH2), 122.35 (O-C-CH-CH), 17.00 (C-CH2-CH3), 14.62 
(C-CH2-CH3), 12.52 (N-C-C-CH3), 11.85 (N=C-CH3). 19F NMR (282 MHz, CDCl3)   δF 
-145.57 (dd, J = 66.5, 32.1 Hz, BF2). ESI-MS: 2963 (m, C-H aromatic), 2925 (m, C-H 
alkene), 2871 (m, C-H alkane), 1471 (s, aromatic C=C) expected m/z = 473.23 [M+Na]+, 
found m/z = 473.2 [M+Na]+. 
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Figure 3.27. 1H NMR spectrum of BODIPYA (CDCl3, 500 MHz) 
 
Figure 3.28. DEPT-135 13C NMR spectrum of BODIPY acrylate (CDCl3, 125 MHz) 
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Figure 3.29. HPLC traces of BODIPY phenol and BODIPYA using UV detection at 520 nm, eluted on a 
gradient of 50% -100% methanol in water. 
3.6.3.3 Synthesis of MRA-PS 
MRA-PS was synthesised using adapted conditions from the literature,26 and from  
section 2.4.3.2. Conditions are detailed in Table 3.6. 
Table 3.6. Polymerisation conditions for the preparation of MRA-PS from MRA-PEGA. Solvent was 1,4-
dioxane. 
  
 Monomer RAFT agent Initiator  [M]0/M [M]0/[macro-RAFT]0 [CTA]0/[I]0 Time/h Conversion (%) 
MRA-PS Styrene MRA-PEGA VA-086 5.5 8 20 18 94 
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3.6.3.4 Nanoparticle synthesis – RAFT emulsion polymerisation 
RAFT emulsion polymerisations were performed as described in section 2.4.3.4. 
Polymerisation conditions are detailed in Table 3.7. Fluorescent derivatives were 
synthesised with the addition of 1 mol% BODIPYA relative to monomer. 
Table 3.7. RAFT emulsion polymerisation conditions used to generate nanoparticles 100H, 100M, 100S, 
50H, 50M and 50S (and non-fluorescent derivatives). 
 
All polymerisations were performed in aqueous conditions, with [M]0 = 2.85 mM and reached full (>99%) 
monomer conversion. 
 
3.6.3.5 Purification of fluorescent nanoparticles/ removal of free BODIPY 
monomer and unconsumed macro-RAFT agent 
The nanoparticle suspension was transferred to a 100 kD MWCO Spectra/Por® Float-A-
Lyzer dialysis device and dialysed against 4 x 1.5 L of 60% 1,4-dioxane 40% deionized 
water, changing the solvent periodically. After 4 days the solvent was changed to 100% 
deionized water and dialysed for 2 days (water changed 3 x) to remove any residual 1,4-
dioxane. A small sample (100 µL) of latex was dried at 70°C, solids content was recorded 
and the polymers were analysed by SEC. Particles were re-analysed after purification 
using DLS to ensure dialysis did not perturb the colloidal stability. 
3.6.3.6 Purification of non-fluorescent nanoparticles/ removal of 
unconsumed macro-RAFT agent 
The nanoparticle suspension was transferred to a 100 kD MWCO Spectra/Por® Float-A-
Lyzer dialysis device and dialysed against pure water for 4 days, with the dialysis water 
changed every day. A small sample (100 µL) of latex was dried at 70°C, solids content 
was recorded and the polymer were analysed by SEC. Particles were re-analysed after 
purification using DLS to ensure dialysis did not perturb the colloidal stability. 
  Macro-RAFT agent I 
[Macro-
RAFT] 
(mM) 
[M]0/ 
[CTA]0 
[CTA]0/ 
[I]0 
T/°
C 
Reaction 
time (h) 
100H P(PEGA)8-b-PS8 ACVA 1.425 400 2.5 80 6 
100M P(PEGA)8-b-P(t-BA)8 ACVA 1.425 200 2.5 70 3 
100S P(PEGA)8-b-P(n-BA)8 ACVA 2.85 170 1.1 70 3 
50H P(PEGA)8-b-PS8 ACVA 2.85 120 1.1 80 6 
50M P(PEGA)8-b-P(t-BA)8 VA-057 2.85 170 1.1 57 3 
50S P(PEGA)8-b-P(n-BA)8 VA-057 2.85 130 1.1 57 3 
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3.6.4 Cell culture, cytotoxicity and membrane activity 
3.6.4.1 Cell culture 
All cell lines in this study were purchased from ECACC (European Collection of Animal 
Cell Culture, Salisbury, UK) and cultured as single monolayers at 310 K in a humidified 
atmosphere containing 5% CO2. Cells were sub-cultured at regular intervals, and passages 
made by trypsinising cells when at 80-90% confluence. Media used to culture cells are as 
follows: A2780 – Roswell Park Memorial Institute medium (RPMI-1680) supplemented 
with 10% foetal calf serum, 1% glutamine and 1% pencillin/streptopmycin, Caco-2 -
50:50 mixture of Dulbecco’s Modified Eagle Medium (DMEM) and HAMS F12 
supplemented with 10% of foetal calf serum, 1% of L-glutamine and 1% 
penicillin/streptomycin, PC3 - Dulbecco’s Modified Eagle Medium (DMEM) 
supplemented with 10% of foetal calf serum, 1% of L-glutamine and 1% 
penicillin/streptomycin, 3T3 - Dulbecco’s Modified Eagle Medium (DMEM) 
supplemented with 10% of bovine calf serum, 1% of L-glutamine and 1% 
penicillin/streptomycin. 
3.6.4.2 Sulforhodamine B cell viability assay 
Cell viability experiments were performed as described in section 2.4.4.2 with A2780, 
Caco-2, PC3 and NIH 3T3 cell lines.  
3.6.4.3 Haemolysis assay/ Membrane activity 
Defibrinated sheep blood (2 mL) was split into two 1.5 mL Eppendorf tubes (1 mL each) 
and centrifuged at 4500 g / 8200 RPM in a mini-spin Eppendorf centrifuge for 60 seconds. 
The supernatant was removed and replaced with 750 µL PBS and mixed until the pellet 
had been fully resuspended. This process was repeated at least twice, until the supernatant 
became colourless. The red blood cell suspension was then diluted 1:150 in PBS. Particles 
were then diluted in PBS to make concentrations of 2 mg mL-1, 1 mg mL-1 and 0.2 mg 
mL-1. 20 µL of each particle suspension was then diluted with 380 µL of diluted red blood 
cells in 1.5 mL Eppendorf tubes such that the final concentration of particles was 0.1 mg 
mL-1, 0.05 mg mL-1 and 0.01 mg mL-1. Additionally, negative control mixtures of PBS 
and sterile water, and a 100% haemolysis positive control of 1% Triton-X in PBS were 
prepared. The mixtures were then incubated at 37°C in a pre-heated water bath for 1 h. 
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Samples were prepared in triplicate. Particle blood mixtures were then separated by 
centrifugation at 4500 g for 5 minutes and 200 µL of the supernatant from each tube was 
removed and transferred to a clear 96 well plate and the absorbance read at 404 nm using 
a Biotek Cytation 3 plate reader. The average Triton-X positive control value was set to 
100% haemolysis. Errors were determined using the standard deviation of the three 
replicates.  
3.6.5 Cellular uptake studies 
Cellular uptake was quantified via measurement of intracellular fluorescence following 
incubation with BODIPY-labelled fluorescent nanoparticles. Experimental details for 
individual experiments can be found below. In all cases cells were seeded into a black 96 
imaging well plate with a clear bottom at a density of 5000 cells per well and allowed to 
grow for 24 h. Cellular fluorescence was measured using a Cytation 3 Cell Imaging Multi-
Mode ReaderTM from Biotek®, with quantification from the Gen5TM software. Single cells 
were isolated using the blue channel (Hoechst 33258), and using a secondary mask, an 
area of (12 µm) and (15 µm) defined as the cell area for PC3 and Caco-2 respectively. 
Following background reduction using a roll ball model (25 µm), fluorescence associated 
with BODIPY (RFP filter, λex = 531 nm, λem = 593 nm) was assigned as intracellular 
fluorescence. Data is represented as the arithmetic mean ± SD with experiments 
conducted in duplicate of triplicates.  
3.6.5.1 Concentration dependent cellular uptake 
For the concentration dependent cellular uptake experiments, after incubation for 24 h 
(from seeding), the cell culture medium was replaced with medium containing either 200, 
100 or 50 µg mL-1 of each of the nanoparticle suspensions, and incubated for 2 h. 
Intracellular fluorescence was measured as described above. 
3.6.5.2 Time dependent cellular uptake 
For kinetic cellular uptake experiments, after incubation for 24 h (from seeding), the cell 
culture medium was replaced with medium containing 100 µg mL-1 nanoparticles, and 
incubated for 24 h, 4 h and 2 h. Then intracellular fluorescence was measured as described 
above. 
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3.6.5.3 Uptake at 4°C 
For cellular uptake experiments at 4°C, after incubation for 24 h, the cells were cooled to 
4°C for 1 h, then the culture medium was replaced with cold medium containing 100 µg 
mL-1 nanoparticles, and incubated at 4°C for 2 h. Then intracellular fluorescence was 
measured as described above. 
3.6.5.4 Pathway inhibitors 
For cellular uptake pathway inhibition experiments, after incubation for 24 h, the cells 
were pre-treated with inhibitors (chloropromazine (5 µg mL-1), amiloride hydrochloride 
(2 mM) and genistein (50 µg mL-1)) for 3 h, then the culture medium was replaced with 
medium containing 100 µg mL-1 nanoparticles, and topped up with the respective 
inhibitor during the course of the experiment. Then intracellular fluorescence was 
measured as described above.  
3.6.6 Confocal laser scanning microscopy/live cell imaging 
3.6.6.1 Experiments performed at 37°C 
Cells (PC3) were seeded at a density of 5,000 cells per well in a 10 well microscopy plate 
and incubated for 24 h prior to starting the experiment.  The culture medium was replaced 
with media containing nanoparticles (100 µg mL-1) and incubated with the cells for 24 h, 
4 h and 2 h. 2 h and 30 min prior to imaging LysoTrackerTM Deep Red and Hoechst 33258 
respectively were added to the appropriate wells such that the final concentrations of 
organelle stain would be 50 nM and 5 µg mL-1 respectively. Cells were washed with PBS 
five times, and fresh phenol red free DMEM was added. Finally, an additional aliquot of 
LysoTrackerTM Deep Red was added to the appropriate wells after washing. Confocal 
microscopy images were obtained with a Zeiss LSM 880 using a 40x oil objective. 
Excitation/Emission wavelengths for measurements were used as follows: nucleus/blue 
channel (405 / 410 – 500 nm), BODIPY/ green channel (488 / 520 – 600 nm) and 
LysoTrackerTM Deep Red/ red channel (633 / 650 – 700 nm). Colocalisation values were 
determined using the Pearson’s Colocalisation Coefficient (PCC) using ImageJ or Fiji 
software. 
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3.6.6.2 Experiments performed at 4°C 
Experiments conducted at 4°C were performed as described in section 3.6.6.1 with the 
following adaptation. Prior to the addition of nanoparticle suspensions, the cells were 
cooled to 4°C for 1 h. Cells were then left to incubate for 2 h at 4°C, with all other 
experimental details identical to experiments conducted at 37°C. 
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Chapter 4  
 
Generating nanoparticles with functional 
alkyne coronas using RAFT emulsion 
polymerisation 
 
The multi-valent presentation of functional groups on nanoparticle surfaces has long 
been exploited to attach biologically active moieties. The conventional chemistries 
typically used (amide, ester, disulfide) however, are non-selective and inefficient. The 
Huisgen azide alkyne [1,4] cycloaddition (CuAAC) ‘click’ reaction has paved the way for 
atom economic, and orthogonal conjugation chemistries, and is now widely used in 
nanoparticle science. In this chapter, alkyne functionalised nanoparticles have been 
generated, without lengthy post-nanoparticle synthesis modification procedures, through 
RAFT emulsion polymerisations stabilised by functional macro-RAFT agents. Our results 
indicated that ester derived RAFT agents and addition of pendant charged groups are 
vital to retain colloidal stability and narrow molecular weight distributions. Finally, the 
nanoparticles and model polymers were functionalised with an azido functional polymer 
and fluorescent dye, showing the surfaces were accessible for post-functionalisation. 
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4.1 Introduction 
One of the major advantages exhibited by nanomaterials, is their large total surface area 
(relative to macroscopic materials), which can be modified to present a high density of 
chemically functional groups. These can then be post-modified to introduce new 
functionality, useful for a variety of applications such as catalysis,1 anti-fouling2 and 
water treatment.3 In the biomedical field this has been utilised to great effect, typically by 
attaching peptides,4 antibodies5 and carbohydrates6 to improve nanoparticle cellular 
uptake and disease targeting. Furthermore, it has been shown that nanoparticles 
conjugated with fluorescent dyes,7 radiolabels8 and MRI contrast agents9, 10 can be used 
to track nanoparticle in vivo distribution, and also act as highly sensitive diagnostic tools. 
Due to the advances in this area, many researchers have combined these approaches to 
generate theranostic nanoparticles, combining therapies and diagnostics on one 
nanoparticle, which is only achievable due to the high density of surface functionality 
available for modification.11, 12 Nonetheless, most nanomaterials utilising these 
chemistries, typically rely on conventional functional groups such as amines,13 carboxylic 
acids14 and thiols,15 which are not only highly prevalent in biological organisms, but can 
react promiscuously. Furthermore, commonly used reactions such as carbodiimide amide 
coupling in aqueous conditions are fraught with side-reactions and low conjugation 
efficiencies.16  
Introduced in 2001, the ‘click’ chemistry concept represents an elegant solution to many 
of the problems found using conventional coupling techniques. Sharpless and co-workers 
laid out a set of criteria that a ‘click’ reaction must fulfil, including: being highly yielding, 
rapidly create physiologically stable products, have high atom economy and performed 
in any solvent, especially water.17 There are now many reactions defined as a ‘click’, 
including (but not limited to) thiol-yne coupling,18 Diels-Alder cycloaddition,19 oxime 
coupling20 and thiol-isocyanate coupling.21 However, perhaps the most iconic and widely 
used, is the Huisgen azide alkyne [3+2] cycloaddition.22 This reaction, between an azide 
and an alkyne, is now heavily used for bioconjugation, as both of the components can be 
used orthogonally with endogenously found functionalities.  
This approach therefore represents a facile route to selectively functionalise the surface 
of nanomaterials, without the drawbacks of the traditional approaches described above. 
For instance, Bolley et al. reported improved functionalisation of superparamagnetic 
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nanoparticles with cyclic RGD integrin binding peptides, using both thiol-yne and Copper 
azide alkyne cycloaddition (CuAAC) click techniques, in comparison to classical 
carbodiimide amidation reactions.23 Additionally, the CuAAC reaction has been used to 
convert otherwise bare gold nanoparticles into glycosylated systems with azido functional 
monosaccharides, capable of binding to cell surface lectins.6 Due to the orthogonality of 
these moieties, Brennen et al. were able to conjugate acetylene-functionalised 
Thermomyces lanuginosus lipase to azide coated gold nanoparticles via the CuAAC 
reaction, which still retained its enzymatic activity post-conjugation.24  
Although a vast array of substrates can be conjugated by introducing the complimentary 
functionality (either azide or alkyne) at the nanoparticle surface, in many cases this is 
non-trivial, and usually requires a multi-step synthesis approach. As mentioned in chapter 
1 and 2, RAFT emulsion polymerisation combines the advantages of RDRP (narrow 
molecular weight distributions, controlled molar masses, block copolymers) and 
emulsion polymerisation (uniform nanoparticles, fast propagation rates and aqueous 
environments). Another major advantage of RDRP techniques is that there are now many 
examples of pre-functionalised RDRP initiators (RAFT agents, ATRP initiators etc) with 
either alkyne or azide groups which after polymerisation would be imparted at the chain 
ends ready for post-modification.25 This could therefore be translated to RAFT emulsion 
polymerisation, through the use of functional macro-RAFT agents, making this an ideal 
method to generate nanoparticles with high surface functionality. An example of this, for 
nanoparticle functionalisation using RAFT emulsion polymerisation, was recently 
reported by Monteiro and co-workers.26 They generated a series of multi-functional 
nanoworms/nanorods through aqueous RAFT emulsion polymerisation of styrene, using 
P(NIPAM) macro-RAFT agents containing pyridyl disulfide, alkyne, dopamine, 
thiolactone and biotin functional end-groups. However, as the emulsion polymerisation 
required stabilisation from an external surfactant, the functional groups were not imparted 
at the surface. After addition of toluene, and upon cooling, the spherical nanoparticles 
morphed into high aspect ratio nanoworms, to which a range of linear polymers and 
fluorescent dyes could be conjugated. While this shows it is possible to introduce a high 
density of functionality, this type of emulsion polymerisation requires the presence of 
cytotoxic surfactants and organic solvents to access the surface functionality. As of yet, 
this technique has not been used to produce any other morphology, such as spherical 
nanoparticles, which can be directly used for conjugation. 
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The aim in this chapter was therefore to introduce functional alkyne groups on the surface 
of our nanoparticles, by performing RAFT emulsion polymerisations with alkyne 
functional macro-RAFT agent (‘R’). These groups would be imparted at the particle 
surface and therefore be available for reaction/conjugation. Herein, we report a synthesis 
of alkyne functional macro-RAFT agent stabilisers, with three different RAFT agents. 
Using some of these stabilisers, RAFT emulsion polymerisations with n-BA were 
performed to generate alkyne functional nanoparticles. Finally, CuAAC reactions were 
performed on both alkyne functional macro-RAFT agents and nanoparticles to assess 
their post-functionalisation properties.  
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4.2 Results and Discussion 
4.2.1 Propagyl amide  
4.2.1.1 Synthesis of amide based alkyne functional RAFT agent 
As biomedical applications were the primary target for these nanoparticles, the chemistry 
used to introduce acetylene functionality should ideally not be susceptible to degradation 
in vivo. Amide bonds would be less vulnerable to hydrolytic or enzyme related 
degradation, making these more preferable than their ester counterparts. Therefore the 
alkyne functional RAFT agent, Alkyne-PAmBTC was synthesised with PABTC and 
propagyl amine using (benzotriazol-1-yl-oxytripyrrolidinophosphonium 
hexafluorophosphate) (PyBOP) as the coupling agent and N,N-Diisopropylethylamine 
(DIPEA) as a mild base, following previously described conditions (Scheme 4.1), at 68% 
yield.27  
 
Scheme 4.1. Synthesis of Alkyne-PAmBTC via amide coupling of PABTC and propagyl amine. 
 
4.2.1.2 PEGA polymerisation with Alkyne-PAmBTC 
Prior to the synthesis of an alkyne functional macro-RAFT agent stabiliser, we verified 
Alkyne-PAmBTCs ability to act as a chain transfer agent, through a solution 
polymerisation of PEGA, targeting a DP of 20, using conditions described in section 2.2.2 
(Figure 4.1a). Samples were taken periodically to assess the molecular weight distribution 
and monomer conversion over the course of the polymerisation.  
Mn,SEC showed a linear increase with monomer conversion, reaching 89% after 5 h (Figure 
4.1c and Figure 4.1d). However, for a controlled polymerisation this linear increase 
should ideally begin at the molar mass of the RAFT agent (275 g mol-1), but in our case 
we observed a Mn,SEC at > 4000 g mol-1 after just 15-30 min. This suggests that during the 
initial stages of the polymerisation, the RAFT agent is unable to perform efficient chain 
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transfer and a small amount of free radical polymerisation takes place, producing much 
larger observed molar masses compared to theoretical values. Furthermore, in the first 
order plot, a deviation from the linear fit is observed after 3 h (80% monomer conversion), 
indicating an increase in termination reactions (Figure 4.1b). Both of these effects result 
in an asymmetric SEC chromatogram, caused by a shoulder at lower molar mass, even 
though the Ð remained < 1.2 (Figure 4.1e). It is likely this was caused by two possible 
phenomena, firstly the presence of a terminal acetylene group, which can readily react 
with radical species (initiator derived, propagating chains etc), especially at high 
monomer conversion where propagation is reduced. Additionally, the amide ‘acrylamide-
like’ reinitiating group of Alkyne-PAmBTC, is highly unstable, therefore pushing the 
pre-equilibrium step of the RAFT polymerisation towards the initiator derived chains 
(Scheme 4.2). This would result in slow consumption of the RAFT agent, and therefore 
imperfect control over the polymerisation. Overall, these results suggest that Alkyne-
PAmBTC was not suitable to generate alkyne functional macro-RAFT agents. 
Table 4.1. Data for the polymerisation kinetics of PEGA using Alkyne-PAmBTC as the CTA.  
Time (h) % conva 
Mn,th  (g mol-1)b
 Mn,SEC (g mol-1)c Mw,SEC  (g mol-1)c
 Ðc 
0 0 275 - - - 
0.25 12 1400 4750 5350 1.13 
0.5 33 3400 6000 6900 1.15 
1 52 5200 7500 8600 1.15 
1.5 66 6600 8500 9700 1.15 
2 73 7200 9000 10400 1.16 
3 82 8100 9500 11100 1.17 
4 87 8600 9700 11400 1.17 
5 89 8800 9800 11550 1.18 
 
aDetermined by 1H NMR spectroscopy. bTheoretical molar masses calculated with Equation 2.12. 
cDetermined by THF-SEC and analysed against PMMA standards. 
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Figure 4.1. (A) Polymerisation of PEGA mediated by Alkyne-PAmBTC, (B) pseudo first order plot, red 
points indicate data masked from the linear fit (red dashed line), (C) time vs conversion, (D) conversion vs 
Mn,SEC and linear fit (dashed black line), (E) evolution of SEC chromatograms over time.  
 
Scheme 4.2. Pre-equilibrium of a RAFT polymerisation of PEGA using Alkyne-PAmbTC.  
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4.2.2 Protected propagyl ester 
4.2.2.1 Synthesis of TMS protected alkyne RAFT agent 
To overcome both of these issues, an alternative RAFT agent was designed containing a 
trimethylsilyl group to protect the terminal alkyne, and an ester linkage to promote 
initiation of the RAFT agent during the pre-equilibrium. TMS-Alkyne-PEsBTC was 
synthesised via the esterification of PABTC with 3-(trimethylsilyl)propargyl alcohol 
using N,N’-Dicyclohexylcarbodiimide (DCC) and dimethylaminopyridine (DMAP) as 
coupling agent and catalyst respectively at 80% yield (Scheme 4.3).28  
 
Scheme 4.3. Esterification of PABTC with 3-(trimethylsilyl)propargyl alcohol to yield TMS-Alkyne-
PEsBTC. 
 
4.2.2.2 Synthesis of TMS protected alkyne diblock macro-RAFT agent 
A P(PEGA)-b-(n-BA) macroRAFT agent was then synthesised in two steps using TMS-
Alkyne-PEsBTC as the CTA. As we were introducing a hydrophobic trimethylsilyl 
(TMS) and removing the negative carboxylate as compared to PABTC based macro-
RAFT agents, we targeted a slightly larger macro-RAFT agent to improve steric 
stabilisation of the resulting nanoparticles. Firstly, PEGA was polymerised with DPtarget 
of 15 mediated with TMS-Alkyne-PEsBTC at 70°C in 1,4-dioxane, using ACVA as the 
thermal initiator (Scheme 4.4). The polymerisation reached 82% monomer conversion in 
5 h yielding TMS-Alkyne-O-P(PEGA)12. THF-SEC analysis revealed a narrow molar 
mass distribution (Ð = 1.11) and similar experimental molecular weights compared to 
theoretical values. Importantly, no high or low molar mass shoulders were evident, 
suggesting this RAFT agent was capable of controlling the polymerisation in comparison 
to Alkyne-PAmBTC. In chapter 3, we showed that the ‘soft’ P(n-BA) nanoparticles were 
preferentially taken up into cells in comparison to P(t-BA) and PS cores, and therefore 
we focussed on this variety of nanoparticles for the following study. Based on this, TMS-
Alkyne-O-P(PEGA)12 was then chain extended with 14 units of n-BA, reaching 90% 
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monomer conversion after 5 h, yielding TMS-Alkyne-O-P[(PEGA)12-b-(n-BA)12], 
which again showed low dispersity values (Ð = 1.14) and similar experimental molar 
masses to theoretical values (Table 4.2). 
 
Scheme 4.4 Preparation of TMS-Alkyne-O-P[(PEGA)12-b-(n-BA)12] via a two-step polymerisation using 
TMS-Alkyne-PEsBTC as the RAFT agent. 
 
Table 4.2. Characterisation data for TMS-Alkyne-O-P(PEGA)12 and TMS-Alkyne-O-P[(PEGA)12-b-(n-
BA)12] 
 % 
conva 
Mn,th  
(g mol-1)b 
Mn,SEC   
(g mol-1)c 
Mw,SEC  
(g mol-1)c Ð
c 
TMS-Alkyne-O-P(PEGA)12 82% 6100 6500 7200 1.11 
TMS-Alkyne-O-P[(PEGA)12-b-(n-BA)12] 90% 7600 8600 9900 1.14 
aDetermined by 1H NMR spectroscopy. bTheoretical molar masses calculated with Equation 2.12. 
cDetermined by THF-SEC and analysed against PMMA standards. 
 
 
Figure 4.2. THF-SEC traces of TMS-Alkyne-O-P(PEGA)12 (blue line) and TMS-Alkyne-O-
P[(PEGA)12-b-(n-BA)12] (red line). 
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4.2.2.3 RAFT emulsion polymerisation with TMS protected macro-RAFT 
agents 
Initially, a RAFT emulsion polymerisation of n-BA was performed using TMS-Alkyne-
O-P[(PEGA)12-b-(n-BA)12] as the macro-RAFT agent stabiliser, with conditions 
established in section 2.2.3, targeting a DP of 200. DLS analysis of the resulting latex 
revealed a highly polydisperse, multimodal particle size distribution (PDi = 0.235), with 
a large proportion of nanoparticles being > 1000 nm diameter (Figure 4.3a). Furthermore, 
a broad, multimodal molecular weight distribution was observed via SEC (Ð = 6.51; 
Table 4.3, Figure 4.3b). It is likely this is due to the neutral hydrophobic surface imparted 
on the nanoparticles by the TMS protecting group, which during the early stages of the 
emulsion polymerisation would promote the migration of multiple propagating z-mers 
into each growing micelle, and therefore induce many termination events leading to broad 
molar mass distributions. Furthermore, the lack of electrostatic stabilisation and increased 
hydrophobicity, compared to PABTC based stabilisers, could result in weaker colloidal 
stability and potentially explain the broad particle size distribution observed by DLS. 
To probe this further, a series of analogous RAFT emulsion polymerisations were 
performed with micelle blends of TMS-Alkyne-O-P[(PEGA)12-b-(n-BA)12] and MRA-
nBA (P(PEGA)8-b-P(n-BA)8) (synthesised in chapter 2). Polymerisations were 
conducted with 0, 10, 25 and 50 mol% TMS-Alkyne-O-P[(PEGA)12-b-(n-BA)12] 
(relative to MRA-nBA) to introduce extra electrostatic stability from the carboxylated 
end group of MRA-nBA, potentially improving the latex stability. To ensure complete 
macro-RAFT agent micelle blends, a thin-film rehydration technique reported by 
O’Reilly and co-workers was conducted.29 Briefly, both amphiphilic macro-RAFT agents 
were dissolved in THF, dried thoroughly at 70°C and were subsequently rehydrated by 
stirring in pure water for 16 h. The low Tg core of the micelles should induce efficient 
micelle blending due to the faster exchange of diblock copolymers.29  
Analogous RAFT emulsion polymerisations were then performed using these blended 
micelle suspensions. Interestingly, with the exception of the polydisperse particle 
suspension of the 100% TMS macro-RAFT agent, a clear decreasing trend in particle 
diameter was observed with an increasing amount of carboxylated MRA-nBA macro-
RAFT agent (143.6, 129.0, 108.6, 99.1 nm for 50, 25, 10 and 0% respectively; Figure 
4.3b1, c1 and d1). Furthermore, these latexes displayed far narrower PDi values (< 0.1), 
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suggesting improved colloidal stability (Figure 4.3b-e). As expected, zeta-potentials of 
the nanoparticle became increasingly negative, with increasing amount of MRA-nBA 
present in the RAFT emulsion polymerisations (Table 4.3). Nonetheless, as with the 
100% TMS macro-RAFT agent polymerisations, broad molar mass distributions were 
observed for reactions conducted with 50, 25 and 10% TMS macro-RAFT agent (Figure 
4.3g-i; Ð ~ 4.5). However, as described in chapter 2, polymerisation with no TMS macro-
RAFT agent (i.e. 100% carboxylated macro-RAFT agent MRA-nBA) yielded a narrower 
molar mass distribution (Ð = 1.62; Figure 4.3i). These observations support our previous 
hypothesis, suggesting the TMS protecting group is interfering with the colloidal stability 
and RAFT emulsion polymerisation, with full details found in Table 4.3. Although, stable 
latexes with narrow PDi values were obtained with 10, 25 and 50% TMS macro-RAFT 
agent, the poor molar mass distributions observed could indicate poor consumption of the 
macro-RAFT agent, and subsequently low level of alkyne functionality at the 
nanoparticle surface.  
Table 4.3 Characterisation data for the n-BA RAFT emulsion polymerisations performed using the micelle 
blends of MRA-nBA and TMS-Alkyne-O-P[(PEGA)12-b-(n-BA)12] targeting a DP of 200. 
% TMS macro-
RAFT agent Dh (nm)
a PDib ZP (mV)c 
Mn,SEC  
(g mol-1) d 
Mw,SEC  
(g mol-1) d Ð
d 
100 100 0.235 -1.5 48100 313100 6.51 
50 144 0.083 -11.7 32800 147300 4.49 
25 129 0.091 -22.6 24400 99100 4.06 
10 109 0.075 -29.4 24900 106600 4.28 
0 99 0.059 -40.2 36300 58800 1.62 
aDetermined by DLS. bCalculated with Equation 2.13. cDetermined with a zetasizer. dMeasured with THF-
SEC and analysed against PMMA standards. All polymerisations reached >99% conversion. Mn,th for all 
polymerisations = 33200 g mol-1.  
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Figure 4.3 DLS (A-E) and THF-SEC (F-J) traces of n-BA RAFT emulsion polymerisations using micelle 
blends containing various ratios of MRA-nBA (COOH) and TMS-Alkyne-O-P[(PEGA)12-b-(n-BA)12] 
(TMS). 
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4.2.2.4 Addition of acrylic acid 
We hypothesised that the poor consumption of macro-RAFT agent, and therefore broad 
molar mass distributions in the above RAFT emulsion polymerisations, arose from 
removing the carboxylated end-group and thus increasing the surface hydrophobicity and 
number of radical present (and therefore termination events) in each growing particle. A 
possible route to reintroduce the negatively charged surface, was to copolymerise a small 
amount of charged monomer with the hydrophilic PEGA block, restoring ionisation in 
the pendant side chains rather than the end group.  
PEGA was therefore copolymerised with acrylic acid (AA) in an 80/20 molar ratio, 
targeting a total DP of 18 in 1,4-dioxane (Scheme 4.5). The polymerisation reached 84% 
total monomer conversion yielding TMS-Alkyne-O-P[(PEGA)12-co-(AA)3]. This was 
then chain extended with 15 units of n-BA which reached >99% monomer conversion 
yielding TMS-Alkyne-O-P[(PEGA)12-co-(AA)3]-b-(n-BA)15. Both polymers had 
narrow molar mass distributions (Ð < 1.2; Figure 4.4), with similar theoretical molar 
masses (determined by 1H NMR spectroscopy) to experimentally determined values (via 
SEC; Table 4.4). Furthermore, a shift towards higher molar mass was evident, suggesting 
efficient chain extension.  
 
Scheme 4.5 Preparation of TMS-Alkyne-O-P[(PEGA)12-co-(AA)3]-b-(n-BA)15 via a two-step 
polymerisation using TMS-Alkyne-PEsBTC as the RAFT agent. 
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Figure 4.4 THF-SEC of TMS-Alkyne-O-P[(PEGA)12-co-(AA)3] (blue line) and TMS-Alkyne-O-
P[(PEGA)12-co-(AA)3]-b-(n-BA)15 (red line).  
Table 4.4 Characterisation data for TMS-Alkyne-O-P[(PEGA)12-co-(AA)3] and TMS-Alkyne-O-
P[(PEGA)12-co-(AA)3]-b-(n-BA)15 
 % conva Mn,th  (g mol-1)b 
Mn,SEC   
(g mol-1)c 
Mw,SEC  
(g mol-1)c Ð
c 
TMS-Alkyne-O-P(PEGA)12 84 5900 5500 6200 1.12 
TMS-Alkyne-O-P[(PEGA)12-b-(n-BA)12] >99 7600 7200 8300 1.15 
aDetermined by 1H NMR spectroscopy. bTheoretical molar masses calculated with Equation 2.12. 
cDetermined by THF-SEC and analysed against PMMA standards. 
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4.2.2.5 RAFT emulsion polymerisation using TMS-Alkyne-O-P[(PEGA)12-
co-(AA)3]-b-(n-BA)15 
 
Figure 4.5. (A) DLS distributions (intensity (black), volume (green) and number (red)) of TMS-Alkyne-
O-P[(PEGA)12-co-(AA)3]-b-(n-BA)12-b-(n-BA)200] nanoparticles (B) THF-SEC of TMS-Alkyne-O-
P[(PEGA)12-co-(AA)3]-b-(n-BA)12- b-(n-BA)200]  (black full line) and TMS-Alkyne-O-P[(PEGA)12-b-
(n-BA)12] macro-RAFT agent (grey dashed line).  
 
Table 4.5 Characterisation data for TMS protected alkyne functional nanoparticles, TMS-Alkyne-O-
P[(PEGA)12-co-(AA)3]-b-(n-BA)12- b-(n-BA)200]. 
 Dh (nm)a PDi b ZP (mV)c Mn,SEC  (g mol-1)d 
 Ð e 
TMS-Alkyne-O-P[(PEGA)12-
co-(AA)3]-b-(n-BA)12- b-(n-
BA)200] 
101.4 0.055 -49.5 33000 
 
1.92 
aDetermined by DLS. bCalculated with Equation 2.13. cDetermined with a zetasizer. dMeasured with THF-
SEC and analysed against PMMA standards. All polymerisations reached >99% conversion. Mn,th  = 33200 
g mol-1.  
A RAFT emulsion polymerisation of n-BA was then performed using only TMS-Alkyne-
O-P[(PEGA)12-co-(AA)3]-b-(n-BA)15 (i.e. no micelle blending), again targeting a DP of 
200. DLS revealed the formation of narrow 101 nm nanoparticles (PDi = 0.055; Table 
4.5, Figure 4.5a). SEC of the dissolved nanoparticles displayed a clear shift towards 
higher molar mass indicating excellent chain extension. The resulting polymer (Figure 
4.5b) had a relatively low dispersity (Ð=1.92) as compared to those where no acrylic acid 
was present in the macro-RAFT agent (Figure 4.3; Table 4.3). These findings support our 
hypothesis that the presence of a charged surface is imperative in maintaining colloidal 
stability, and the production of narrow dispersity polymers.  
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4.2.2.6 Test deprotection of TMS group on TMS macro-RAFT agent 
Our previous results give a clear indication that TMS-Alkyne-O-P[(PEGA)12-co-
(AA)3]-b-(n-BA)15, is a suitable macro-RAFT agent to stabilise RAFT emulsion 
polymerisations. However, to utilise the imparted alkyne functionality, the TMS group 
must be removed. It is well known that these groups can be deprotected via the addition 
of fluoride ions, due to the strong Si-F bond created during the reaction. This is typically 
achieved using tetrabutyl ammonium fluoride (TBAF), as it is commercially available as 
a 1.0 M solution in THF, and can be used in organic solvents. When considering the 
deprotection of TMS groups on our nanoparticles, the presence of a large quantity of 
organic solvent could reduce the colloidal stability of the synthesised latexes as 
mentioned in section 3.2.2. Some reports however, describe the deprotection of TMS 
esters using potassium fluoride (KF), representing a promising route to remove the TMS 
group from our nanoparticles in aqueous conditions.30 
The above TMS protected alkyne functional nanoparticles were subjected to 10 eq of KF 
for 16 h. The nanoparticles were subsequently dialysed to remove the resulting 
fluorotrimethylsilane by-product and then diluted in D2O. 1H NMR spectroscopy revealed 
the presence of a large singlet at ~0 ppm, suggesting the TMS deprotection was 
unsuccessful (Figure 4.6).  
 
Figure 4.6 1H NMR spectrum of TMS protected nanoparticles after an attempted deprotection with 10 eq 
of KF in D2O measureed with a 300 MHz spectrometer. 
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To investigate this further, the TMS protected macro-RAFT agent (TMS-Alkyne-O-
P[(PEGA)12-co-(AA)3) was utilised as a model for a deprotection reaction with KF and 
TBAF. As before, the macro-RAFT agent was treated with 10 eq KF or TBAF (1.0 M in 
THF), dialysed and analysed with 1H NMR spectroscopy. After treatment with TBAF, a 
large proportion of the salt had not been removed via dialysis likely due to poor water 
solubility (Figure 4.7). Nonetheless a clear reduction in the TMS peak at 0 ppm was 
observed, suggesting partial deprotection had indeed occurred. However, upon addition 
of KF, a less pronounced reduction in the TMS peak was evident, most probably due to 
the stronger ion pair formed between fluoride ions and potassium ions than with 
tetrabutylammonium ions (Figure 4.7). While these results indicate that deprotection is 
indeed possible in aqueous conditions, KF is not as efficient as TBAF, but is likely easier 
to removed after the reaction.  
 
Figure 4.7 1H NMR spectra of TMS-Alkyne-O-P[(PEGA)12-co-(AA)3] before deprotection (bottom), after 
treatment with potassium fluoride (10 eq; middle), and after treatment with tetrabutyl ammonium fluoride 
(10 eq; top).  
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4.2.3 Unprotected propagyl ester 
The results presented clearly show that an ester based RAFT agent is required to produce 
controlled molecular weight macro-RAFT agents. Furthermore, the addition of negative 
charge in the pendant chain of the nanoparticle shell is necessary to maintain colloidal 
stability. We envisaged that the inefficient polymerisation with Alkyne-PAmbTC could 
solely be due to the amide reinitiating group, and not the presence of a terminal alkyne. 
Therefore, with the unsuccessful deprotection of the TMS-alkyne coated nanoparticles 
with KF, a non-protected analogue of TMS-Alkyne-PEsBTC was synthesised, retaining 
the ester R group for more efficient initiation.  
 
4.2.3.1 Synthesis of non-protected alkyne RAFT agent 
 
Scheme 4.6 Preparation of non-protected alkyne functional RAFT agent, Alkyne-PEsBTC.  
Alkyne-PEsBTC was synthesised according to the conditions described in literature 
procedures (Scheme 4.6).31 PABTC was esterified with propargyl alcohol, using N,N’-
Dicyclohexylcarbodiimide (DCC) and dimethylaminopyridine (DMAP) as coupling 
agent and catalyst respectively at 70% yield. 
4.2.3.2 Non-protected alkyne macro-RAFT agent synthesis 
 
 Scheme 4.7 Preparation of TMS-Alkyne-O-P[(PEGA)12-co-(AA)3]-b-(n-BA)15 
An analogous non-protected alkyne functional macro-RAFT agent to TMS-Alkyne-O-
P[(PEGA)13-co-(AA)3]-b-(n-BA)15 was prepared via a two-step polymerisation. 
Copolymerisation of PEGA and AA (87% monomer conversion), and subsequent chain 
extension with n-BA (81% monomer conversion) mediated by Alkyne-PEsBTC yielded 
Alkyne-O-P[(PEGA)12-co-(AA)3]-b-(n-BA)15. Both blocks had narrow molar mass 
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distributions (Ð < 1.2), with similar M,th and Mn,SEC (Table 4.6). Additionally, a significant 
shift towards higher molar mass was evident, indicating successful chain extension 
(Figure 4.8). Although the terminal alkyne was not protected during the polymerisation, 
no low molecular weight shoulder or broadening was observed, suggesting the alkyne did 
not get consumed in the reaction. Furthermore, comparing the 1H NMR spectrum of 
Alkyne-PEsBTC and Alkyne-O-P[(PEGA)12-co-(AA)3]-b-(n-BA)15, the singlet at 4.6 
ppm attributed to the CH2 adjacent to the acetylene group, was retained, confirming this 
theory (Figure A 4.3). It is likely therefore that the poor molecular weight control, when 
using Alkyne-PAmBTC, could be mainly attributed to the amide reinitiating group as 
previously described, and not the unprotected alkyne.  
 
Scheme 4.8 Preparation of Alkyne-O-P[(PEGA)12-co-(AA)3]-b-(n-BA)15 via a two-step polymerisation 
using Alkyne-PEsBTC as the RAFT agent. 
 
Figure 4.8 THF-SEC traces for Alkyne-O-P[(PEGA)12-co-(AA)3] (blue line) and Alkyne-O-P[(PEGA)12-
co-(AA)3]-b-(n-BA)15 (red line).  
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Table 4.6 Characterisation data for Alkyne-O-P[(PEGA)12-co-(AA)3] and Alkyne-O-P[(PEGA)12-co-
(AA)3]-b-(n-BA)15. 
 % 
conva 
Mn,th  
(g mol-1)b 
Mn,SEC   
(g mol-1)c 
Mw,SEC  
(g mol-1)c Ð
c 
Alkyne-O-P[(PEGA)12-co-(AA)3] 87 5350 6500 7400 1.14 
Alkyne-O-P[(PEGA)12-co-(AA)3]-b-(n-BA)15 81 6900 7800 9100 1.16 
aDetermined by 1H NMR spectroscopy, bTheoretical molar masses calculated with Equation 2.12, 
cDetermined by THF-SEC and analysed against PMMA standards. 
4.2.3.3 Test click reactions on model polymer 
Although the above 1H NMR spectra indicates the presence of an alkyne, the large steric 
bulk from the P(PEGA) chains may make this functionality inaccessible for further 
reactions. We envisaged that an azido functional fluorescent dye could be used as a model 
molecule in a CuAAC conjugation reaction, and the reaction monitored via UV detection 
SEC as in section 3.6.2.2 for the BODIPY labelled nanoparticles. Initially Fluorescein-
N3 was synthesised via the amidation of the active ester derivative Fluorescein-NHS with 
azidopropanamine (Scheme 4.9). The reaction was shown to be quantitative, via the shift 
observed in HPLC, and the single molecular ion peak present in mass spectra, attributed 
to Fluorescein-N3. Due to the low yield of the isolated compound (< 5 mg), unfortunately 
1H NMR and 13C NMR spectra were not obtained.  
 
Scheme 4.9 Synthesis of Fluorescein-N3 and CuAAC conjugation of Fluorescein-N3 to Alkyne-O-
P[(PEGA)12-co-(AA)3] yielding Fluorescein-O-P[(PEGA)12-co-(AA)3].  
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Table 4.7 THF-SEC of Fluorescein-O-P[(PEGA)12-co-(AA)3] using RI detection (black line) and UV 
detection at 488 nm (green dashed line).  
Using previously described conditions, a CuAAC reaction was performed on Alkyne-O-
P[(PEGA)12-co-(AA)3] with Fluorescein-N3 using copper sulfate as the Cu(II) source, 
and ascorbic acid as a reducing agent to generate Cu(I) in situ (Scheme 4.9).32 After the 
reaction, a clear overlap between the RI and UV488 nm (488 nm is the absorbance maxima 
of fluorescein; Table 4.7) traces could be observed, suggesting Fluorescein-N3 had been 
conjugated. 
As some potential azide substrates may be larger than small molecules, the CuAAC 
reaction was further investigated using a 2 kDa azido function PEG (PEG-2k-N3) and the 
same conditions as above (Scheme 4.10). The reaction was monitored using SEC, and 
after 2 h stirring at room temperature a clear shift towards higher molar mass (6500 g 
mol-1 for Alkyne-O-P[(PEGA)12-co-(AA)3] to  8000 g mol-1 for PEG-2k-P[(PEGA)12-
co-(AA)3]) was observed, suggesting successful conjugation (Figure 4.9; Figure 4.8). A 
residual amount of PEG-2k-N3 was observed as a low molar mass shoulder, and is likely 
to be the extra 0.2 eq present at the end of the reaction. Overall, these results suggest that 
after producing the macro-RAFT agent with a non-protected alkyne end-group, it is still 
available for post polymerisation modification.  
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Scheme 4.10 CuAAC conjugation of PEG-2k-N3 to Alkyne-O-P[(PEGA)12-co-(AA)3] yielding PEG-2k-
O-P[(PEGA)12-co-(AA)3]. 
 
Figure 4.9 THF-SEC traces of PEG-2k-N3 (black dashed line), Alkyne-O-P[(PEGA)12-co-(AA)3] (blue 
line) and PEG-2k-O-P[(PEGA)12-co-(AA)3] (red line). 
Table 4.8 Characterisation data for PEG-2k-N3, Alkyne-O-P[(PEGA)12-co-(AA)3], PEG-2k-
P[(PEGA)12-co-(AA)3]. 
 
 Mn,th  
(g mol-1)a 
Mn,SEC   
(g mol-1)b 
Mw,SEC  
(g mol-1)b Ð
c 
PEG-2k-N3 2000 3400 3560 1.05 
Alkyne-O-P[(PEGA)12-co-(AA)3] 5350 6500 7400 1.14 
PEG-2k-P[(PEGA)12-co-(AA)3] 7900 8000 9600 1.20 
 
aDetermined using Equation 2.12. cDetermined by THF-SEC, calibrated with PMMA standards. 
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4.2.3.4 RAFT emulsion polymerisation with non-protected alkyne macro-
RAFT agent 
Using the conditions described above, a RAFT emulsion polymerisation was performed 
using the non-protected alkyne macro-RAFT agent, Alkyne-O-P[(PEGA)12-co-(AA)3]-
b-(n-BA)15, targeting a DP of 200, to produce non-protected alkyne functional 
nanoparticles (Scheme 4.11). 
 
Scheme 4.11  RAFT emulsion polymerisation of n-BA using macro-RAFT agent Alkyne-O-P[(PEGA)12-
co-(AA)3]-(n-BA)15  to generate Alkyne-O-P[(PEGA)12-co-(AA)3]-(n-BA)15-(n-BA)200. 
 
Figure 4.10. (A) SEC chromatograms of dissolved Alkyne-O-P[(PEGA)12-co-(AA)3]-(n-BA)15-(n-BA)200 
nanoparticles before dialysis (black line), after dialysis (green dashed line) and macro-RAFT agent Alkyne-
O-P[(PEGA)12-co-(AA)3]-(n-BA)15  (grey dashed line).  
Table 4.9 Characterisation data for non-protected alkyne functional nanoparticles, Alkyne-O-P[(PEGA)12-
co-(AA)3]-b-(n-BA)12- b-(n-BA)200]. 
 Dh 
(nm)a PDi
 b ZP (mV)c 
Mn,SEC   
(g mol-1)e Ð
 f 
TMS-Alkyne-O-P[(PEGA)12-co-(AA)3]-b-(n-BA)12- 
b-(n-BA)200] 101.4 0.055 -52.1 37000 2.12 
 
aDetermined by DLS. bCalculated with Equation 2.13. cDetermined with a zetasizer. dMeasured with THF-
SEC and analysed against PMMA standards. All polymerisations reached >99% conversion. Mn,th  = 33100 
g mol-1.  
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Interestingly, the particles produced with this non-protected macro-RAFT agent had a far 
smaller diameter (54 nm; Figure 4.10b) than those extended from the TMS protected 
derivative (101 nm; Figure 4.5a). This is likely due to the increased surface hydrophilicity 
and electrostatic stability without the TMS protecting group and with the acrylic acid 
moieties respectively. As before, SEC analysis revealed a high chain extension efficiency 
and a relatively narrow dispersity compared to those obtained with the macro-RAFT 
agent without acrylic acid, and with the hydrophobic TMS group. Furthermore, similar 
Mn,th and Mn,SEC were observed (33100 and 37000 g mol-1 respectively) indicating good 
molecular weight control.  
Prior to any CuAAC reactions directly on the nanoparticles, the latex was dialysed to 
remove any unconsumed macro-RAFT agent, resulting in a reduction of the lower molar 
mass region in the size exclusion chromatogram Figure 4.10a. This is of particular 
importance, as the residual macro-RAFT agent also had alkyne functionality and may 
compete against the acetylene groups at the nanoparticle surface during a CuAAC 
reaction.  
4.2.3.5 Click reactions on nanoparticles 
CuAAC reactions with both PEG-2k-N3 and Fluorescein-N3 were performed with the 
above alkyne functional nanoparticles, assuming that 100% of the macro-RAFT agent, 
and therefore alkyne moieties were available at the particle surface. After addition of the 
azido functional PEG, no shift in the SEC was observed, while some of the PEG-2k-N3 
could still be seen at lower molar mass, likely due to incomplete conversion. However, 
any cycloaddition which did occur may not be detectable via SEC due to the small 
increase in molar mass in comparison to the original trace before reaction. Nonetheless, 
as in the CuAAC reactions with the model polymer, after addition of Fluorescein-N3 to 
the nanoparticles in the presence of CuSO4 and ascorbic acid, a clear overlap could be 
observed between the RI and UV488 nm channel. These results indicate Fluorescein-N3 
had been successfully clicked onto the nanoparticles. DLS analysis comparing before and 
after the reaction, showed negligible differences in particle size and PDi suggesting this 
process did not perturb colloidal stability. The above results could suggest that larger 
molecules cannot be conjugated to our nanoparticles, possibly due to the dense brush of 
P(PEGA) at the nanoparticle surface, while smaller molecules such as Fluorescein-N3 
are able to diffuse close to the acetylene moieties at the surface and react successfully 
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Figure 4.11 CuAAC reactions on the surface of the alkyne functional nanoparticles with (A) left side – 
PEG-2k-N3 and right side – Fluorescein-N3. (B) THF-SEC for dissolved nanoparticles after (red line) 
CuAAC with PEG-2k-N3 (black dashed line), compared with chromatogram for before reaction (blue line). 
(C) THF-SEC RI and UV488 nm detection after (green dashed line) CuAAC with Fluorescein-N3, compared 
with before the reaction (black line).  
 
4.2.3.6 Purification of Cu2+ and unreacted substrate on model 
nanoparticles 
To use this approach for applications in biological systems, the Cu2+ source should ideally 
be removed from the latex to maintain biocompatibility.33  
To test different purification techniques, the alkyne-functional nanoparticles were spiked 
with 10 mM Cu2SO4 and subjected to two purification techniques (a two-step dialysis 
against 10 mM EDTA, then against pure water, or a Sephadex SEC) and a control. After 
purification the particles were concentrated using Amicon centrifugation dialysis tubes 
such they were all at the same concentration, and treated with 100 mM EDTA and left to 
stir overnight. Any residual copper was monitored via the formation of the EDTA-Cu2+ 
which appears bright blue in aqueous solution. For the control treatment, as expected a 
bright blue colour was indeed observed. However, after both dialysis and Sephadex 
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column purification no colour change was seen, suggesting most, if not all, of the copper 
had been successfully removed. Having two possible purification approaches could be 
highly useful, as the dialysis approach can take up to 72 h, whereas the Sephadex column 
requires only 30 min to perform, which is perhaps beneficial for sensitive samples 
(proteins, radiolabels etc.)    
 
Figure 4.12 Digital photograph of Alkyne-O-P[(PEGA)12-co-(AA)3]-(n-BA)15-b-(n-BA)200 nanoparticles 
spiked with 10 mM CuSO4 and then purified via dialysis (right) or sephadex size exclusion chromatography 
(middle) or non-purified (left) post-addition of 100 mM EDTA.  
Finally, to investigate the efficiency of removing a model substrate, the azide functional 
nanoparticles were instead spiked with Fluorescein-N3 and purification attempted with 
Sephadex SEC. 1 mL fractions were collected (11 fractions total), then the fluorescence 
intensity (λex = 488 nm, λem = 512 nm; Fluorescein-N3) and the scattering intensity 
(nanoparticles) was measured for each fraction.  
It was found that the nanoparticles eluted quickly from the column, between fractions 2 
and 5, while the spiked Fluorescein-N3 eluted slower between fractions 5 and 11. This 
shows that small compounds can be separated effectively from the larger nanoparticles, 
with only 1 overlapping fraction (F4).    
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Figure 4.13 Scattering intensity (black squares; measured with DLS), and fluorescence intensity (λex = 488 
nm, λem = 512 nm) of Fluorescein-N3 spiked alkyne functional Alkyne-O-P[(PEGA)12-co-(AA)3]-(n-
BA)15-b-(n-BA)200 nanoparticles, for each fraction post-separation with a PD-10 sephadex column.  
 
4.3 Conclusion 
In conclusion, through a systematic polymerisation study using three different alkyne 
functional RAFT agents (amide coupled, ester coupled and TMS protected ester coupled), 
we have investigated the requirements for generating alkyne functional nanoparticles via 
RAFT emulsion polymerisation. Our results indicate that the presence of an amide bond 
at the reinitiating group severely reduces molecular weight control. Furthermore, 
protection of terminal alkynes throughout the synthesis is required to generate low 
dispersity macro-RAFT agent stabilisers. However, replacement of the carboxylate end-
group dramatically impacts the colloidal stability of the nanoparticles. This was overcome 
by reintroducing this functionality into the side chain by copolymerisation of acrylic acid 
into the hydrophilic block of the stabilising macro-RAFT agent. Finally, we showed that 
the resultant alkyne functional nanoparticles could be post-modified with either an azido-
functional linear PEG or fluorescein azide. This methodology, as a way to introduce 
functionality at the nanoparticle surface, paves the way for the generation of complex 
biomaterials.  
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4.4 Experimental 
4.4.1 Materials 
Propagyl amine, propagyl alcohol, 3-(Trimethylsilyl)propargyl alcohol, DCC, DMAP, 
PyBOP, DIPEA, polyethylene glycol methyl ether acrylate, n-butyl acrylate, acrylic acid, 
CuSO4 and ascorbic acid were purchased from Sigma Aldrich. All monomers were passed 
through basic aluminium oxide to remove inhibitors before polymerisation. Deuterium 
oxide, chloroform-d3 were obtained from Sigma Aldrich and used for NMR spectroscopy. 
Thermal initiator 4,4′-azobis(4-cyanovaleric acid) (ACVA, >98%, Aldrich) was used as 
received. RAFT agent PABTC was synthesised as previously described.34 Macro-RAFT 
agent MRA-nBA (P[(PEGA)8-b-(n-BA)8]) was synthesised as described in chapter 2. 
Solvents were acquired from commercial sources. PD-10 acquired from GE healthcare.  
 
4.4.2 Instrumentation and Analysis 
4.4.2.1 NMR spectroscopy 
1H NMR and 13C NMR spectra were recorded as described in section 2.4.2.1 
4.4.2.2 Size exclusion chromatography  
THF-SEC was performed using conditions described in section 2.4.2.2 
 
4.4.2.3 Theoretical molar mass calculation 
Theoretical molar masses were calculated as described in section 2.4.2.3 
 
4.4.2.4 Dynamic light scattering and ζ-potential  
DLS and ζ-potential measurements were carried out as described in 2.4.2.4.  
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4.4.3 Synthesis 
4.4.3.1 Synthesis of Alkyne-PAmBTC27 
A stirred solution of PyBOP (1.64 g, 3.15 mmol, 1 eq) and DIPEA (0.97 g, 6.74 mmol, 
2.4 eq) in DCM (5 mL) was added to a separate solution of  PABTC (0.75 g, 3.15 mmol, 
1 eq; dissolved in 5 mL DCM) in a 25 mL round bottomed flask fitted with a magnetic 
stirrer, turning the solution deep red. Propagyl amine (173 mg, 3.15 mmol, 1 eq) was 
added subsequently dropwise to the PABTC solution. After all of the amine had been 
added, the solution returned to its original yellow colour and was left to stir at room 
temperature overnight. The reaction was monitored with TLC using a 50/50 hexane/ethyl 
acetate eluent. The reaction mixture was then concentrated under reduced pressure, and 
purified via automatic column chromatography using a gradient eluent (10% -50% ethyl 
acetate in hexane, over 30 min) yielding Alkyne-PAmBTC (589.6 mg, 68% yield) as a 
pale yellow solid. 1H NMR (500 MHz, CDCl3) δ 6.57 (br, J = 45.1 Hz, 1H, NH), 4.77 (q, 
J = 7.4 Hz, 1H, CH3-CH), 4.05 (qdd, J = 17.6, 5.3, 2.5 Hz, 2H, NH-CH2), 3.41 (t, 2H, S-
CH2), 2.25 (t, J = 2.4 Hz, 1H, C≡CH), 1.72 (p, 2H, S-CH2-CH2), 1.61 (d, J = 7.3 Hz, 3H, 
CH-CH3), 1.46 (h, 2H, CH2-CH3), 0.97 (t, J = 7.4 Hz, 3H, CH2-CH3). 13C NMR (126 
MHz, CDCl3) δ 224.04 (C=S), 170.16 (C=O), 79.05 (C≡CH), 71.82 (C≡CH), 47.48 (S-
CH), 37.35 (S-CH2), 29.86 (NH-CH2), 29.55 (S-CH2-CH2), 22.06 (CH3-CH2), 16.06 
(CH-CH3), 13.59 (CH2-CH3). FTIR ν cm-1: 3281(s, C-H alkyne), 2957 + 2927 (m, N-H 
amide), 2868 (m, C-H alkane), 1656 (s, C=O amide). ESI-MS m/z: 276.0 [M+H]+. 
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Figure 4.14 1H NMR spectrum of Alkyne-PAmBTC measured at 500 MHz in CDCl3. 
 
Figure 4.15 DEPT-135 13C NMR spectrum of Alkyne-PAmBTC measured at 126 MHz in CDCl3. 
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4.4.3.2 Synthesis of TMS-Alkyne-PEsBTC28 
DCC (0.714 g, 3.46 mmol, 1.1 eq) and DMAP (38 mg, 0.315 mmol, 0.1 eq) was added to 
a stirred solution of PABTC (0.750 g, 3.15 mmol, 1 eq) in DCM (20 mL), in a 50 mL 
round bottomed flask turning the solution deep red. 3-(Trimethylsilyl)propargyl alcohol 
(0.444 g, 3.46 mmol, 1.1 eq) was added to the activated PABTC solution and stirred 
overnight at room temperature. The mixture was washed with 50 mL water (3x) and 1 M 
HCl (3 x), the organic phase dried over sodium sulfate, and purified via flash column 
chromatography using a gradient eluent (0% - 20% ethyl acetate in hexane over 30 min), 
yielding TMS-Alkyne-PEsBTC as a bright yellow oil (0.53 g, 48% yield). 1H NMR (500 
MHz, CDCl3) δ 4.84 (q, J = 7.4 Hz, 1H, S-CH), 4.73 (d, J = 3.1 Hz, 2H, O-CH2), 3.36 (t, 
J = 7.4 Hz, 2H, S-CH2), 1.68 (quint, 2H, S-CH2-CH2), 1.62 (d, J = 7.4 Hz, 3H, CH-CH3), 
1.43 (sext, 2H, CH3-CH2) 0.93 (t, J = 7.4 Hz, 3H, CH2-CH3), 0.18 (s, 9H, Si-CH3). 13C 
NMR (126 MHz, CDCl3) δ 222.07 (C=S), 170.81 (C=O), 98.64 (C≡C-Si), 93.10 (C≡C-
Si), 54.29 (O-CH2), 48.10 (S-CH), 37.30 (S-CH2), 30.24 (S-CH2-CH2), 22.39 (CH3-
CH2), 17.04 (CH-CH3), 13.91 (CH2-CH3), -0.01 (Si-CH3). FTIR ν cm-1: 2958 + 2931 (m, 
N-H amide), 2872 (m, C-H alkane), 2186 (w, C≡C alkyne), 1741 (s, C=O ester). ESI-MS 
m/z: 349.6 [M+H]+. 
 
Figure 4.16 1H NMR spectrum of TMS-Alkyne-PEsBTC measured at 500 MHz in CDCl3. 
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Figure 4.17 DEPT-135 13C NMR spectrum of Alkyne-PEsBTC measured at 126 MHz in CDCl3. 
4.4.3.3 Synthesis of Alkyne-PEsBTC31 
EDC (3.86 g, 20.1 mmol, 1.2 eq) and DMAP (0.240 g, 2.1 mmol, 0.12 eq) was added to 
a stirred solution of PABTC (4 g, 16.7 mmol, 1 eq) in DCM (20 mL), in a 50 mL round 
bottomed flask turning the solution deep red. Propargyl alcohol (1.13 g, 20.1 mmol, 1.2 
eq) was added to the activated PABTC solution and stirred overnight at room temperature. 
The mixture was washed with 50 mL water (3x) and 1 M HCl (3 x), the organic phase 
dried over sodium sulfate, and purified via flash column chromatography using a gradient 
eluent (0% - 50% ethyl acetate in hexane over 30 min), yielding Alkyne-PEsBTC (4.20 
g, 91% yield) as an orange oil. 1H NMR (500 MHz, CDCl3) δ 4.85 (q, J = 7.4 Hz, 1H, S-
CH), 4.73 (t, J = 2.8 Hz, 2H, O-CH2), 3.36 (t, J = 7.4 Hz, 2H, S-CH2), 2.50 (t, J = 2.4 Hz, 
1H, C≡C-H), 1.72 – 1.65 (m, 2H, S-CH2-CH2), 1.62 (d, J = 7.4 Hz, 3H, S-CH-CH3), 1.47 
– 1.38 (m, 2H, CH3-CH2), 0.93 (t, J = 7.4 Hz, 3H, CH2-CH3). 13C NMR (126 MHz, 
CDCl3) δ 221.75 (C=S), 170.51 (C=O), 75.43 (C≡CH), 53.18 (O-CH2), 47.62 (S-CH), 
37.03 (S-CH2), 29.91 (S-CH2-CH2), 22.07 (CH3-CH2), 16.70 (CH-CH3), 13.60 (CH2-
CH3). FTIR ν cm-1: 3290(s, C-H alkyne) 2957 + 2930 (m, N-H amide), 2871 (m, C-H 
alkane), 2131 (w, C≡C alkyne), 1738 (s, C=O ester). ESI-MS m/z: 277.0 [M+H]+. 
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Figure 4.18 1H NMR spectrum of Alkyne-PEsBTC measured at 500 MHz in CDCl3. 
 
Figure 4.19 DEPT-135 13C NMR spectrum of Alkyne-PEsBTC measured at 126 MHz in CDCl3. 
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4.4.3.4 Preparation of macro-RAFT agents 
Macro-RAFT agents TMS-Alkyne-O-P[(PEGA)12-b-(n-BA)12], TMS-Alkyne-O-
P[(PEGA)12-co-(AA)3]-(n-BA)15 and Alkyne-O-P[(PEGA)12-co-(AA)3]-(n-BA)15 were 
prepared using the conventional RAFT polymerisation procedure described in section 
2.4.3.3. Full details for polymerisation conditions can be found in Table A4.3. 
4.4.3.5 Preparation of micelle blends29 
Micelle blends of TMS-Alkyne-O-P[(PEGA)12-b-(n-BA)12] and MRA-nBA, were 
prepared by dissolving both di-block macro-RAFT agents in THF (10 mg mL-1), which 
were mixed in separate test tubes in 5 molar ratios (see Table 4.3).  The mixtures were 
then dried thoroughly at 70°C, were rehydrated in 1 mL of water, and were left to stir 
overnight. RAFT emulsion polymerisations were then performed using these micelle 
blends using conditions described in section 2.4.3.4. 
4.4.3.6 RAFT emulsion polymerisation  
RAFT emulsion polymerisations (without micelle blending) were performed using 
conditions described in section 2.4.3.4. Monomer conversion was determined using 
gravimetric techniques.  
4.4.3.7 Deprotection of TMS protected nanoparticles 
The TMS protected alkyne functional nanoparticles (1 eq alkyne), were treated with KF 
(10 eq) and stirred overnight. The nanoparticle suspension was then dialysed three times 
in D2O (30 mL) using a 30,000 Da MWCO centrifugation dialysis tube. The nanoparticle 
suspension was then analysed directly with 1H NMR spectroscopy.  
4.4.3.8 Deprotection of TMS protecting group using TBAF or KF 
TMS-Alkyne-O-P[(PEGA)12-co-(AA)3] (20 mg, 3.38 µmol, 1 eq) was dissolved in water 
(1 mL) and treated with either TBAF (1M in THF; 33.8 µmol, 10 eq) or KF (33.8 µmol, 
10 eq). The mixtures were stirred overnight, then dialysed (3500 Da MWCO) against pure 
water for 24 h. Both solutions were then freeze-dried and the product extracted with 
CDCl3, then analysed with 1H NMR spectroscopy directly. 
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4.4.3.9 Synthesis of Fluorescein-N3 
N-methyl morpholine (NMM; 19 mg, 0.19 mmol, 3 eq) was added to solution of 
Fluorescein-N3 (30 mg, 63.4 µmol, 1 eq) dissolved in 1 mL DMSO and stirred for 5 min. 
Azidopropanamine (6.3 mg, 63.4 µmol, 1.0 eq) was added directly and stirred overnight. 
The reaction mixture was analysed via HPLC showing complete conversion into 
Fluorescein-N3. This was then precipitated into methyltertbutyl ether (5 mL), collected 
via centrifugation, and dried under reduced pressure yielding Fluorescein-N3 (5 mg, 10.5 
mmol, 16%) as an orange powder. ESI-MS m/z: 457.1 [M-H]-. 
4.4.3.10 CuAAC reactions on P(PEGA)12-co-(AA)3 
Alkyne-O-P[(PEGA)12-co-(AA)3] (25 mg, 4.67 µmol, 1 eq), CuSO4 (1.75 mg, 7.00 
µmol, 1.5 eq) and either Fluorescein-N3 (2.13 mg, 4.7 µmol, 1. eq) or PEG-2k-N3 (11.2 
mg, 5.6 µmol, 1.2 eq) were dissolved in 1 mL water, and purged with dinitrogen for 5 
min. A 0.5 mL solution of ascorbic acid (3.29 mg, 18.7 µmol, 4 eq) was then transferred 
via syringe and stirred overnight. The reaction mixture was then lyophilised, the organic 
components extracted in CHCl3 and analysed with THF-SEC and 1H NMR spectroscopy.  
4.4.3.11 CuAAC reactions on alkyne functional nanoparticles 
The alkyne functional nanoparticles (100 µL, 0.285 µmol alkyne, 1 eq), CuSO4 (0.128 
mg, 0.513 µmol, 1.8 eq) and PEG-2k-N3 (0.855 mg, 0.427 µmol, 1.5 eq) were dissolved 
in 1 mL water, and purged with dinitrogen for 5 min. A 0.5 mL solution of ascorbic acid 
(0.2 mg, 1.14 µmol, 4 eq) was then transferred via syringe and stirred overnight. CuAAC 
reactions were performed on the alkyne functional nanoparticles with Fluorescein-N3 
with identical conditions.  
4.4.3.12 Removal of CuSO4 from latex nanoparticles via dialysis 
The alkyne functional nanoparticles (200 µL) were spiked with 10 mM CuSO4 and 
dialysed against 1 L 10 mM EDTA for 48 h (changing the media 3 x), then against 1L 
pure water for 48 h (changing the media 3 x). The nanoparticle suspension was then 
concentrated to 100 µL using dialysis centrifuge tubes (30000 Da MWCO). The presence 
of Cu2+ was monitored via the addition of 100 mM EDTA.  
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4.4.3.13 Removal of CuSO4 from nanoparticles via SEC 
As above, the alkyne functional nanoparticles (200 µL) were spiked with 10 mM CuSO4, 
diluted to 2 mL and passed through a prepacked PD10 G25 sephadex column. 1 mL 
fractions were collected until all of the nanoparticles had eluted, which were then 
combined and concentrated with dialysis centrifugation (30000 Da MWCO). The 
presence of Cu2+ was monitored via the addition of 100 mM EDTA.  
4.4.3.14 Removal of Fluorescein-N3 from latex nanoparticles via SEC 
The alkyne functional nanoparticles (200 µL) were spiked with 2 mg Fluorescein-N3, 
diluted to 2 mL, and passed through a prepacked PD10 G25 sephadex column. 11 1 mL 
fractions were collected, and the fluorescence intensity (λex = 488 nm, λem = 512 nm) and 
scattering intensity monitored with via dynamic light scattering with a fixed attenuation, 
for each fraction.  
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Chapter 5  
 
Heparin mimicking sulfonated nanoparticles 
via RAFT emulsion polymerisation-induced 
self-assembly 
 
Heparin plays a significant role in wound-healing and tissue regeneration applications, 
through stabilisation of fibroblast growth factors (FGF). Risks associated with batch-to-
batch variability and contamination from its biological sources have led to the 
development of synthetic highly sulfonated polymers as promising heparin mimics. In this 
work, a systematic study of an aqueous polymerisation-induced self-assembly (PISA) of 
styrene from poly(2-acrylamido-2-methylpropane sodium sulfonate) (P(AMPS)) macro-
RAFT agents produced a variety of spherical heparin mimicking nanoparticles, which 
were further characterised with light scattering and electron microscopy techniques. 
None of the nanoparticles tested showed toxicity against mammalian cells, however 
significant haemolytic activity was observed. Nonetheless, the heparin mimicking 
nanoparticles outperformed both heparin and linear P(AMPS) in cellular proliferation 
assays, suggesting increased bFGF stabilisation efficiencies possibly due to the high 
density of sulfonated moieties at the particle surface.  
HE
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5.1 Introduction 
Heparin is an endogenous highly sulphated polysaccharide imperative to many biological 
processes such as anticoagulation, protein binding and the anti-inflammatory response.1-
3 Its biological activity is typically associated with its high charge density, which allows 
for strong electrostatic interactions with over 400 different proteins.4 In particular, 
heparins ability to bind to and stabilise the basic fibroblast growth factor (bFGF), and its 
role in aiding complexation with the receptor, has attracted significant interest due to its 
essential function in cell proliferation, tissue regeneration and wound healing. Despite its 
heavy clinical use, this versatile polysaccharide can only be sourced from animal tissues 
(typically bovine and porcine), raising major biological safety concerns (virus 
contamination and large batch-batch variation/variable patient response). To overcome 
these challenges, researchers have studied the bFGF stabilisation efficiency of a variety 
of linear polysulfated/sulfonated heparin mimics, including sulfated glycopolymers, 
polyaromatics and polystyrenes and polyacrylamides.5-9 For example, Maynard and co-
workers recently showed 200% proliferative activity (similar to heparin + bFGF) of 
human dermal fibroblast cells after addition of bFGF stabilised with polystyrenesulfonate 
copolymers.9 
Nanoparticles (NPs) are now well established in biomedicine for enhanced drug 
delivery,10 bio-imaging11 and diagnostics applications.12 Their large size promotes 
extended circulation times and in the case of cancer treatment, they demonstrate passive 
tumour accumulation via the enhanced permeability and retention (EPR) effect.13, 14 
Furthermore, their high surface area can be functionalised with a broad range of moieties, 
making them ideal candidates for protein binding.15 Although the synthesis of 
sulfonated/sulfated polymeric NPs has already been explored,16-18 only one report exists 
on synthetic heparin mimicking NPs as growth factor stabilisers.19 Koide et al. recently 
reported a library of polymeric NPs based on glycosylated sulfated/sulfonated 
polyacrylamides able to stabilise a vascular endothelial growth factor (VEGF165) which 
outperformed heparin in protein binding and anti-angiogenic experiments.19 This 
pioneering study revealed huge potential for NP heparin mimics, but as of yet has not 
been explored in the stabilisation of bFGF.  
NP’s designed with advanced controlled radical polymerisation techniques, such as 
reversible addition fragmentation chain transfer mediated (RAFT) polymerisation 
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induced self-assembly (PISA) can be exploited to overcome these challenges.20, 21 PISA 
is typically performed through chain extension of a solvophilic macro-RAFT agent with 
either: a solvophilic monomer which when polymerised becomes solvophobic (RAFT 
dispersion polymerisation); or a solvophobic monomer (RAFT emulsion 
polymerisation).22-24 This results in the formation of sterically stabilised, diblock 
copolymer core-shell NPs, where the particle surface is decorated with the solvophilic 
block of the stabilising macro-RAFT agent. Using this approach many parameters such 
as particle size, and stabiliser chain length can be modified, hence most PISA studies 
focus on nano-object synthesis and morphology control.25-28 However, this synthetic 
approach has also been used for a wide range of applications. For instance, Whittaker and 
co-workers reported polyethylene glycol (PEG) coated NPs, copolymerised with a 19F 
containing monomer synthesised via PISA for an in vitro cellular uptake study using 
magnetic nuclear resonance (MRI).29 Furthermore, Ladmiral et al. reported PISA using a 
galactose functional monomer to enhance delivery of a model drug via cell surface lectin 
binding.30 We have recently reported synthesis of polyacrylamide coated NPs via RAFT 
emulsion polymerisation, and their use as micro-RNA vectors and their in vivo 
biodistribution.23, 31  Outside of biological applications, Armes and co-workers recently 
reported the synthesis of sulfated NPs via PISA both in dispersion and emulsion to further 
understand NP occlusion in calcite and zinc oxide crystals.32, 33 Due to the highly sulfated 
nature of the above NPs, we envisaged that similar systems may be able to act as heparin 
mimics. However, to the best of our knowledge, there are no reports of synthetic heparin 
mimicking NPs specifically applied to bFGF stabilisation, or indeed any other growth 
factor than VEGF165.19  
Herein we report the synthesis of a series of heparin mimicking core-shell NPs via RAFT 
mediated PISA of styrene from poly(2-acrylamido-2-methyl propane sulfonic acid) 
(P(AMPS)) macro-RAFT agents. The NPs were characterised via dynamic light 
scattering and electron microscopy. Their toxicity and membrane (haemolytic) activity 
was evaluated in vitro on murine embryonic fibroblast cells (NIH-3T3) and erythrocytes, 
respectively. Finally, the bFGF stabilisation efficiency was determined through an in vitro 
proliferation assay using IL-3 dependent murine pro B cells (BaF3), which are engineered 
to over-express FGF receptors and do not produce heparin themselves. 
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5.2 Results and Discussion 
5.2.1 Synthesis of linear polymers 
Firstly, a series of three P(AMPS) homopolymers (DP20, DP50 and DP100) were 
prepared via aqueous RAFT polymerisation at 90°C using BDMAT as chain transfer 
agent, and VA-086 as thermal initiator (Figure 5.1a) (Prepared by Caroline P. Bray).34 
All three polymers had narrow molar mass distributions (Ð < 1.2; Figure 5.1) with similar 
experimental and theoretical molecular weights determined via 1H NMR spectroscopy 
and aqueous SEC respectively (Figure 5.1). Molecular weights determined by aqueous 
SEC deviated slightly from the theoretical values, likely due to the differences in 
hydrodynamic volume of the P(AMPS) homopolymers with the poly(ethyleneglycol) 
calibration. 
Table 5.1 Polymerisation conditions for P(AMPS) macro-RAFT agents 
aDetermined with 1H NMR spectroscopy. bCalculated with Equation 2.12. cDetermined with aqueous SEC 
against PEG/PEO standards. Data obtained by Caroline P. Bray. 
 
Figure 5.1 Aqueous size exclusion molecular weight distributions of P(AMPS)20, P(AMPS)50 and 
P(AMPS)100 macro-RAFT agents. Data obtained by Caroline P. Bray. 
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(g mol-1)c Ð
c 
P(AMPS)20 AMPS® 1.5 20 30 >99 4,800 5,200 8,100 1.10 
P(AMPS)50 AMPS® 1.5 50 12 >99 11,600 11,400 13,000 1.11 
P(AMPS)100 AMPS® 1.5 100 6 >99 23,000 21,900 17,600 1.16 
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5.2.2 Preliminary synthesis 
In the previous chapters, diblock macro-RAFT agents were synthesised as the stabilisers 
for RAFT emulsion polymerisations. However, the vast differences in solubility between 
P(AMPS) and hydrophobic monomers would make the synthesis of analogous diblock 
macro-RAFT agents non-trivial. Therefore, as our P(AMPS) macro-RAFT agent 
synthesis reached full monomer conversion, and were performed in water, emulsion 
polymerisations could be performed directly without macro-RAFT agent purification. In 
a preliminary NP synthesis, P(AMPS)50 was diluted in distilled water and directly chain 
extended with styrene (5 wt% monomer; 450 units) at 80°C, using ACVA as a thermal 
initiator, 1 mM P(AMPS)50 and 400 RPM stirring (Table A5.1; Figure 5.1a). The reaction 
was sampled periodically for 8 h to measure conversion, molar mass and particle size 
evolution over time. Between 0 - 1 h, negligible monomer conversion was observed 
(determined via gravimetry, Figure 5.1e), likely due to the low aqueous styrene 
concentration prior to micellisation. However, after 1 h, both monomer conversion and 
particle size (measured with DLS; Figure 5.1c) rapidly increased, suggesting the 
formation of nano-objects and transport of styrene monomer into the growing particles. 
Both particle size and monomer conversion plateaued after 6 h at 78.5 nm and 96% 
respectively, indicating completion of the reaction. It should be noted that the latter time 
points exhibited artificial conversion values greater than 100%, which we anticipate was 
due to small weighing errors associated with the scale and volume of both the 
polymerisation and the samples taken. TEM analysis of the final latex (t = 8 h) revealed 
spherical NPs (Figure 5.1f) with relatively high polydispersity not revealed by DLS (PDi 
= 0.052; Table A5.1– Latex 1), possibly due to skewed sensitivity for larger species in 
light scattering. The polydispersity may be attributed to the ionic macro-RAFT agents 
reducing chain extension efficiency, affecting the uniformity of particle growth by 
electrostatic repulsion of similarly charged species in the aqueous phase.35 This finding 
may also be attributed to the swollen corona in DLS measurements, which may artificially 
decrease the resulting PDi in comparison to TEM, in which the corona is fully collapsed.  
The highly amphiphilic block copolymer NPs were insoluble in traditional SEC eluents 
for polystyrene characterisation (THF, CHCl3), therefore analyses were performed in 
DMF eluent with 0.1 wt% LiBr with polar columns. Since PS is known to swell in DMF 
and is not ideal for molecular weight determination, SEC chromatograms were only used 
to qualitatively assess molecular weight evolution and macro-RAFT agent consumption. 
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Using these, a clear increasing trend in molar mass over time was observed (Figure 5.1d), 
suggesting chain extension from P(AMPS)50 had indeed occurred, however, some macro-
RAFT agent remained unconsumed. Nonetheless, the highly negative zetapotentials of 
the NPs (-56.4 mV) suggests a dense sulfonated polymeric shell at the NP surface.   
 
Figure 5.1 General synthesis scheme (A) and schematic representation (B) for the preparation of P(AMPS) 
macro-RAFT agents, and subsequent PISA via chain extension of styrene to generate heparin mimicking 
nanoparticles. Kinetic data for Latex 1 (A) particle diameter (green circles) and polydispersity index (red 
circles) measured with DLS, (B) molar mass evolution of the dissolved nanoparticle unimers via DMF SEC 
(C) conversion measured with gravimetric techniques and (D) representative TEM image at the 8 h time 
point.  
A 
B 
C D 
t = 8 h 
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Chain extension 
Polymerisation 
induced self-
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5.2.3 Systematic study 
A systematic study on initiator type, temperature, initiator concentration, stirring speed, 
polystyrene DP, P(AMPS) DP and hydrophobic monomer type was then performed to 
improve nanoparticle polydispersity and control particle size. It should be noted that 
many of the latexes described below were completely insoluble in the DMF + 0.1 wt% 
LiBr SEC eluent, therefore for clarity only the particle size via DLS and TEM is 
discussed. Full characterisation and reaction conditions can be found in the appendix 
(Table A5.1). 
5.2.3.1 Effect of initiator 
The above-mentioned polymerisation was repeated using similar conditions but replacing 
ACVA (Latex 1) with VA-086 (Latex 2) and VA-057 (Latex 3). To account for the 
different 10 h half-life temperatures, the concentration of each initiator was adjusted such 
that the same number of radicals was generated within 6 h (Equation S2 and S3). 
Interestingly, the NPs synthesised with VA-086 were larger (94.2 nm) than with ACVA 
(78.5 nm), while those with VA-057 were smaller (59.6 nm). It is likely that, as a neutral 
initiator, VA-086 imparted less electrostatic stabilisation to the growing particles, 
resulting in fewer larger particles comprised of a higher number of polymer chains. A 
charged initiator, ACVA, was therefore used for all future polymerisations as no clear 
differences other than particle size were observed. 36, 37 
5.2.3.2 Effect of temperature 
Similarly, the preliminary polymerisation at 80°C (Latex 1) was repeated at both 70°C 
(Latex 4) and 90°C (Latex 5), again with adjusted amounts of initiator as detailed above. 
At 70°C, only 71% conversion was attained, while at higher temperatures (80 and 90°C) 
monomer conversions higher than 90% were achieved likely due to higher propagation 
rates. Both temperatures yielded larger nanoparticles (91.4 nm at 70°C and 100.4 nm at 
90°C). The difference at 70°C, could be explained by a decreased solubility of styrene 
during the early phase of the emulsion polymerisation, resulting in fewer macro-RAFT 
agents being chain extended, cumulating in less colloidal stability.38 At 90°C the increase 
in size could also be attributed to particle-particle coalescence at high temperatures.39 
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5.2.3.3 Effect of initiator concentration 
By increasing the concentration of initiator (ACVA) (Latex 1; [CTA]0/[I]0 = 4.65) to 
double (Latex 6; [CTA]0/[I]0 = 2.33) and quadruple (Latex 7; [CTA]0/[I]0 = 0.93) the 
original amount, only a small increase in particle size was observed (78.5 nm (Latex 1) 
to approximately 95 nm for both concentrations). In both cases, it is likely that an 
increased number of radicals may result in more termination in the aqueous phase, thus 
leaving the effective radical concentration unaffected by [I]0 in the growing particles.  
5.2.3.4 Effect of stirring speed 
Increasing the stirring speed from 400 RPM (Latex 1) to 800 RPM (Latex 8) and 1200 
RPM (Latex 9) resulted in larger NP diameters, (128.5 nm (800 RPM) and 157.7 nm 
(1200 RPM)). The faster, and possibly asymmetrical agitation (1200 RPM), may promote 
inter-particle coalescence and therefore larger diameters.40 However, transmission 
electron micrographs of these NPs revealed uniform suspensions at 800 rpm, which most 
likely had uniform stirring. This stirring speed was therefore used for all future 
experiments.  
5.2.3.5 Effect of polystyrene chain length 
It has been widely reported that the balance of hydrophilic and hydrophobic chain length 
can heavily influence particle size and morphology in PISA formulations.21 It was 
possible to modify the hydrophobic length (core forming block) by either increasing 
[P(AMPS)50]0 or reducing [Styrene]0 in the emulsion polymerisations. This was 
attempted by targeting a polystyrene core with a DP of 250 (Latex 10 and Latex 12) and 
50 (Latex 11 and Latex 13), compared to the Latex 8 (DPtarget = 450), by reducing 
[Styrene]0 or increasing [macro-RAFT]0. Targeting a DP of 250 both gave smaller NPs, 
120.7 nm and 92.4 nm for [Styrene]0 equal to 250 and 50 mM respectively, of which both 
phenomena have been previously reported for similar systems.24, 35 Further decreasing the 
DPtarget to 50 however, resulted in the absence of nano-object formation, suggesting that 
this was below the critical hydrophobic chain length for self-assembly using this type of 
anionic macro-RAFT agent. If compared to non-ionic stabilisers, many reports indicate 
that very short hydrophobic chain lengths are able to induce micellisation, e.g. below DP 
20.25 
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5.2.3.6 Effect of P(AMPS) chain length 
Using the synthesised homopolymers P(AMPS)20 (Latex 15) and P(AMPS)100 (Latex 16), 
RAFT emulsion polymerisations analogous to Latex 8 (P(AMPS)50) were then performed. 
For the shorter macro-RAFT agent (DP = 20), a large increase in particle size was 
observed (248.8 nm) compared to DP 50 (120.7 nm), probably due to the reduced 
electrostatic stability of the growing particles, leading to coalescence. Unexpectedly, 
larger diameters (161.6 nm) were also observed with increased chain length (Latex 16, 
P(AMPS)100 macro-RAFT agent). It is possible that this higher overall charge may 
promote chain-chain repulsion and therefore a reduced number at the surface of the 
growing particles, with the total effect of less colloidal stability and larger particles. This 
could also improve the rate of radical entry and therefore account for the increase in NP 
uniformity with P(AMPS)20 and P(AMPS)100 stabilisers. It is also possible that the larger 
(DP 100 vs DP 50) swollen anionic corona is partially responsible for this increase in size 
observed in DLS.41 
5.2.3.7 Effect of hydrophobic monomer 
Finally, polymerisations were conducted by replacing styrene (Latex 8) with n-butyl 
acrylate, another well-established monomer for emulsion polymerisations (Latex 14). 
This resulted in larger NPs (200.5 nm), which can be attributed to the poorer reinitiation 
of an acrylamide macro-RAFT agent with an acrylate monomer, thus reducing the number 
of sulfonated chains at the particle surface. It should be noted that due the low Tg of P(n-
BA), Latex 14 was imaged with cryo-transmission electron microscopy, instead of in the 
dry state. 
In general, altering the conditions of polymerisation of these sulfonated systems did not 
dramatically affect the resulting NP size. However, stirring speed and P(AMPS) chain 
length had the greatest effect on particle size and polydispersity. The average diameter of 
all NPs synthesised was found to be comparable between DLS and TEM measurements, 
while all zeta-potentials remained similar (~ -55 to -65 mV) regardless of polymerisation 
conditions. All of the final latexes had pH values between 6.5 and 6.6 which was most 
probably caused by the P(AMPS) macro-RAFT agent/surface functionality.  
Furthermore, unlike other monomer combinations, our emulsion system only yielded 
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spherical NPs, which was also observed by Armes and co-workers when using sulfated 
polymethacrylate macro-RAFT agent stabilisers.32, 33  
 
Table 5.1 Characterisation data for the nanoparticles used in biological studies (cytotoxicity, haemolysis 
and cellular proliferation).  
    Water  PBS 
 Target 
structure Monomer 
Conv 
(%)a 
Dh 
(nm)b PDi
c ZP (mV)d  
Dh 
(nm)b PDi
c 
Latex 
8 
P(AMPS)50-b-
PS450 
Styrene 90 128.5 0.052 -60.3  122.0 0.072 
Latex 
14 
P(AMPS)50-
P(n-BA)450 
n-BA 93 200.5 0.051 -62.9  206.4 0.044 
Latex 
16  
P(AMPS)100-
PS450 
Styrene 89 161.6 0.050 -61.6  165.7 0.047 
 
aDetermined using gravimetric techniques. bDetermined using DLS (intensity distribution). cCalculated 
using equation S4. dDetermined using a zetasizer.  
 
 
Figure 5.2 DLS particle size distributions (top row) (intensity = green, volume = black, number = red) 
measured in water at 25˚C and TEM images (bottom row) of Latex 8, Latex 14 (cryogenic TEM) and Latex 
16.  
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5.2.4 Biological studies 
 
Figure 5.3 (A) bFGF stabilisation / BaF3 proliferation (controls of untreated cells and bFGF only) (B) 
haemolytic activity (controls of PBS and water) and (C) cytotoxicity against NIH-3T3 fibroblasts of heparin 
(controls of untreated cells), P(AMPS)50, Latex 16 P(AMPS)100-PS450, Latex 14 P(AMPS)50-P(n-BA)450 and 
Latex 8 P(AMPS)50-PS450. Data shown represent mean ± standard deviation across triplicates from two 
independent experiments (N=6).    
Latex 8 (P(AMPS)50-b-PS450), Latex 14 (P(AMPS)50-P(n-BA)450) and Latex 16 
(P(AMPS)100-PS450) were chosen to study their heparin mimicking behaviour in order to 
isolate differences between the influence of core monomer (n-BA and styrene) and AMPS 
chain length (DP 50 and DP 100) on bFGF stabilisation. Additionally, these samples 
appeared as the most uniform from TEM images (Figure 5.2). Prior to these experiments, 
the NPs were dialysed for 48 h against a 100 kDa MWCO membrane to remove any 
styrene monomer, and unconsumed macro-RAFT agent which may compete against the 
NPs in biological studies. Importantly, the hydrodynamic diameter of the chosen latexes 
was comparable in PBS and in water, suggesting the NPs would be colloidally stable in 
biological experiments (Table 5.1). P(AMPS)50 and heparin itself were also included in 
these experiments for comparison. 
The haemolytic activity of all compounds was assessed by incubating red blood cells (1 
h at 37°C) with the chosen NPs and polymers at four concentrations (100 µg mL-1 to 1 
µg mL-1 in PBS) and monitoring the release of haemoglobin via UV spectroscopy at 414 
nm. Positive (Triton-X) and negative (PBS) membrane disruption controls were also 
performed in parallel, with water (5% in PBS) also used as a vehicle control. Low 
haemolytic activity (~20%), comparable to H2O, was observed for heparin and 
P(AMPS)50, however much higher activity (> 50% haemolysis) was seen for all of the 
NPs following the trend Latex 8 (P(AMPS)50-PS450 particles) > Latex 14 (P(AMPS)50-
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P(n-BA)450 particles) > Latex 15 (P(AMPS)100-PS450 particles) (Figure 5.3a). In contrast, 
none of the compounds (polymers or NPs) showed acute toxicity towards murine 
embryonic fibroblast cells for concentrations up to 1 mg mL-1 (Figure 5.3b). This major 
difference between haemolysis and cytotoxicity could be due to the highly amphiphilic 
‘surfactant-like’ nature of the particle surface-core interface, which is known to have 
significant membrane disruption activity.41 The observed trends appear to support this 
hypothesis, as the large P(AMPS)100 chains present on the surface of Latex 15 will better 
shield erythrocytes from the PS interface compared to the shorter P(AMPS)50. 
Furthermore, P(n-BA) is less hydrophobic than PS, and therefore NPs with these cores 
may be less amphiphilic, accounting for the reduction in haemolytic activity of Latex 14.  
Finally, stabilisation of bFGF was tested using a typical proliferation assay using BaF3 
cells, an IL-3 dependent murine pro B cell line which was modified to lack cell-surface 
heparin sulfate, and express the bFGF receptor (FGFr1c). Using this assay, heparin or a 
heparin mimic must be present to stabilise bFGF and promote its binding to FGFr1c 
receptor, thus inducing enhanced cellular proliferation. To assess this, the NPs, 
P(AMPS)50 and heparin (100, 10 and 1 µg mL-1) were incubated with BaF3 cells and 
bFGF (5 ng mL-1) for 48 h, and the cellular proliferation evaluated with a cell viability 
assay (CellTiter-Blue®). Results were normalised to untreated cells (100%) (Figure 5.3c). 
Addition of heparin induced a small amount of proliferation (150%) which appeared 
independent of concentration for the range studied.8 The linear polymer, P(AMPS)50, 
resulted in approximately 250% proliferation. In contrast, all of the NPs displayed greater 
than 400% cellular proliferation, with no obvious differences between core composition, 
P(AMPS) shell length, or concentration. The full mechanism of the bFGF-heparin-
bFGFR proliferation pathway is not yet fully understood, however the key requirements 
are now known.42 Heparin must induce dimerization of bFGF and simultaneously bind to 
bFGFR to achieve the active bFGF-heparin-bFGFR triplex required for effective 
proliferation.42 A recent study by Zbinden et al. revealed that polymer conjugates with 
increased display of bFGF drastically enhanced proliferation of endothelial cells.43 They 
also noted that higher densities of bFGF resulted in larger conjugate hydrodynamic 
volumes, which may also contribute to this effect.43  It is probable that our large NPs with 
numerous surface-active P(AMPS) chains may be able to bind multiple bFGF on the same 
species, thus improving its multivalent display. However, the smaller size of linear 
P(AMPS)50 and heparin could mean that only one, or a few of the polymers could interact 
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with a single bFGF molecule, potentially explaining the greater cellular proliferation with 
the NPs. Furthermore, Garcia-Fernandez et al. showed that greater hydrophobicity of 
sulfonated linear polymers had a profound increase on bFGF stability, therefore exposed 
styrene from the hydrophobic NP cores may also have a similar effect.44 It should be 
noted that our study evaluates cellular proliferation heparin as a function of treatment 
weight (e.g. 1 g of NP’s vs 1 g of polymer). However, due to the higher weight proportion 
of PS compared to P(AMPS) in our NPs, the molar concentration of sulfonated residues 
is exceptionally low compared to the counterpart polymers. This highlights how the use 
of NP architecture could have an even greater efficacy if the number of P(AMPS) chains 
per particle could be elucidated, and sulfonated moieties directly compared. 
5.3 Conclusions 
In conclusion, we have shown a parameter screening study to generate uniform, heparin 
mimicking polystyrene NPs via aqueous RAFT emulsion polymerisation/PISA from 
P(AMPS) hydrophilic macro-RAFT agents. The optimised NPs showed no cytotoxic 
effect against NIH-3T3 fibroblasts. However, compared to linear P(AMPS) and heparin, 
the NPs displayed major disruption of erythrocytes rationalised by the highly amphiphilic 
nature of the P(AMPS)-PS interface. Finally, all of the tested NPs exhibited much greater 
cellular proliferation, in comparison to heparin and linear P(AMPS) control polymers, 
likely due to the multivalent presentation of sulfonated chains at the NP surface. However, 
no apparent trends were observed between nanoparticle varieties (core properties and 
surface chain length) on cell proliferation. Overall, the polymerisation-induced self-
assembly approach allows the facile generation of highly sulfonated NPs, and represent 
a promising platform for heparin mimicry in the future.  
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5.4 Experimental 
5.4.1 Materials  
Sodium 2-acrylamido-2-methylpropane sulfonate (AMPS®2405, 50 wt% in water) was 
donated by Lubrizol. Thermal initiators 4,4′-azobis(4-cyanovaleric acid) (ACVA, 98%), 
2,2′-azobis[2-methyl-N-((2-hydroxyethyl)propionamide] (VA-086, 98%) and 2,2’-
Azobis[N-(2-carboxyethyl)-2-methylpropionamidine]tetrahydrate (VA-057, 98%) were 
obtained from Wako Chem. Bovine calf serum (BCS, Sterile-Filtered), IL-3 mouse 
recombinant expressed in E. coli (> 98%, Sterile), Heparin sodium salt from porcine 
intestinal mucosa (180 USP units/mg); 2,3-Bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-
tetrazolium-5-carboxanilide inner salt (XTT sodium salt, > 90%), Phenazine methosulfate 
(PMS, > 90%), Triton X-100 and Styrene (>99%) were purchased from Sigma Aldrich. 
RPMI1640 medium with GlutaMAX supplement (Invitrogen, Sterile), Geneticin 
selective antibiotic (G418 Sulfate, Invitrogen, 50 mg mL-1 in water, Sterile), Basic 
Fibroblast Growth Factor human recombinant (bFGF, Corning, Sterile-Filtered-
Lyophilised, > 95%) and Defibrinated sheep blood (Thermo Scientific Oxoid) were 
purchased from Fischer Scientific. CellTiter-Blue Cell Viability Assay was purchased 
from Promega. Dulbecco’s Modified Eagle Medium (DMEM), Foetal bovine serum 
(FBS), Phosphate-buffered saline (PBS), L-glutamine and sterile water were prepared 
under sterile condition by the media preparation service at the School of Life Science at 
the University of Warwick. Methanol-d4 (MeOD, 99.8% D atom) was purchased from 
Sigma Aldrich and used for 1H NMR spectroscopy. TEM grids were purchased from EM 
Resolutions (Sheffield, UK). 2-(((butylthio)-carbonothioyl)thio)-2-methylpropanoic acid 
(BDMAT) was synthesised using previous literature conditions.1 
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5.4.2 Instrumentation and Analysis 
5.4.2.1 1H NMR spectroscopy 
1H NMR were recorded as described in section 2.4.2.1 
5.4.2.2 Calculation of initiator consumption over time 
Initiator consumptions were calculated using Equation 2.1 and Equation 2.2 
5.4.2.3 Size exclusion chromatography 
Aqueous SEC 
Agilent PL50 instrument equipped with differential refractive index (DRI) detector. The 
system was equipped with 2 x PL Aquagel OH Mixed M columns (30 cm x 7.5 mm ID) 
with 8 µm pore size and an Aquagel 8 µm guard column. The mobile phase used was 
80:20 0.1 M NaNO3(aq):methanol. Samples were run at 1 mL min-1 at 35°C regulated 
with a column oven. Poly(ethylene oxide) standards (Agilent EasyVials) were used for 
calibration between 1,368,000 – 106 g/mol. Analyte samples were prepared at a final 
concentration of 1 mg mL-1 and filtered through a membrane with 0.22 μm pore size 
before injection. Respectively, experimental molar mass (Mn,SEC) and dispersity (Đ) 
values of synthesised polymers were determined by conventional calibration using 
Agilent GPC/SEC software. 
DMF + 0.1 wt% LiBr SEC 
Agilent PL50 instrument equipped with differential refractive index (DRI) and ultra-
violet (UV) detectors. The system was equipped with 2 x PolarGel M columns (30 cm x 
7.5 mm ID) and a PolarGel 5 µm guard column. The mobile phase used was DMF with 
0.1% (w/v) LiBr additive. Samples were run at 1 mL/min at 50°C regulated with a column 
oven. Poly(methyl methacrylate) standards (Agilent EasyVials) were used for calibration 
between 955,000 – 550 g/mol. Analyte samples were prepared at a final concentration of 
1 mg mL-1 and filtered through a nylon membrane with 0.22 μm pore size before injection 
Respectively, experimental molar mass (Mn,SEC) and dispersity (Đ) values of synthesised 
polymers were determined by conventional calibration using Agilent GPC/SEC software. 
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5.4.2.4 Dynamic light scattering, size and zeta-potential measurements 
DLS and zetapotential measurements were performed as described in 2.4.2.4. PDi values 
were calculated as described in Equation 2.13. 
5.4.2.5 Transmission electron microscopy 
Transmission electron micrographs were obtained as described in section 3.6.2.10 
5.4.2.6 Cryogenic transmission electron microscopy 
Cryogenic transmission electron micrographs were obtained as described in section 
2.4.2.7 
5.4.3 Synthetic Procedures 
5.4.3.1 P(AMPS) macro-RAFT agent synthesis via RAFT polymerisation 
P(AMPS) macro-RAFT agents were synthesised using previously reported conditions.1 
A general procedure for DP 50 is described below. BDMAT (26 mg, 0.1 mmol), AMPS® 
(2.00 g, 5.1 mmol), phosphate buffer (1.5 mL), sodium hydroxide (5.1 x 10-2 mmol, 2 
mg) and VA-086 (8.4 x 10-3 mmol, 2.4 mg) (from stock solution at 20.0 mg mL-1) were 
introduced into a flask equipped with a magnetic stirrer bar and sealed with a rubber 
septum. The solution was purged with dinitrogen for 10 minutes, and the vial immersed 
in an oil bath a set to 90°C for 2 h. At the end of the reaction, the mixture was allowed to 
cool down to room temperature and exposed to air. The final mixture was characterised 
using 1H NMR spectroscopy and SEC, and used further without purification. 
5.4.3.2 Nanoparticle synthesis via PISA RAFT emulsion polymerisation 
A general procedure for Latex 1 is detailed below. P(AMPS)50 solution (338 µL (343 mg 
mL-1 solution), 116 mg, 10 µmol), ACVA (predissolved in water with 2 eq NaOH at 5 
mg mL; 140 µL, 0.7 mg, 2.5 µmol) and water (8.95 mL) were added to a 30 mL 
microwave vial equipped with a magnetic stirrer, and sealed with a disposable septum 
cap purged with dinitrogen for 10 minutes. Deoxygenated styrene (570 µL, 520 mg, 5 
mmol) was added via syringe. The mixture was then immersed in an oil bath set to 80°C, 
and stirred at 400 RPM for 8 h. The polymerisation turned a milky white after 
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nanoparticle formation. Before biological assays, the suspensions were dialysed against 
water with a 100 kDa dialysis membrane for 48 h.    
5.4.4 Biological Studies 
5.4.4.1 Cell culture 
NIH-3T3 cells were purchased from Sigma Aldrich and cultured as monolayers at 37°C 
in a humidified atmosphere containing 5% CO2. Cells were cultured in Dulbecco’s 
Modified Eagle Medium (DMEM) supplemented with 10% foetal calf serum, 1% L-
Glutamine and 1% penicillin/streptomycin. Cells were sub-cultured at regular intervals 
and passages made by trypsinising cells when at 80-90% confluence.  BaF3-FR1C cells 
were kindly provided by Prof. Jerry Turnbull (Liverpool University, UK) and were 
cultivated at 37°C in suspension in a humidified atmosphere containing 5% CO2. Cells 
were cultured in RPMI1640 GlutaMAX media supplemented with 10% foetal bovine 
serum (FBS), 2 ng/mL of recombinant mouse IL-3, 600 µg/mL of G418. Cells were sub-
cultured at regular intervals and passages made by centrifuging them at 1000 rpm for 5 
min and diluted to keep a density between 500,000 to 1,000,000 cells/mL and were used 
for up to one month.  
 
5.4.4.2 Cell viability assay 
NIH-3T3 cells were seeded at a density of 10,000 cells per well in a flat bottomed clear 
96 well plate and incubated for 24 h. The medium was replaced with 100 µL of fresh 
medium containing the tested compounds (heparin, P(AMPS)50, Latex 16, Latex 14 and 
Latex 8) at 0.01 µg mL-1, 1 µg mL-1, 10 µg mL-1, 100 µg mL-1 and 1 mg mL-1. The cells 
were incubated with the compounds for 48 h, and cell viability established with the XTT 
assay. The media in each well was removed and replaced with fresh culture medium 
containing 25 µL of XTT (1 mg mL-1) and PMS (25 µmol/L) and was further incubated 
for 12 hours. Absorbance of each well was measured using a Synergy HTX plate reader 
at 475 nm and 650 nm (background) with A = A475nm - A475nm(blank) – A650nm. The cell 
viability was normalised to untreated cells. All experiments were carried out as duplicates 
of triplicates in two independent experiments (N=6).  
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5.4.4.3 Haemolysis assay 
Haemolytic activity of the nanoparticles was determined using procedures described in 
section 3.6.4.3. 
5.4.4.4 Cell proliferation assay 
BaF3-FR1C cells were seeded at a density of 20,000 cells/well (in 50 µL media) in the 
internal wells of a 96-well plate with medium absent of IL-3 and G418. A further 50 µL 
of medium containing polymers or nanoparticles (heparin, P(AMPS)50, Latex 16, Latex 
14 and Latex 8) and bFGF were added such that the final concentrations were 100 µg mL-
1, 50 µg mL-1, 10 µg mL-1 and 5 ng mL-1 respectively. Controls of untreated cells and cells 
in the presence of 5 ng mL-1 of bFGF were used as reference. External wells were filled 
with 100 µL of PBS and a gas permeable moisture barrier seal (4titude) was used to 
decrease the evaporation from the plate. After incubation for 48 hours, 20 µL of the 
CellTiter-Blue® assay was added into each well and further incubated for 6 hours. 
Fluorescence of each well was measured using a Synergy HTX plate reader with the 
excitation wavelength set to 560 nm and emission at 590 nm. Cell proliferation was 
calculated by normalising treated cells to untreated cells (100%). Each sample had four 
replicates and the experiment was repeated four times independently 
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Chapter 6  
 
Conclusions and outlook 
The initial chapter detailed the current state of these synthetic strategies to produce 
nanoparticles useful for biological applications. The overall conclusion of this thorough 
study revealed that the limited monomer families, surfactant use, scalability concerns and 
non-aqueous polymerisation environments meant that dispersion, miniemulsion and 
suspension polymerisations may be incompatible. In contrast, RAFT emulsion 
polymerisation is a highly modular synthetic approach and allows the modification of 
individual nanoparticle components (core size, core composition, corona functionality 
and shell composition), however, it remains underused for biological applications. The 
aim of this thesis was therefore to exploit RAFT emulsion polymerisation, to overcome 
current limitations in nanoparticle synthesis and design. 
In chapter 2, using PEGylated macro-RAFT agents, the RAFT emulsion polymerisation 
of n-BA and t-BA was optimised (initiator and pH) to yield low dispersity nanoparticle 
suspensions with narrow molecular weight distributions. A library of nanoparticles of 
different sizes for each core type was synthesised, with all polymerisations achieving full 
monomer conversion and fully characterised with static light scattering and electron 
microscopy. This work is the first to study the toxicity of nanoparticles synthesised with 
RAFT emulsion polymerisation in vivo, with our results showing excellent tolerability, 
similar to in vitro experiments. The biodistribution of fluorescently labelled 50 nm 
derivatives was then evaluated using an in vivo fluorescence imager, with particles 
displaying > 76 h retention and accumulation in the liver post-administration. Considering 
the excellent biocompatibility, and ‘green’ polymerisation conditions, this synthetic 
approach may have some potential for industrial scale up, assuming limitations on macro-
RAFT agent scalability could be overcome.  
The main aim in chapter 3 was to evaluate if rigidity played a significant role in 
nanoparticle cellular uptake, and in particular, if there were any secondary effects with 
particle size. By utilising RAFT emulsion polymerisation, a series of nanoparticles with 
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different core Tg were generated simply by modifying the monomer composition (styrene, 
t-BA and n-BA for hard medium and soft respectively). Clear differences in uptake were 
observed, with softer nanoparticles taken up faster and in greater quantities than harder 
analogues in two malignant mammalian cell lines. Perhaps most interestingly, these 
observations were only seen in 100 nm derivatives, with 50 nm nanoparticles showing 
negligible differences in uptake, which have been attributed to less correlation between 
Tg and core rigidities at this reduced size scale. While all of the nanoparticle displayed 
strong colocalisation in lysosome compartments, their cellular entry mechanisms were 
indeed largely different. Most prominently, the increasing trend in cavolae- mediated 
endocytosis of hard > medium > soft potentially revealed the drastic differences the 
mechanosensing behaviour that caveolae may have on nanoparticle cellular uptake. 
Overall, these results highlight that rigidity does indeed have a major effect on cellular 
uptake, with size being important when considering this parameter. Moreover, this study 
clearly represents the precise control over maintained individual nanoparticle properties 
when using RAFT emulsion polymerisation, allowing for complex fundamental 
biological studies.  
Chapter 4 details a synthetic study, outlining the requirements to generate alkyne surface 
functional nanoparticles via RAFT emulsion polymerisation. Initial attempts to simply 
repeat procedures detailed in chapters 2 and 3 with alkyne functional macro-RAFT agents 
revealed significant colloidal instability and poor molecular weight control. A systematic 
study revealed that ester functional RAFT agents, and carboxylated macro-RAFT agents 
were essential to overcome the limitations above. Test CuAAC reactions with azido 
functional PEG and fluorescein showed efficient ligation with model polymer. However, 
only the smaller substrate (fluorescein azide) was efficiently conjugated when repeated 
on the alkyne functional nanoparticles, attributed to steric hindrance from the PEG brush 
polymeric shell. Overall, this study reveals that introducing surface functionality using 
RAFT emulsion polymerisation is indeed possible, however careful attention must be 
paid to the macro-RAFT agent design.  
Finally, in chapter 5, moving away from the PEGA based macro-RAFT agents, 
polysulfonated nanoparticles were prepared using a one-pot RAFT emulsion stabilised 
by linear poly(2-acrylamido-2-methylpropane sodium sulfonate) macro-RAFT agents, as 
potential heparin mimics for bFGF stabilisation. A systematic study of various reaction 
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conditions revealed that macro-RAFT agent length and stirring speed had the greatest 
effect on particle size and polydispersity, evaluated with DLS and TEM. A selection of 
the nanoparticles were taken forward for biological studies and revealed minimal 
cytotoxicity against NIH-3T3 cells. Finally, all of the nanoparticles displayed enhanced 
bFGF stabilisation compared to heparin and linear P(AMPS) through greater proliferation 
of BaF3 cells. This was attributed to the potentially greater display of bFGF on the 
nanoparticle surface, which was able to stabilise a multitude of growth factors on each 
nanoparticle species. In general, this study highlights that nanoparticles represent a 
promising candidate as heparin mimics. 
In summary, the presented thesis demonstrates that the RAFT emulsion polymerisation 
process is highly beneficial for generating nanoparticles for biomedical applications. The 
ability to modify individual components, has allowed the study of a variety of biological 
research questions, including in vivo toxicology, fundamental in vitro cellular uptake and 
growth factor stabilisation. There are however some limitations to this study. 
For instance, only a brief in vivo study was performed looking at body weight and 
preliminary biodistribution with one injection route. Ideally, a more detailed toxicology 
identifying any stress markers could have been performed along with multiple injection 
routes and studying the long term (> 1 week) accumulation of the nanoparticles in vivo. 
Furthermore, in our cellular uptake study described in chapter 3, instead of relative 
intracellular fluorescence measurements, a fully quantitative measure (i.e. exact number 
of particles per cell) would allow us to look more deeply at the differences between 50 
and 100 nm particles, as here they cannot directly compared. When preparing alkyne 
functional diblock copolymers and nanoparticles, ester and amide reinitiating groups with 
and without pendant acrylic acid moieties were tested for their stabilisation of RAFT 
emulsion polymerisation. There is however a gap in this study, as in the final instance we 
assumed that the acid groups were completely essential, as seen for the TMS protected 
derivative. It would be interesting to see if using the non-protected analogue without 
pendant acrylic acids causes the same destabilisation observed for the TMS versions. 
Finally, although we are potentially the first to show heparin mimicking nanoparticles for 
bFGF stabilisation, we did not quantify exactly how many sulfonates are at the surface of 
each nanoparticle and as such cannot be directly compared to the linear equivalent. 
However, as stated at the end of the chapter, by weight, the linear derivatives contain a 
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higher proportion of sulfonate moieties which would only accentuate the difference if 
compared by molar amount of sulfonate groups.   
Although synthesis and design of biomedical nanoparticles is an active field of work, 
there are still very few formulations which are in clinical trials, and even fewer which are 
clinically used. As the long-term effects of nanoparticles are still unknown, it is expected 
that new designs aimed at the clinic should be degradable such that they do not 
accumulate indefinitely. This is potentially the major drawback of all RDRP techniques, 
including the systems described in this thesis, as the inert C-C backbone of common 
poly(acrylates/methacrylates/acrylamides etc.) cannot be physiologically destroyed. Due 
to this, the systems presented would not at their current stage, be targeted towards clinical 
use.  
Given this, the major challenge going forward would be to introduce degradable units 
within the polymer backbone, without much modification of the RAFT emulsion 
procedures described. This could be achieved through the addition of cyclic ketene acetal 
monomers, which impart ester groups within the polymeric backbone. If this was 
achieved, coupled with the findings in this work that these nanoparticles accumulate in 
the liver, and softer particles are internalised better by cells, one can imagine that future 
systems could be used to target liver diseases, without the current limitations of 
bioaccumulation. Without degradability, the precision in which the nanoparticles 
described can be tuned means that they would be more useful to study fundamental 
aspects (i.e. particle size, surface charge/functionality etc.), which would lead the design 
of future clinical therapies. 
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Appendix 2  
 
 
Figure A2.1 1H NMR spectrum of MRA-PEGA in CDCl3. 
 
Figure A2.2 1H NMR spectrum of MRA-nBA in CDCl3. 
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Figure A2.3 1H NMR spectrum of MRA-tBA in CDCl3. 
 
Figure A2.4 Fluorescence images (800 nm channel) of (A) mouse treated with Cy7.5 loaded 50 nm P(n-
BA) nanoparticles after 76 h post injection. (B) Untreated mouse with a faecal pellet (C) Ex vivo organs 
taken 76 h post injection. All images have the same brightness and contrast settings, indicating a small 
degree of 800 nm fluorescence emitted by the faecal pellet. 
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Appendix 3  
 
 
Figure A3.1 Intensity (black), volume (green) and number (red) DLS size distributions of 100H, 100M, 
100S, 50H, 50M and 50S fluorescently labelled nanoparticles within this study before and after dialysis in 
60% 1,4-dioxane, 40% water to remove unconsumed BODIPY acrylate and unconsumed macro-RAFT 
agent. 
 
Figure A3.2 Intensity (black), volume (green) and number (red) DLS size distributions of 100HNF, 100MNF, 
100SNF, 50HNF, 50MNF and 50SNF non-fluorescent nanoparticles. 
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Figure A3.3 THF-SEC chromatograms of dried and dissolved fluorescent nanoparticles 100H, 100M, 
100S, 50H, 50M and 50S using UV detection at 520 nm (top chart) and RI detection (bottom chart) both 
before (dashed light pink line for UV and dashed grey line for RI) and after (full pink line for UV and full 
black line) dialysis against a 60/40 1,4-dioxane/water (v/v) solvent mixture. Chromatograms for the 
respective macro-RAFT agents are also shown (full green line). 
 
 
Figure A3.4 THF-SEC of dried and dissolved non-fluorescent nanoparticles 100HNF, 100MNF, 100SNF, 
50HNF, 50MNF, 50SNF using (RI detection) both before (dashed grey line) and after (full black line) dialysis 
against pure water. Chromatograms for the respective macro-RAFT agents are also shown (full green line). 
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Figure A3.5 Fluorescence emission (red line; λex = 528 nm) and excitation spectra (black line: λex = 542 
nm) for fluorescent nanoparticles 100H, 100M, 100S, 50H, 50M and 50S. 
 
 
Figure A3.6 Normalised DSC thermograms of dried fluorescent nanoparticles 100H, 100M, 100S, 50H, 
50M, 50S. 
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Figure A3.7 Normalised DSC thermograms of dried non-fluorescent nanoparticles 100HNF, 100MNF, 
100SNF, 50HNF, 50MNF, 50SNF. 
 
Figure A3.8 AFM images of 100H, 100M, 100S, 50H, 50M and 50S deposited on silanised glass at 0.05 
mg mL-1. Data obtained by Dr Kai Yu and Dr Christopher Hodges at the University of Leeds. 
 
 
 
 
  
214 
 
Note: ANOVA tests were performed in SPSS 14 software, with the nanoparticles 100H, 
100M, 100S, 50H, 50M and 50S labelled as 1, 2, 3, 4, 5, 6 respectively. 
PC3 time dependent cellular uptake – 2 h, 4 h and 24 h 100 nm particles 
 
Table A3.1 Analysis of variance (ANOVA) results table comparing intracellular fluorescence (PC3 cells) 
of the 100 nm nanoparticles after 2 h incubation. 
 
Table A3.2 Post-hoc Tukey-Kramer test results comparing intracellular fluorescence (PC3 cells) of the 100 
nm nanoparticles after 2 h incubation. 
 
Table A3.3Analysis of variance (ANOVA) results table comparing intracellular fluorescence (PC3 cells) 
of the 100 nm nanoparticles after 4 h incubation. 
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Table A3.4 Post-hoc Tukey-Kramer test results comparing intracellular fluorescence (PC3 cells) of the 100 
nm nanoparticles after 4 h incubation. 
 
Table A3.5 Analysis of variance (ANOVA) results table comparing intracellular fluorescence (PC3 cells) 
of the 100 nm nanoparticles after 24 h incubation. 
 
Table A3.6 Post-hoc Tukey-Kramer test results comparing intracellular fluorescence (PC3 cells) of the 100 
nm nanoparticles after 24 h incubation. 
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PC3 time dependent cellular uptake – 2 h, 4 h and 24 h 50 nm particles 
 
Table A3.7 Analysis of variance (ANOVA) results table comparing intracellular fluorescence (PC3 cells) 
of the 50 nm nanoparticles after 2 h incubation. 
 
Table A3.8 Post-hoc Tukey-Kramer test results comparing intracellular fluorescence (PC3 cells) of the 50 
nm nanoparticles after 2 h incubation.  
 
 
Table A3.9 Analysis of variance (ANOVA) results table comparing intracellular fluorescence (PC3 cells) 
of the 50 nm nanoparticles after 4 h incubation. 
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Table A3.10 Post-hoc Tukey-Kramer test results comparing intracellular fluorescence (PC3 cells) of the 
50 nm nanoparticles after 4 h incubation. 
 
Table A3.11 Analysis of variance (ANOVA) results table comparing intracellular fluorescence (PC3 cells) 
of the 50 nm nanoparticles after 24 h incubation. 
 
Table A3.12 Post-hoc Tukey-Kramer test results comparing intracellular fluorescence (PC3 cells) of the 
50 nm nanoparticles after 24 h incubation. 
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Comparison between time points 
Table A3.13 Analysis of variance (ANOVA) results table comparing intracellular fluorescence (PC3 cells) 
between time points for all nanoparticles. 
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Table A3.14 Post-hoc Tukey-Kramer test results comparing intracellular fluorescence (PC3 cells) between 
time points for all nanoparticles. 
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Inhibitors 
Table A3.15 Analysis of variance (ANOVA) results table comparing intracellular fluorescence (PC3 cells) 
between 100 nm particles after treatment with endocytosis inhibitors. 
 
Table A3.16 Post-hoc Tukey-Kramer test results comparing intracellular fluorescence (PC3 cells) between 
100 nm particles after treatment with endocytosis inhibitors. 
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Table A3.17 Analysis of variance (ANOVA) results table comparing intracellular fluorescence (PC3 cells) 
between 100 nm particles after treatment with endocytosis inhibitors. 
 
Table A3.18 Post-hoc Tukey-Kramer test results comparing intracellular fluorescence (PC3 cells) between 
50 nm particles after treatment with endocytosis inhibitors. 
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Caco-2 timecourse 
Table A3.19 Analysis of variance (ANOVA) results table comparing intracellular fluorescence (Caco-2 
cells) of the 100 nm nanoparticles after 2h, 4 h and 24 h incubation. 
 
Table A3.20 Post-hoc Tukey-Kramer test results comparing intracellular fluorescence (Caco-2 cells) 
between 100 nm particles after 2h, 4 h and 24 h incubation. 
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Table A3.21 Analysis of variance (ANOVA) results table comparing intracellular fluorescence (Caco-2 
cells) of the 50 nm nanoparticles after 2h, 4 h and 24 h incubation. 
 
Table A3.22 Post-hoc Tukey-Kramer test results comparing intracellular fluorescence (Caco-2 cells) 
between 50 nm particles after 2h, 4 h and 24 h incubation. 
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Table A3.23 Post-hoc Tukey-Kramer test results comparing intracellular fluorescence (Caco-2 cells) 
between time points for all nanoparticles. 
 
 
 
 
 
 
 
 
Tukey HSD
Lower Bound Upper Bound
4 -0.0424122913 0.1196061385 0.9333400300 -0.3530856782 0.2682610956
24 -.399139643000000* 0.1196061385 0.0117889795 -0.7098130302 -0.0884662563
2 0.0424122913 0.1196061385 0.9333400300 -0.2682610956 0.3530856782
24 -.356727352000000* 0.1196061385 0.0237924745 -0.6674007389 -0.0460539650
2 .399139643000000* 0.1196061385 0.0117889795 0.0884662563 0.7098130302
4 .356727352000000* 0.1196061385 0.0237924745 0.0460539650 0.6674007389
4 -0.0468903567 0.1123114387 0.9089620520 -0.3386159778 0.2448352643
24 -.560758793000000* 0.1123114387 0.0004441717 -0.8524844140 -0.2690331719
2 0.0468903567 0.1123114387 0.9089620520 -0.2448352643 0.3386159778
24 -.513868436000000* 0.1123114387 0.0009990254 -0.8055940573 -0.2221428152
2 .560758793000000* 0.1123114387 0.0004441717 0.2690331719 0.8524844140
4 .513868436000000* 0.1123114387 0.0009990254 0.2221428152 0.8055940573
4 -0.0984941535 0.0712591608 0.3745641934 -0.2835877040 0.0865993970
24 -.504895207000000* 0.0712591608 0.0000105220 -0.6899887580 -0.3198016570
2 0.0984941535 0.0712591608 0.3745641934 -0.0865993970 0.2835877040
24 -.406401054000000* 0.0712591608 0.0001170070 -0.5914946045 -0.2213075034
2 .504895207000000* 0.0712591608 0.0000105220 0.3198016570 0.6899887580
4 .406401054000000* 0.0712591608 0.0001170070 0.2213075034 0.5914946045
4 -0.1145611069 0.0940173956 0.4608836751 -0.3587684954 0.1296462816
24 -1.061716452000000* 0.0940173956 0.0000000340 -1.3059238408 -0.8175090639
2 0.1145611069 0.0940173956 0.4608836751 -0.1296462816 0.3587684954
24 -.947155345000000* 0.0940173956 0.0000001355 -1.1913627339 -0.7029479570
2 1.061716452000000* 0.0940173956 0.0000000340 0.8175090639 1.3059238408
4 .947155345000000* 0.0940173956 0.0000001355 0.7029479570 1.1913627339
4 -0.0807915600 0.0821691599 0.5997680422 -0.2977540608 0.1361709407
24 -.469813140000000* 0.0821691599 0.0001949908 -0.6867756408 -0.2528506392
2 0.0807915600 0.0821691599 0.5997680422 -0.1361709407 0.2977540608
24 -.389021580000000* 0.0734943309 0.0003984322 -0.5830787401 -0.1949644198
2 .469813140000000* 0.0821691599 0.0001949908 0.2528506392 0.6867756408
4 .389021580000000* 0.0734943309 0.0003984322 0.1949644198 0.5830787401
4 -0.0590763410 0.0772621527 0.7296523598 -0.2597624843 0.1416098023
24 -.284441063000000* 0.0772621527 0.0059168754 -0.4851272067 -0.0837549202
2 0.0590763410 0.0772621527 0.7296523598 -0.1416098023 0.2597624843
24 -.225364722000000* 0.0772621527 0.0270524949 -0.4260508658 -0.0246785792
2 .284441063000000* 0.0772621527 0.0059168754 0.0837549202 0.4851272067
4 .225364722000000* 0.0772621527 0.0270524949 0.0246785792 0.4260508658
Multiple Comparisons
Dependent Variable Mean Difference (I-J) Std. Error Sig.
95% Confidence Interval
100H 2
4
24
100M 2
4
24
100S 2
4
24
50H 2
4
24
50M 2
4
24
50S 2
4
24
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Caco-2 inhibitors 
Table A3.24 Analysis of variance (ANOVA) results table comparing intracellular fluorescence (Caco-2 
cells) between 100 nm particles after treatment with endocytosis inhibitors. 
 
Table A3.25 Post-hoc Tukey-Kramer test results comparing intracellular fluorescence (Caco-2) between 
100 nm particles after treatment with endocytosis inhibitors. 
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Table A3.26 Analysis of variance (ANOVA) results table comparing intracellular fluorescence (Caco-2 
cells) between 50 nm particles after treatment with endocytosis inhibitors. 
 
Table A3.27 Post-hoc Tukey-Kramer test results comparing intracellular fluorescence (Caco-2 cells) 
between 50 nm particles after treatment with endocytosis inhibitors. 
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Appendix 4  
 
 
Figure A4.1. (A) Polymerisation of PEGA mediated with TMS-Alkyne-PEsBTC, (B) pseudo first order 
plot, red points indicate data masked from the linear fit (red dashed line), (C) time vs conversion, (D) 
conversion vs Mn,SEC and linear fit (dashed black line), (E) evolution of SEC chromatograms over time.  
Table A4.1 Data for the polymerisation kinetics of PEGA using with TMS-Alkyne-PEsBTC as the CTA.  
Time (h) % conva 
Mn,th  (g mol-1)b
 Mn,SEC (g mol-1)c Mw,SEC  (g mol-1)c
 Ðc 
0 0 348 - -  
0.25 2 500 - -  
0.5 7 1000 2700 2900 1.05 
1 18 2100 3300 3600 1.1 
1.5 27 3000 4100 4600 1.12 
2 41 4300 5100 5700 1.13 
3 64 6500 6900 7900 1.14 
4 76 7700 8000 9100 1.14 
5 76 7700 8300 9500 1.15 
aDetermined by 1H NMR spectroscopy, bTheoretical molar masses calculated with Equation 2.12, 
cDetermined by THF-SEC and analysed against PMMA standards. 
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Figure A4.2. (A) Polymerisation of PEGA mediated with Alkyne-PEsBTC, (B) pseudo first order plot, 
red points indicate data masked from the linear fit (red dashed line), (C) time vs conversion, (D) conversion 
vs Mn,SEC and linear fit (dashed black line), (E) evolution of SEC chromatograms over time.  
 
Table A4.2 Data for the polymerisation kinetics of PEGA using with Alkyne-PEsBTC as the CTA.  
Time (h) % conva 
Mn,th  (g mol-1)b
 Mn,SEC (g mol-1)c Mw,SEC  (g mol-1)c
 Ðc 
0 0 276 - -  
0.25 10 1200 2900 3100 1.13 
0.5 22 2400 3900 4300 1.15 
1 41 4200 6000 6800 1.15 
1.5 66 6600 7700 8800 1.15 
2 75 7500 8400 9700 1.16 
3 85 8400 9200 10700 1.17 
4 88 8800 9500 11100 1.17 
5 89 8900 9600 11200 1.18 
aDetermined by 1H NMR spectroscopy, bTheoretical molar masses calculated with Equation 2.12, 
cDetermined by THF-SEC and analysed against PMMA standards. 
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Table A4.3 Polymerisation conditions for macro-RAFT agents synthesised in chapter 4. 
All reactions were performed at [M] = 1M, at 70°C using ACVA as thermal initiator and 1,4-dioxane as the solvent. 
 Monomer RAFT agent [M]0/ [RAFT]0 
Polymerisation  
Time (h) 
[CTA]0
/[I]0 
Conversion (%) 
TMS-Alkyne-O-P[(PEGA)12 PEGA TMS-Alkyne-PEsBTC 15 5 20 82 
TMS-Alkyne-O-P[(PEGA)12-b-(n-BA)12] n-BA TMS-Alkyne-O-P[(PEGA)12 14 5 20 90 
TMS-Alkyne-O-P[(PEGA)12-co-(AA)3] PEGA + AA TMS-Alkyne-PEsBTC 15+3 5 20 84 
TMS-Alkyne-O-P[(PEGA)12-co-(AA)3]-(n-BA)15 n-BA TMS-Alkyne-O-P[(PEGA)12-co-(AA)3] 15 5 10 99 
Alkyne-O-P[(PEGA)12-co-(AA)3] PEGA + AA Alkyne-PEsBTC 15+3 5 20 87 
Alkyne-O-P[(PEGA)12-co-(AA)3]-(n-BA)15 n-BA Alkyne-O-P[(PEGA)12-co-(AA)3] 15 5 20 81 
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Figure A 4.3 1H NMR spectrum of Alkyne-O-P[(PEGA)12-co-(AA)3] in CDCl3. 
 
Scheme A4.1 Preparation of Fluorescein-N3 from Fluorescein-NHS and azidopropanamine 
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Figure A4.4 HPLC traces of Fluorescein-NHS and Fluorescein-N3 using absorbance detection at 490 nm 
over a 5-95% gradient (MeOH/water). 
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Appendix 5  
 
 
Figure A5.1 DLS particle size distributions (intensity = green, volume = black, number = red) measured in 
water at 25˚C for Latex 1-7, Latex 9-10, Latex 12 and Latex 15. 
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Figure A5.2 TEM images for Latex 2-7, Latex 9-10, Latex 12 and Latex 15. 
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Table A5.1 Polymerisation conditions for the systematic nanoparticle synthesis study. Orange cells represent changes from Latex 1 for Latex 2-9 and Latex 8 for Latex 10-16. 
 
 
 
 
 
 
 
 
 
 
 
 
aMeasured using gravimetry. bDetermined with DLS. cCalculated using equation S4. cMeasured with a zetasizer.
  
Macro-
RAFT 
agent 
Monomer Initiator [M]/ [CTA] 
[M] 
(mM) 
[CTA] 
(mM) 
[CTA] 
/[I] T/°C 
Time 
(h) 
Stirring 
speed 
(RPM) 
Conv 
(%)a 
Particle 
diameter 
(nm)b 
PDic ZP (mV)d 
 Latex 1 P(AMPS)50 Styrene ACVA 450 450 1 4.65 80 6 400 96 78.5 0.052 -56.4 
Effect of initiator 
Latex 2 P(AMPS)50 Styrene VA-086 450 450 1 0.85 80 6 400 86 94.2 0.076 -50.8 
Latex 3 P(AMPS)50 Styrene VA-057 450 450 1 4.65 80 6 400 87 59.6 0.096 -51.5 
Effect of 
temperature 
Latex 4 P(AMPS)50 Styrene ACVA 450 450 1 1.8 70 6 400 71 91.4 0.091 -56.3 
Latex 5 P(AMPS)50 Styrene ACVA 450 450 1 4.65 90 6 400 95 100.4 0.056 -60.7 
Effect of initiator 
concentration 
Latex 6 P(AMPS)50 Styrene ACVA 450 450 1 2.325 80 6 400 88 97.2 0.073 -59.1 
Latex 7 P(AMPS)50 Styrene ACVA 450 450 1 0.93 80 6 400 85 95.5 0.083 -54.7 
Effect of stirring 
speed 
Latex 8 P(AMPS)50 Styrene ACVA 450 450 1 4.65 80 6 800 90 128.5 0.052 -60.3 
Latex 9 P(AMPS)50 Styrene ACVA 450 450 1 4.65 80 6 1200 85 157.7 0.052 -54.9 
Effect of DP 
(differing [M]) 
Latex 10 P(AMPS)50 Styrene ACVA 250 250 1 4.65 80 6 800 96 120.7 0.049 -67.2 
Latex 11 P(AMPS)50 Styrene ACVA 50 50 1 4.65 80 6 800 85 - - - 
Effect of DP 
(differing [CTA]) 
Latex 12 P(AMPS)50 Styrene ACVA 250 450 1.75 8.12 80 6 800 96 92.4 0.071 -57.7 
Latex 13 P(AMPS)50 Styrene ACVA 50 450 8.75 40.6 80 6 800 85 - - - 
Effect of monomer Latex 14 P(AMPS)50 n-BA ACVA 450 450 1 4.65 80 6 800 93 200.5 0.051 -62.9 
Effect of macro-
CTA length 
Latex 15 P(AMPS)20 Styrene ACVA 450 450 1 4.65 80 6 800 89 248.8 0.049 -58.3 
Latex 16 P(AMPS)100 Styrene ACVA 450 450 1 4.65 80 6 800 95 161.6 0.050 -61.6 
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